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Abstract 
Rheumatoid arthritis (RA) is a chronic, autoimmune joint disease characterized by a 
massive infiltration of immune cells and synovial lining hyperplasia. This ultimately 
leads to synovitis, i.e. inflammation of the synovial membrane, and excessive bone 
loss. Certain bone remodeling components are known to play a key role in the RA 
pathogenesis: receptor activator of nuclear factor-κB ligand (RANKL), 
osteoprotegerin (OPG), and dickkopf homolog 1 (DKK1). RANKL is a ligand 
essential to differentiation of the bone-degrading osteoclasts, while OPG can hinder 
this by competitive binding of RANKL. DKK1 inhibits activation of the bone-
forming osteoblasts. In addition, toll-like receptors (TLRs) are believed to be central 
in RA. TLRs bind pathogen associated molecular patterns (PAMPs), but also damage 
associated molecular patterns (DAMPs) found on molecules present in inflamed 
joints. TLR ligand binding activates production of pro-inflammatory mediators. 
 
The exact events and pathways involved in RA are not fully understood. By using the 
synovial fibroblast (SF) cell line, SW982, as a model for synovitis, this master’s 
thesis aims to clarify certain signaling events. More specifically, the potential 
involvement of phospholipase A2 (PLA2) and cyclooxygenase (COX) in expression of 
bone remodeling genes, in response to TLR agonists and tumor necrosis factor (TNF)-
α, was investigated. A known downstream effect of TLR activation is production of 
the pro-inflammatory cytokine TNF-α. Consequently, TNF-α’s effect on the TLR 
expression was also studied.  
 
Gene expression analysis, by quantitative polymerase chain reaction (qPCR), revealed 
that the SW982 cells express OPG and DKK1, and probably RANKL. In addition, the 
cells express TLR1-6, and possibly TLR7 too. It was shown, for the first time, that a 
TLR1/2 agonist (Pam3CSK4), a TLR2/6 agonist (FSL-1), and a TLR3 agonist  
(Poly(I:C)), increase the OPG and DKK1 gene expression in SW982 cells. The OPG 
mRNA increase was also detected at protein level by performing enzyme-linked 
immunosorbent assay (ELISA). Furthermore, activation of TLR1/2 and TLR2/6 was 
found to strongly induce IL-6 and COX-2 gene expression. It was discovered that 
cPLA2 and COX are involved in TLR1/2-mediated induction of DKK1, IL-6 and 
COX-2 gene expression, and possibly OPG expression. For the TLR2/6-mediated 
expression of these genes, the involvement of cPLA2 and COX is not as pronounced 
as for TLR1/2, but still likely. Altogether, these results indicate that the prostaglandin 
(PG) pathway is triggered upon TLR activation. Besides affecting the mentioned 
genes, this will lead to increased production of PGs. Prominent PG production is often 
observed in inflammatory conditions like RA.  
 
The activity of PLA2s in response to TLR agonists was studied by radioactivity 
assays. Activation of TLR1/2, TLR2/6 and TLR3 was found to increase the release of 
the inflammatory intermediate arachidonic acid (AA) – the first precursor of PG 
synthesis. Further assays suggested that the GIVA cPLA2 is the main PLA2 
responsible for the increase in AA release, with possible involvement of Ca2+-
independent PLA2 (iPLA2).  
 
Upon investigation of TNF-α’s effects, it was found that the SW982 cells increase 
their DKK1, TLR2 and TLR3 gene expression. The no-response results for RANKL, 
OPG, TLR1, and TLR4-7, and the no-response results regarding cPLA2’s 
involvement, were inconclusive due to non-optimal TNF-α stimulation.  
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In conclusion, even though the bone-protective OPG is up-regulated by TLR 
activation, this activation may have more negative effects in the context of RA: 
DKK1, COX-2, IL-6 and AA release are increased, and these are all contributors of 
joint destruction in RA. In addition, OPG may also exert a negative effect. The 
protein can prevent apoptosis of SFs and thereby contribute to synovial hyperplasia. 
Because cPLA2 seems to be involved in the increase of the mentioned components, 
the enzyme may be an attractive target for reducing inflammatory responses set off by 
TLRs.  
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Sammendrag 
Revmatoid artritt (RA) er en kronisk, autoimmun leddsykdom karakterisert ved 
massiv immuncelle-infiltrasjon og hyperplasi av synovialhinnen. Dette fører til 
synovitt, dvs. betennelse i synovialmembranen, og bentap. Det er kjent at visse 
benutformingskomponenter er viktige i RA-patogenesen, nemlig reseptoraktivator av 
nukleær faktor-κB-ligand (RANKL), osteoprotegerin (OPG) og dickkopf-homolog 1 
(DKK1). RANKL er nødvendig for differensiering av bennedbrytende osteoklaster, 
mens OPG kan forhindre dette ved konkurrerende binding av RANKL. DKK1 
hemmer aktivering av bendannende osteoblaster. I tillegg er Toll-lignende reseptorer 
(TLRer) også sentrale i RA. TLRer binder til patogen-assosierte molekylære mønstre 
(PAMPer), men kan også binde til skade-assosierte molekylære mønstre (DAMPer) 
som finnes på visse molekyler i betente ledd. TLR-ligandbinding aktiverer produksjon 
av proinflammatoriske faktorer. 
 
De eksakte hendelsene og signalsporene involvert i RA er ikke fullsteding kjent. Ved 
å bruke synovial fibroblast (SF) -cellelinjen, SW982, som modell for synovitt har 
denne masteroppgaven som mål å avklare enkelte signaleringshendelser. Det ble 
undersøkt om fosfolipase A2 (PLA2) og syklooksygenase (COX) er medansvarlige for 
uttrykk av benutformingsgener ved respons på TLR-agonister eller 
tumornekrosefaktor (TNF) -α. Produksjon av det proinflammatoriske cytokinet TNF-
α er en kjent nedstrøms konsekvens av TLR-aktivering. Derfor ble det også undersøkt 
om TNF-α hadde innvirkning på TLR-uttrykk. 
 
Genuttrykksanalyse, gjort ved hjelp av kvantitativ polymerase kjedereaksjon (qPCR), 
viste at SW982-celler uttrykker OPG og DKK1, og sannsynligvis RANKL. I tillegg 
uttrykker cellene TLR1-6, og trolig også TLR7. For første gang ble det vist at en 
TLR1/2-agonist (Pam3CSK4), en TLR2/6-agonist (FSL-1), og en TLR3-agonist 
(Poly(I:C)) resulterer i økt OPG- og DKK1-genuttrykk i SW982-celler. Økningen av 
OPG på mRNA-nivå ble også funnet på protein-nivå ved å utføre enzymkoblet 
immunabsorbsjonsanalyse (ELISA). Videre ble det påvist at aktivering av TLR1/2 og 
TLR2/6 induserer IL-6- og COX-2-genuttrykk i stor grad. Det ble også funnet ut at 
cPLA2 og COX er involvert i TLR1/2-mediert induksjon av DKK1-, IL-6- og COX-
2-genuttrykk, og muligens OPG-uttrykk. For TLR2/6-mediert uttrykk av disse genene 
er ikke medvirkningen til cPLA2 og COX like tydelig, men likevel sannsynlig. Disse 
resultatene indikerer at prostaglandin (PG)-signalsporet aktiveres ved TLR-
signalisering. I tillegg til å påvirke de nevnte genene vil dette føre til økt produksjon 
av PGer, noe som ofte forekommer ved inflammatoriske sykdommer som RA. 
 
Aktiviteten til PLA2-enzymer ved respons på TLR-agonister ble undersøkt ved hjelp 
av radioaktivitetsanalyser. TLR1/2-, TLR2/6- og TLR3-aktivering førte til økt 
frigjøring av den inflammatoriske komponenten arakidonsyre (AA) - den første 
forløperen i syntese av PGer. Ytterligere analyser antydet at GIVA cPLA2 er 
hovedansvarlig for den økte AA-frigjøringen, med mulig medvirkning av Ca2+-
uavhengig PLA2 (iPLA2). 
 
Det ble funnet at SW982-cellene øker sitt DKK1-, TLR2- og TLR3-genuttrykk etter 
TNF-α-stimulering. Det at ingen induksjon ble detektert for RANKL, OPG, TLR1, og 
TLR4-7, og likeså den manglende responsen i forhold til cPLA2s medvirkning, 
gjenspeiler muligens ikke realiteten. Dette fordi TNF-α-stimuleringen i disse 
forsøkene ikke var optimal. 
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Selv om ben-beskyttende OPG oppreguleres ved TLR-aktivering, ser det ut til at 
aktiveringen vil kunne ha flere negative konsekvenser i en RA-sammenheng: Nivåene 
av DKK1, COX-2, IL-6 og AA-frigjøring er også forhøyet, og disse bidrar alle til 
leddødeleggelse i RA. OPG kan i tillegg ha negativ virkning. Proteinet kan nemlig 
forhindre apoptose av SFer og dermed bidra til synovial hyperplasi. Ettersom cPLA2 
synes å være involvert i økningen av de nevnte komponentene, kan dette enzymet 
være et attraktivt mål for å redusere inflammatoriske responser som utløses av TLRer. 
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1. INTRODUCTION 	  
1.1 The pathogenesis of rheumatoid arthritis 
About 0.5-1% of the population in the industrialised world is affected with 
rheumatoid arthritis (RA), which is the most common chronic joint disease [1]. This is 
an autoimmune disease, meaning that the immune system is activated by self-
molecules. RA is not caused by one specific event, but rather by a complex interplay 
of certain genotypes, environmental triggers, and chance. For example, several RA 
risk alleles have been identified, and smoking and infectious agents have been linked 
to the disease. Moreover, women have a greater risk of developing RA than men [2]. 
The disease can appear at any age, but most commonly affects people in their forties 
to sixties [3]. 
 
The most common joints attacked in RA patients are those of hands, feet and knees 
[3]. The joints acquire a characteristic synovitis, which is inflammation of the 
synovial membrane. The synovitis has a special tendency to invade cartilage and 
articular bone – the formation of a so-called pannus. The pannus consists of immune 
cells, blood vessels and fibrous cells [4].  The pannus invades both cartilage and bone, 
comparable with the behaviour of an invasive tumour [5]. Joint pain, stiffness, and 
swelling are some of the perceptible symptoms of RA. The disease causes disability 
and without proper treatment the outcome can be premature death [1, 4]. The saying 
“misfortunes never come singly” also applies to RA. Several co-morbid conditions 
are identified. Some of the major ones are cardiovascular disease, infection, 
lymphoproliferative malignancy, gastrointestinal disease, and osteoporosis [6]. 	  
1.1.1 The innate immune system signals to the adaptive immune system 
The sequence of the disease events of RA is not fully elucidated. However, a natural 
place to start is with the abundance of immune cells that enter the synovium when a 
joint is affected by RA, as shown in figure 1.1.1 [1]. The entering process is called 
extravasation. It is mediated by special cell adhesion molecules (CAMs) expressed by 
the activated vascular endothelium cells and the corresponding receptors for these 
CAMs on the immune cells. The CAMs are expressed in response to specific 
cytokines produced in inflammatory responses [7]. Cells of the innate immune 
system, such as dendritic cells and macrophages, express pattern recognition receptors 
(PRRs). Toll-like receptors (TLRs) are examples of PRRs, which recognize specific 
pathogen associated molecular patterns (PAMPs). Recently, it has been discovered 
that the TLRs also can detect endogenous molecules; so-called damage associated 
molecular patterns (DAMPs) [8]. A more detailed description of the TLRs and their 
involvement in RA can be found in section 1.3.  
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A cell becomes activated when TLR bind its ligand, and the cell will then send the 
message further on to the adaptive immune system. Some of the immune cells bearing 
TLRs are professional antigen-presenting cells (APCs), such as the dendritic cells and 
macrophages. When activated, these cells will take up and present RA antigens, via 
their membrane bound class II major histocompatibility complex (MHC) molecules, 
to T cells. The interaction of the T cell receptor with the presented antigen is the first 
requirement for T cell activation. The second requirement is the binding of a co-
stimulatory ligand, either cluster of differentiation (CD) 80 or CD86, on an APC to 
the CD28 receptor on the T cell. This will fully activate the T cell to start producing 
various cytokines. Secretion of cytokines like interleukin (IL)-2 and interferon (IFN)-
γ causes the activated T cell to proliferate and differentiate into memory or effector T 
cell populations [1]. A subset of T cells, called regulatory T cells (Treg), function as a 
control of T cell activation by suppression. In RA, it is found that these regulatory 
cells have reduced function [1, 4].  
The effector T cells in RA synovium are mostly of the T helper 1 (Th1) subset. The 
Th1 cells induce activation of macrophages, B cells, fibroblasts, and osteoclasts. B 
cells express membrane-bound immunoglobulins (Igs), which are molecules that bind 
antigens. Antigen binding by the Igs leads to increased expression of class II MHC 
molecules with bound antigen, and the B cells thus act as APCs to the Th1 cells. At 
the same time, the CD40 receptor on the B cells interacts with the CD40 ligand on the 
Th1s leading to activation of the B cells. Because the B cell also function as an APC 
to activate T cells, this can initiate a vicious cycle that keeps the autoimmune 
response going. When activated, B cells will start their differentiation into antibody 
© 2003 Nature Publishing Group
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The reason for the joint-specific localization of the
ensuing immuno-inflammatory response is also
unknown. It could result from an arthrotropism of the
trigger, cross-reactivity of the trigger or its products with
structures primarily present in the joint tissues, or acti-
vation of other mechanisms that lead to homing of
involved cells to the joint. The products of such foreign
agent(s) could activate the innate immune system by
binding to Toll-like receptors (TLRs)13 or CD14 (REF. 14),
and subsequently triggering a T-cell response. T cells
undergo polarization into either TH1 or TH2 cells
15,
which can be mutually inhibitory. TH2 cells are induced
by interleukin-4 (IL-4), whereas IL-12 is the strongest
TH1-inducing cytokine. TH1 cells mainly secrete inter-
feron-γ (IFN-γ) and tumour-necrosis factor-β (TNF-β);
TH2 cells produce IL-4, IL-5, IL-13 and IL-10. The polar-
ity of TH cells is decisive for the type of B-cell activation.
TH1 cells exert pro-inflammatory activities and promote
certain humoral responses, whereas TH2 cells have anti-
inflammatory potential and promote other types of
humoral responses, including immunoglobulin (Ig) E
production. In this context, it is important to bear in
mind that RA is regarded as an autoimmune disease16. In
particular, there is a strong association between RA and
several types of autoantibodies17; the longest known and
most important is rheumatoid factor (RF), which
is directed against the Fc fragment of IgG. Aside from
RF, responses to other autoantigens occur very com-
monly, both at the B- and T-cell level18,19. Whether such
autoantigens initiate the T-cell activation cascade and
the consequent inflammatory changes, or step in at a
later point in time to bolster and/or perpetuate the
process, is unknown. The potential role of autoimmune
responses in the chronicity and destructiveness of the
disease will be discussed later.
RA has a polygenic basis20, although the genes
involved have not yet been defined. So, it is assumed
that, in a genetically predisposed host, TH1 cells become
activated by arthritogenic antigen(s) in conjunction
with co-stimulatory signals and an appropriate cytokine
environment (FIG. 2). The earliest event(s) might involve
activation of the innate immune response, such as the
triggering of dendritic cells (DCs) through TLRs (several
of which are known to be expressed on synovial cells) by
exogenous material or by a combination of such foreign
stimuli together with autologous antigens, before or in
parallel to T-cell involvement.
The T cells infiltrating the synovial membrane are
primarily CD4+ memory cells, which produce IL-2 and
IFN-γ to a similar extent as antigen-triggered T cells18,21
and so clearly have a TH1 bias
22–24. This polarity of the
T-cell response in RA is further supported by a vast pre-
ponderance of TH1 T-cell clones derived from RA
patients18,25,26 and by the presence of a milieu favouring
the generation of myeloid DCs that preferentially activate
TH1 cells
27. These T cells, by cell–cell contact — for
example, through CD11- and CD69-mediation28,29 —
and activation by different cytokines, such as IFN-γ,
TNF-α and IL-17, activate monocytes, macrophages and
synovial fibroblasts30–33 (FIG. 2). These latter cells then over-
produce pro-inflammatory cytokines — mainly TNF-α,
Figure 1 | Schematic view of a normal joint and its changes in rheumatoid arthritis.
a | T e synovial joint is composed of two adjacent bo y ends each cover d wi h a lay r of cartilage,
separated by a joint space and surrounded by the synovial membrane and joint capsule. The
synovial membrane is normally <100  µm thick and the synovial lining (facing the cartilage and bone)
consists of a thin (1–3 cells) layer of synoviocytes (type A are macrophage derived, and type B are
fibroblast derived); there is o basement membrane. Only a few, if any, mononuclear cells are
interspersed in the sublining connective tissue layer, which has considerable vascularity. The synovial
membrane covers all intra-articular structures except for cartilage and small areas of exposed bone
(‘bare areas’) and inserts near the cartilage–bone junction. The ‘radiographic joint space’ (seen in c,
which shows a radiograph of the second, third and fourth metacarpophalangeal joints in a normal
hand), in contrast to the usually minute ‘anatomic j int space’, consists of the latter, as we l as of the
two neighbouring, radiotranslucent portions of cartilage covering the non-translucent subchondral
bone. b | Like many other forms of arthritis, rheumatoid arthritis (RA) is initially characterized by an
inflammatory response of the synovial membrane (‘synovitis’) that is conveyed by a transendothelial
influx and/or local activation of a variety of mononu l ar cells, such a  T cells, B cells, plasma
cells, dendritic cells, macrophages, mast cells, as well as by new vessel formation. The lymphoid
infiltrate can be diffuse or, commonly, form lymphoid-follicle-like structures. The lining layer
becomes hyperplastic (it can have a thickness of >20 cells) and the synovial membrane expands
and forms villi. However, in addition, the hallmark of RA is bone destruction (seen in d, which shows
three metacarpophalangeal joints from a hand radiograph of a patient with established RA: the joint
spaces have narrowed or disappeared as a sign of cartilage degradation and destructions of the
adjacent bone, also termed ‘erosions’, have occurred). The destructive portion of the synovial
membrane is termed ‘pannus’, and the destructive cellular element is the osteoclast; destruction
mostly starts at the cartilage–bone–synovial membrane junction. Bone repair by osteoblasts
usually does not occur in active RA. Polymorphonuclear leukocytes are found in high numbers in
the joint fluid, but very rarely are seen in the synovial membrane, suggesting very rapid
transgression from blood to the joint space. The neutrophils’ enzymes, together with enzymes
secreted by synoviocytes and chondrocytes, lead to cartilage degradation.
Figure 1.1.1 The differences between a) a normal joint and b) a RA affected joint [3]. 
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secreting plasma cells. The secretion includes autoantibodies, such as rheumatoid 
factor (RF; autoantibody to IgG), autoantibody to RA antigen of 33 kDa (anti-RA33), 
and autoantibody to endogenous citrullinated peptides (anti-CP) like vimentin or 
fibrinogen [1]. RFs are reactive with the Fc region of the IgG and can form immune 
complexes by binding to normal circulating IgGs. These complexes can activate the 
complement system leading to an inflammatory response called type III 
hypersensitivity, which is mediated by massive infiltration of neutrophils. In addition, 
the autoantibodies can bind to Fc receptors (FcRs) on e.g. macrophages, causing 
increased production of pro-inflammatory cytokines, such as tumor necrosis factor 
(TNF) [1, 7]. The events of RA pathogenesis are graphically summarized in figure 
1.1.2. 
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T cells in the synovial membrane usually belong to the 
T-helper 1 subset. T-cell upregulation is associated with 
secretion of various lymphokines such as interleukin 2 
and interferon γ. These stimulated T-cells induce 
activation of macrophages, B cells, fi broblasts, and 
osteoclasts.10,11 B lymphocytes express various cell-surface 
molecules, especially their antigen receptor, immuno-
globulin, and diﬀ erentiation antigens, such as CD20 
and CD22. They diﬀ erentiate into plasma cells that 
secrete antibodies, including autoantibodies, for 
example, to IgG (rheumatoid factor), to citrullainated 
peptides such as vimentin, fi brinogen, or cyclic 
citrullinated peptide, or to rheumatoid arthritis antigen 
of 33 kDa (RA33).12 Autoantibodies can form immune 
complexes that reinforce production of proinfl ammatory 
cytokines such as tumour necrosis factor  (TNF) via 
complement and Fc-receptor activation;13 presence of 
autoantibodies is associated with severe rheumatoid 
arthritis.14,15 Activated B cells also serve as APCs,16 leading 
to T-cell activation and potentially to a vicious cycle and 
perpetuation of the (auto)immune response.17,18 B-cell 
survival and activation, including production of specifi c 
immunoglubulin isotypes, is mediated by T-cell help 
and co-stimulation, and by B-lymphocyte stimulator 
expressed on macrophages binding to one of its 
receptors on B cells, such as TACI. Another newly 
licensed agent for rheumatoid arthritis—rituximab—is 
a monoclonal antibody against CD20 that targets and 
depletes B cells. 
Within the rheumatoid arthritis synovial membrane, 
various other cell populations accumulate via activated 
endothelial cells (fi gure 1). Besides the traditional cell 
populations of the innate and adaptive immune system, 
neovascularisation takes place and there is a large increase 
in fi broblast-like synoviocytes, which are highly activated 
and produce cytokines (partly in an autocrine fashion), 
infl ammatory mediators such as prostaglandins, and 
matrix metalloproteinases.19,20 By secretion of matrix 
metalloproteinases into the synovial fl uid, but possibly also 
by direct invasion, fi broblast-like synoviocytes can destroy 
cartilage and assist in bone destruction.21,22 However, 
erosions of bony tissue happen mainly via activation of 
osteoclasts by virtue of their bone-resorbing machinery 
including cathepsin K. Osteoclasts are derived from 
monocytes and macrophages and diﬀ erentiate within the 
synovial membrane.23,24
Many cytokines are activated in the synovium by 
various cell populations, several of them secreted by 
macrophage-like cells (fi gure 1).25–32 They include TNF 
and interleukin 1, which constitute the therapeutic 
targets of several compounds for rheumatoid arthritis—
licensed over the past few years—that directly inhibit 
these infl ammatory mediators or interfere with their 
receptor binding, or both. Another proinfl ammatory 
cytokine, interleukin 6, which can be induced by both 
TNF and interleukin 1, has been the focus of much 
interest. This cytokine could have various important 
activities in the context of pathogenesis of rheumatoid 
arthritis: it induces antibody production by B cells; it 
activates T cells, macrophages, and osteoclasts; and it is 
a major activator of the hepatic acute-phase response.29 
The actions of interleukin 6 are targeted by tocilizumab, 
a monoclonal antibody to the interleukin 6 receptor. 
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Figure 1: Current views on pathogenesis of rheumatoid arthritis
Arrows show some of many interactions in rheumatoid arthritis pathogenesis. Schematic depiction of events 
presumably occurring in synovial membrane, as well as articular cartilage and subchondral bone, which are 
surrounded by aggressive rheumatoid synovitis. Blys=B lymphocyte stimulator. C’=complement. CP=citrullinated 
peptide. CR=complement receptor. FcR=receptor for the Fc portion of IgG. IC= immune complex. IFN=interferon. 
IFN1=type 1 interferons. IL=interleukin. RF=rheumatoid factor. TACI=transmembrane activator and calcium-
modulator and cyclophilin ligand interactor. TCR=T-cell receptor. Th1=T-helper 1 cell. TLR=Toll-like receptor. 
Treg=regulatory T cell. 
  Figure 1.1.2 An overview of the events in RA pathogenesis [1]. anti-CP, autoantibody to endogenous 
citrullinated peptides; ti-RA33, autoantibody to RA antigen f 33 kDa; APC, antigen-pres nti g cell;  
Blys, B lymphocyte stimulator; C’, complement; CD, luster of differentiation; CR, complement receptor; 
FcR, rec ptor for the Fc portion of IgG; IC, immune complex; IFN, interfer n; IL, interleukin; MHC II, 
major histo o atibility complex class II; RANK, receptor activator of nuclear factor-κB; RANKL, 
receptor activator of nuclear factor-κB ligand; RF, rheumatoid factor; TACI, transmembrane activator and 
calcium-modulator and cyclophilin ligand interactor; TCR, T cell receptor; Th1, T helper 1 cell; TLR, Toll-
like receptor; TNF, tumor necrosis factor; Treg, regulatory T cell 
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Except from the antibodies being self-reactive, all the processes described above take 
place in a normal inflammatory response initiated to destroy and eliminate invading 
pathogens. This response will eventually come to an end when the mission is 
accomplished. However, in RA the immune response persists and becomes chronic 
[9]. 
1.1.2 Synovial fibroblasts are key players in RA 
Beside the already mentioned immunocompetent cells, synovial fibroblasts (SFs) are 
also known to accumulate in the synovium. SFs are often accused of being the key 
effector cells in RA [1, 5]. In a normal joint, the synovial membrane is about 1-2 cells 
deep and consists of two synoviocyte types; type A and type B. Type A are 
macrophage-like synovial cells and type B are the SFs. In a RA synovial membrane, 
however, the amount of both cell types increases significantly, as shown in figure 
1.1.1. The lining can expand to a depth of 10-20 cells. What triggers this expansion of 
the synoviocyte population is not fully elucidated. It is likely to be caused by an 
imbalance between cell proliferation, survival, and death. The environment in a RA 
synovium seems to prevent apoptosis of SFs and favor their survival [5]. 
The expanded macrophage-like cell population in the synovium becomes highly 
activated. This leads to production of an abundance of cytokines, chemokines, and 
growth factors, which further activate the SFs. Activated SFs also secrete a number of 
inflammatory mediators, such as cytokines (especially IL-6), chemokines, 
prostanoids, and matrix metalloproteinases (MMPs). These compounds act in a 
paracrine and/or autocrine fashion, and in this way they perpetuate the synovitis and 
attract new immune cells [5, 10]. In addition, the cytokines also stimulate the 
chondrocytes, which subsequently secrete MMPs. The MMP enzymes contribute to 
destruction of cartilage [11]. 
Since SFs in RA synovium express high levels of class II MHC molecules, it has been 
reasoned that these cells also act as APCs for the T cells. However, studies have 
shown that the SFs are not as efficient in taking up and presenting antigens as the 
professional APCs. Still, it is of interest to evaluate their role in autoimmunity as non-
professional APCs [10]. 
RA originates in a few joints, but it is progressive and can spread to several joints. 
Studies have shown that the cells responsible for this spreading are the SFs. Using 
severe combined immunodeficient (SCID) mouse models it was demonstrated that 
human RA SFs could attach to and invade distant cartilage of unaffected joints after 
migrating through the bloodstream [12]. 
1.1.3 Bone destruction by osteoclasts 
A cell type called osteoclasts, which differentiate within the synovial membrane from 
monocyte and macrophage precursors, causes the bone erosion observed within joints 
of RA patients [1]. The osteoclasts are an essential part of the normal bone 
metabolism, and they are the primary bone resorbing cells with their two central 
resorbing machineries. These two are the proton/protein pump that acidifies the 
milieu, allowing calcium to get solubilized, and the matrix degrading enzymes like 
MMPs and cathepsins. Because of these inherent properties, the osteoclasts can create 
resorption pits in bone. Normally, the bone synthesizing osteoblasts will fill these pits 
again to maintain bone homeostasis [13]. This balance is disrupted in RA and bone 
degradation is favored, as will be described in further detail in section 1.2.  
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The main requirement for the osteoclast precursors to differentiate into mature 
osteoclasts and to be activated, is that their membrane-bound receptor activator of 
nuclear factor-κB (RANK) must bind the receptor activator of nuclear factor-κB 
ligand (RANKL) [14]. As shown in figure 1.1.2, the cells that stand out by their 
RANKL expression in RA are the activated T cells and SFs [15]. Macrophage colony-
stimulating factor (M-CSF) is also necessary for osteoclast differentiation. Synovial 
mesenchymal cells and T cells secrete M-CSF. Like RANKL, M-CSF binds to its 
receptor on the osteoclast precursors [4]. 
1.1.4 Cytokines  
As they do in all inflammatory responses, cytokines play a major role in RA [1]. The 
cytokines are a part of a complex regulatory network. By binding to their receptors on 
different cells acting in series and in parallel, they contribute to autoimmunity, 
chronic inflammation and tissue destruction in RA [4, 16]. 
 
The cytokines are pleiotropic, meaning that one single cytokine can have several 
effects. They are also redundant. That is, none of the mediated events depend on only 
one cytokine [16]. All the accumulating cells hereto mentioned, secrete various 
cytokines and are affected by them. Only a few selected cytokines will be described 
here to demonstrate their importance. E.g., IL-15 is a major cytokine growth factor for 
synovium T cells. The Th1 subset is an important effector in RA, as previously 
mentioned. A more recent model suggests that IL-17 producing T cells (Th17 cells) 
also are crucial effectors. The differentiation of Th1 and/or Th17 cells are promoted 
by several cytokines derived from macrophages and SFs, such as IL-1β, IL-6, IL-7, 
IL-12, IL-15, IL-18, IL-23p19, and transforming growth factor (TGF) -β. Dendritic 
cells also produce some of these cytokines, and are therefore thought to influence the 
T-cell differentiation [4]. 
 
B cells contribute to RA pathogenesis by producing cytokines like IL-6, IL-10 and 
lymphotoxin (LT) -β. These cytokines participate in events such as activation of 
follicular dendritic cells and in lymphoid regeneration [4]. 
 
The most important cytokine producers in the synovium are the macrophages, which 
are derived from monocytes. TLR ligand binding is likely to be responsible for the 
activation of these cells and their subsequent cytokine production [4]. FcR binding of 
immune complexes can also stimulate monocytes to produce cytokines. Macrophages 
release a range of different cytokines. The pro-inflammatory cytokine TNF is one of 
them, and is considered of primary importance in RA. Studies have shown that TNF 
inhibition suppresses arthritis in different models, and TNF overexpression conduces 
to erosive, inflammatory arthritis. Among the effects of TNF is induction of some of 
the major pathological processes in RA, such as leukocyte and endothelial-cell 
activation, SF activation and survival, pain-receptor sensitization and development of 
new blood vessels (angiogenesis) [4]. Consequently, TNF was considered an 
attractive therapeutic target and the development of TNF inhibitors revolutionized the 
treatment of RA. Although the inhibitors cannot cure the disease, they make it more 
manageable for a majority of patients [17]. IL-1 and IL-6 are also important pro-
inflammatory cytokines derived from macrophages. Both TNF and IL-1 can induce 
IL-6 production. IL-6 contributes to RA through its induction of B cell antibody 
production, T cell, macrophage, and osteoclast activation. It also has an important role 
in activation of the acute-phase response in the liver [1]. On a similar level to TNF 
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inhibition, blockade of the IL-6 receptor is quite effective in reducing bone 
degradation in RA. Other pro-inflammatory cytokines, such as IL-1, IL-15 and IL-17, 
are also subjected as therapeutic targets [18]. 
 
In summary, pro-inflammatory cytokines are central in RA. A direct example is that 
TNF-α, IL-1, IL-6 and IL-17 affect bone erosion by increasing the expression of 
RANKL [13]. In addition, TNF and IL-7 promotes M-CSF production, which, 
together with RANKL, is required for osteoclast differentiation and activation. IL-1β 
also regulates the expression of RANK, and contributes to cartilage degradation 
through matrix synthesis inhibition and induction of matrix-degrading enzymes. IL-17 
induces both TNF and IL-1β expression in SFs, perpetuating the inflammation. 
Moreover, cytokines are likely to play a part in regulation of bone formation. TNF has 
been shown to inhibit differentiation and function of osteoblasts, and to up-regulate 
secretion of dickkopf homolog 1 (DKK1) [4]. The DKK1 protein inhibits bone 
formation, and its involvement in RA is further explained in section 1.2.  
 
A simplified overview of the cytokine-mediated events in the RA synovium is given 
in figure 1.1.3. All the processes presented in the figure are not explained in this 
introductory chapter, due to restriction of what is considered relevant for this master’s 
thesis. The aspects that are elaborated in this introduction are highlighted in red. 
 
  
Figure 1.1.3 A simplified overview of the cytokine-mediated events in the RA synovium [4]. The red highlighting indicates the 
aspects that are described in further detail in this introductory chapter. APRIL, a proliferation inducing ligand; BAFF, B cell activating 
factor; CCL, CC-chemokine ligand; CXCL, CXC-chemokine ligand; DC, dendritic cell; FcR, receptor for the Fc portion of IgG; IFN, 
interferon; IL, interleukin; LT, lymphotoxin; M-CSF, macrophage colony-stimulating factor; RANKL, receptor activator of nuclear 
factor-κB ligand; TGF, transforming growth factor; Th, T helper cell; Th17, IL-17 producing T cells; TLR, Toll-like receptor; TNF, 
tumor necrosis factor 
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Some cytokines can also have anti-inflammatory effects. In RA, these and other 
endogenous anti-inflammatory compounds, like soluble cytokine receptors, enzyme 
inhibitors and receptor antagonists, have insufficient activity to counteract the 
inflammatory response [3]. 
1.1.5 Other important molecules 
There are other important molecules involved in RA, such as chemokines and cell 
adhesion molecules. Both bind to specific receptors and in this way carry out 
functions like cell interactions, migration, and chemoattraction of cells [1]. 
Macrophages and SFs in the synovial lining produce chemokines and other small 
chemoattractant molecules that recruit immune cells, which are essential for synovitis 
development. Most chemokines from the synoviocytes makes immune cells migrate 
into the joint, but some also facilitate angiogenesis. For example IL-8 is a chemokine 
that act both as a potent neutrophil attractant and a stimulator of blood vessel 
formation [5]. 	  
1.2 Key proteins involved in bone remodeling 
Bone remodeling is a process that takes place throughout life. It is essential for 
adapting bone strength, repairing damage, and maintaining blood calcium levels. As 
stated earlier, osteoclasts are the cells responsible for the formation of resorption pits. 
The osteoblasts follow behind, filling in these pits again with new bone matrix, as 
shown in figure 1.2.1. Normally there is a balance between the functions of these two 
cell types, but in RA this balance is disrupted. The inflammatory bone loss observed 
in RA is due to increased activity of osteoclasts and decreased activity of osteoblasts 
[19]. 
1.2.1 RANKL and OPG: inducing or preventing osteoclast activation 
The osteoblasts express a range of characteristic cell membrane molecules. Among 
these are RANKL. RANKL is a cytokine of the TNF superfamily, and exists in a 
soluble form too. As previously mentioned, RANKL binds to RANK on osteoclasts. 
This interaction is essential to osteoclast differentiation and activation. In RA affected 
joints, RANKL is also expressed by SFs and T cells [14, 19]. 
  
Figure 1.2.1 Bone homeostasis is maintained by bone remodeling carried 
out by osteoclasts and osteoblasts [19]. 
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Osteoblasts also produce and secrete a protein called osteoprotegerin (OPG). OPG is a 
part of the TNF superfamily of receptors, and functions as a soluble decoy receptor 
for RANKL. By competitively binding RANKL, OPG prevents osteoclast activation 
and consequently bone resorption [14, 19]. In RA synovium, other cells also express 
OPG, predominantly macrophages and endothelial cells, but there is still an excess of 
RANKL. This imbalance promotes bone loss [20]. In a study done by Feuerherm and 
co-workers, both sera and synovial fluids from RA patients were found to have 
elevated levels of OPG protein [21], whereas other reports show that OPG protein 
levels are down-regulated in RA synovial fluids [22]. These different discoveries may 
reflect the fact that it is the RANKL/OPG ratio that controls bone homeostasis, not 
RANKL or OPG individually. This is supported by the finding that RA patients with 
an active disease have up-regulated expression of both RANKL mRNA and protein in 
the synovial tissue, but reduced levels of OPG protein [23]. Such a microenvironment 
favors osteoclast differentiation and activation [24]. Moreover, it has been found that 
RA tissue express the RANKL protein in all the cells throughout the synovial lining, 
but it is considerably up-regulated at the pannus-bone interface. In contrast, OPG 
protein expression was minimal at this interface. However, cells of the synovial 
membrane not in the vicinity of bone had a higher OPG protein expression [25]. This 
points to the likelihood of RANKL/OPG ratio at the pannus-bone interface being the 
critical factor of the bone erosion in RA [24].  
1.2.2 DKK1: inhibiting osteoblast differentiation 
Among the systems necessary to activate the osteoblasts is the Wingless (WNT)-
Frizzled-β-catenin signaling pathway [24]. WNTs are a group of highly conserved 
glycoproteins, especially secreted in areas of mixed cell populations. Frizzled, 
together with lipoprotein receptor-related proteins (LRPs), form the receptor complex 
that the WNTs bind to. Upon binding, Frizzled passes on the signal to β-catenin, 
which then acts as a transcription factor. It enters the nucleus and, together with co-
activators, it activates transcription of genes involved in osteoblast differentiation. 
[19, 24]. This pathway is demonstrated in figure 1.2.2. A consequence of ongoing 
WNT signaling is increased OPG production, along with decreased RANKL 
expression [26]. In absence of WNT signaling, a complex of proteins degrades β-
catenin and it is no longer available to activate gene transcription [24]. 
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Several endogenous molecules act as inhibitors of the WNT pathway, hence 
restricting osteoblast function. One of them is the previously introduced DKK1. This 
protein is secreted in increased amounts by cytokine-activated cells, but can in general 
be found in normal tissues like the spleen and the skin. The DKK1 works by binding 
to LRP4, LRP5 or LRP6 with assistance from a co-receptor. This complex is 
subsequently endocytosed, and the LRP is no longer accessible to WNT binding on 
the cell surface [19]. It has been found that DKK1 levels are increased in arthritic 
synovial tissues and in blood serum of RA patients [26]. The SFs was especially 
prominent in expressing DKK1 in the synovium. Moreover, TNF induces increased 
DKK1 expression in both mouse and human arthritic SFs. Consequently, the up-
regulated DKK1 levels lead to increased inhibition of WNT signaling and reduced 
osteoblast function. As a result the balance between bone resorption and deposition 
ceases in RA, and it tips towards resorption as shown in figure 1.2.3 [24, 27].  
  
Figure 1.2.3 To the left, the normal balance that exists between bone resorption and deposition is shown. In RA, 
however, increased DKK1 levels due to TNF expression disrupt this balance, and consequently the weight tips toward 
resorption, as shown to the right [27]. Dkk-1; dickkopf homolog 1; OPG, osteoprotegerin; RANKL, receptor activator of 
nuclear factor-κB ligand; TNF, tumor necrosis factor; Wnt, wingless 
!
pro-osteogenic bone morphogenic protein-2 (BMP2) has
been shown to induce Wnt1 and Wnt3a expression in mesen-
chymal stem cell lines and in the preosteoblast cell line
MC3T3-E1, resulting in a feedback loop in which Wnt signal-
ing induces cellular differentiation, accompanied by the
expression of alkaline phosphatase, and subsequent matrix
mineralization (101). Secreted Wnt proteins such as Wnt 3a
bind to and activate specific membrane-bound receptor com-
plexes consisting of the low-density lipoprotein receptor
related protein-5 (LRP-5) and LRP-6 and a member of the G-
protein-coupled receptor family of frizzled proteins. Loss-of-
function mutations in the Lrp5 gene have been shown in both
mice and humans to result in a decrease in bone formation
and associated low bone mass (102). Conversely, in humans,
gain-of-function mutations in the Lrp5 gene lead to increased
bone mass (103).
b-catenin is an important regulator of canonical Wnt signal-
ing. In the absence of Wnt ligand binding, b-catenin is
sequestered by a protein complex consisting of axin, dishev-
eled (Dsh), and glycogen synthase kinase-3b (GSK-3b).
b-catenin is phosphorylated by GSK-3b and targeted for deg-
radation. Alternatively, when Wnt ligands engage the corecep-
tor complex, there is phosphorylation of disheveled and axin,
leading to inhibition of GSK-3b activity and the release of
b-catenin, which translocates to the nucleus. There it interacts
with the transcription factors T-cell factor or lymphoid enhan-
cer-binding factor-1 and induces transcription of Wnt target
genes (reviewed in 104)(Fig. 1A).
Modulation of b-catenin expression or its signaling activity
not only regulates bone formation but also bone resorption.
Inhibition of GSK-3b activity using a small molecule inhibitor
in the mouse mesenchymal cell line C3H10T1 ⁄2 activated
Wnt signaling (mediated by b-catenin) and resulted in
enhanced osteoblast differentiation. When administered to
ovariectomized rats, this GSK-3b inhibitor increased markers
of bone formation in bone tissue and resulted in increased
bone mineral density in mice treated with the inhibitor com-
pared with vehicle-treated control mice (105). Further evi-
dence for a critical role of b-catenin in bone remodeling
comes from studies in genetically altered mice deficient in
b-catenin expression in differentiated osteoblasts. These mice
are characterized by severe osteopenia attributed primarily
to an increase in osteoclast numbers due to increased RANKL:
OPG expression ratios (106, 107). Conversely, activation of
b-catenin-mediated Wnt signaling in differentiated osteoblasts
led to increased bone mass in vivo, associated with increased
osteoblast expression of OPG (106–108). The phenotype of
osteoblasts deficient in b-catenin signaling is reminiscent
of the osteoblast phenotype observed at sites of focal bone
erosion in inflammatory arthritis, suggesting that inhibition
A B
Fig. 1. Schematic of the Wnt signaling pathways. (A) Canonical Wnt signaling. Activated Wnt Signaling: Wnts binding Frizzled ⁄ LRP5 ⁄ 6 receptors
induce phosphorylation of Dishevelled (Dsh) and axin leading to inhibition of GSK-3, preventing it from interacting with b-catenin. This allows b-
catenin to translocate to the nucleus to activate gene transcription. Inhibition of Wnt signaling: sFRPs sequester Wnt ligands, preventing them from
interacting with receptor. DKKs or sclerostin bind LRP5 ⁄ 6 preventing interaction with the Frizzled co-receptor. In these settings, GSK-3 phosphorylates
b-catenin, targeting it for degradation. (B) Non-canonical Wnt signaling: Binding of specific Wnt ligands to their Fz ⁄ROR ⁄ RYK co-receptor complexes
can result in signaling via (1) the calcium signaling pathway which leads to activation of nemo-like kinase (NLK) or nuclear factor of activated T cells
(NFAT); or (2) Wnt ⁄ planar cell polarity (PCP) pathway resulting in activation of members of Rho family GTPAases (ROK) or c-jun NH2-terminal
kinase (JNK).
Walsh & Gravallese Æ Bone remodeling in rheumatic disease
306 ! 2009 John Wiley & Sons A/S • Immunological Reviews 233/2010
!
Figure 1.2.2 Signaling of WNT pathway [24]. APC, adenomatous 
polyposis coli gene product; Dsh, disheveled; GSK3, glycogen synthase 
kinase-3; LRP, lipoprotein receptor-related protein; Wnt, Wingless 
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1.3 Toll-like receptors and their role in rheumatoid arthritis 
As previously stated, the TLRs are a part of the innate immune system. Cells like 
fibroblasts, myeloid cells, epithelial and endothelial cells, express these receptors [8]. 
TLRs are single-span transmembrane receptors, and they have their name from the 
homology with the Toll gene in Drosophila melanogaster [28]. Up until now there 
are 14 mammalian TLRs identified, with 10 of them found in humans. Each TLR 
recognize different subsets of highly conserved PAMPs derived from viruses, 
bacteria, protozoa and fungi. Their localization in the cell coincides with the type of 
ligand they recognize [8].  
 
1.3.1 Toll-like receptors on rheumatoid arthritis effector cells 
The key-effector cells of RA, the SFs, are identified as innate immune cells. The 
literature reporting SFs’ TLR expression is not cosistent. There is agreement that SFs 
express TLR1-6 [5], but certain articles also state the presence of TLR7 [8, 29]. When 
the TLRs bind their ligands, the expression of inflammatory mediators like CAMs, 
cytokines, chemokines and MMPs increases [5, 30]. TLR1, TLR2, TLR4, TLR5 and 
TLR6 are found in the plasmamembrane, and thus bind to surface associated PAMPs. 
In contrast, TLR3 and TLR7 are located in endosomal membranes and respond to 
internalized PAMPs [31]. More specifically, TLR1, TLR2 and TLR6 bind bacterial 
lipoproteins, such as peptiodoglycan (PGN). Dimerization of TLR2 with either TLR1 
or TLR6 gives further ligand specificity. Moreover, TLR4 senses bacterial 
lipopolysaccharide (LPS), while TLR5 has the flagellar protein, flagellin, as its 
ligand. The endosomal TLR3 and TLR7 both respond to ribonucleic acid (RNA) from 
viruses. TLR3 recognizes double stranded RNA, whereas TLR7 binds single stranded 
RNA [8, 31]. Table 1.3.1 gives an overview of the TLRs expressed by SFs and the 
PAMPs they recognize. The table includes DAMPs and synthetic agonists, which also 
can activate TLRs. 
 
 
 
 
 
 
 
 
 
 
 
 
	   12 
Table 1.3.1 An overview of the PAMPs and DAMPs the different TLRs recognize, including examples of 
synthetic agonists [32]. 
Receptor PAMPs DAMPs Synthetic agonists 
TLR2 
(dimerization with 
TLR1 or TLR6) 
Bacterial 
lipoproteins 
Heat shock  
proteins 
Pam3CSK4 
(TLR1/TLR2) 
FSL-1 
(TLR2/TLR6) 
TLR3 Viral dsRNA dsRNA from 
necrotic cells 
Poly(I:C) 
TLR4 Bacterial LPS Heat shock 
proteins, fibrinogen 
or hyaluronan 
LPS (natural) 
TLR5 Flagellin - Flagellin (natural) 
 
TLR7 Viral ssRNA - Imidazoquinolines 
 
 
 
The SFs are reported to have especially high levels of functional TLR2, TLR3, and 
TLR4 [5]. There are data suggesting that ligand binding by these TLRs leads to 
increased RANKL expression by RA SFs, and thus enabling osteoclast differentiation 
[15, 33]. Moreover, studies have shown that RA SFs highly express TLR3 and TLR4 
[34], and these cells have especially high levels of TLR2 where cartilage and bone 
destruction occurs [35]. When compared to non-inflammatory cells, TLR2, TLR3 and 
TLR7 are found to be significantly elevated in RA SFs [8]. Furthermore, 
macrophages in the synovial tissue show increased expression of TLR2 and TLR4 in 
RA [9]. 
Early analysis of RA synovial tissue showed presence of PGN, bacterial 
deoxyribonucleic acid (DNA), and viral DNA [36, 37]. It was therefore hypothesized 
that infection may be the underlying reason for RA development. Due to the fact that 
healthy joints were found to have comparable levels of pathogenic molecules [38], 
this remains a highly debated hypothesis.  
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1.3.2 Toll-like receptors and endogenous molecules 
As previously mentioned, it has been discovered that TLRs can recognize DAMPs. 
Endogenous molecules that are released during cell necrosis or components of the 
extracellular matrix that are up-regulated after tissue damage, are categorized as 
DAMPs. Upon tissue injury, DAMPs are essential factors necessary to initiate 
inflammatory responses in the absence of infection. Nonetheless, DAMPs have been 
linked to the pathophysiology of inter alia autoimmune diseases [8]. Heat shock 
proteins (HSPs), fibrinogen and hyaluronan are examples of DAMPs that are 
commonly found in inflamed joints. These can bind to TLR2 and TLR4, consequently 
activating cells. The synovial fluid of RA patients has also been shown to contain 
double stranded RNA from necrotic cells, and can activate e.g. RA SFs by binding to 
TLR3 [5]. Studies regarding this topic have shown that activation of TLR3 in RA SFs 
by endogenous RNA from necrotic cells, results in IL-6, IFN-β, and Th1-associated 
chemokine expression [30]. Moreover, evidence points towards DAMPs having 
different ways of activating TLRs and different resulting immune responses than 
PAMPs [8]. Endogenous TLR ligands are, as indicated, released due to the 
inflammatory response in RA. The ligands may be some of the contributing factors in 
perpetuating the disease, as demonstrated in figure 1.3.1 [9]. 
 
 	  	  	  
  
Figure 1.3.1 A proposed connection between the processes and 
molecules involved in RA pathogenesis. It is likely that endogenous 
TLR ligands and immune complexes are the main factors driving the 
self-perpetuating inflammatory response [9]. DAMP, damage associated 
molecular pattern; FcR, receptor for the Fc portion of IgG; gp96, 
endoplasmic reticulum stress response protein; NLR, Nod-like receptor; 
PAMP, pathogen associated molecular pattern; TLR, Toll-like receptor  	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mediated by the recruitment of FADD [32]. Additionally, 
cross-regulation mediated through immunoreceptor tyro-
sine-based activation motives, such as Fc-J receptors by 
immune complexes present in the RA joint, may enhance 
or suppress TLR signaling, depending upon the intensity 
of the signaling [33•]. Thus, cross-regulation of TLR acti-
vation, which occurs within the RA joint, offers potential 
novel mechanisms to modulate TLR signaling. 
TLR activation has also been shown to induce a num-
ber of pathways that suppress TLR activation, which may 
also be harnessed to suppress TLR signaling. These path-
ways include the induction of A20 that suppresses NF-NB 
activation [34], ATF3 that attenuates activation by NF-NB 
and C/EBPG [35], and induction of the microRNA miR-
9, which is induced by TLR2 and TLR7/8 agonists and 
provides feedback suppression of NF-NB activation [36]. 
A20 is particularly interesting because mice de! cient in 
A20 develop a lethal in" ammatory response that is medi-
ated by the inability to suppress the in" ammation induced 
by commensal microbial " ora [34]. Further studies will 
be required to determine if the expression of A20 in the 
RA joint is reduced, and if this might contribute to the 
increased response of RA synovial macrophages to TLR2 
and TLR4 ligands [9•]. Therefore, TLR signaling, not 
only generates proin" ammatory mediators, but at the 
same time generates self-regulating signals to suppress 
activation (Fig. 1), which may potentially be excellent 
therapeutic targets for RA.
Overview of the Role of TLRs in RA
Endogenous TLR ligands are expressed and released as 
a result of the in" ammation in early RA and may con-
tribute to persistent, destructive disease (Fig. 2). In shared 
epitope–positive individuals, the initial insult may be 
the result of immune complexes containing anti–cyclic 
citrullinated peptides. The pathogenic immune com-
plexes providing the initial danger signal, together with 
the released endogenous TLR ligands, such as gp96, may 
result in a self-perpetuating in" ammatory process, driven 
by the persistent expression of macrophage-related cyto-
kines, such as TNF-D and IL-6. Nonapoptotic Fas-FasL 
signaling may lower the threshold for the activation of 
synovial macrophages, and possibly synovial ! broblasts, 
sensitizing them to activation by the endogenous TLR 
ligands, thereby promoting the development of chronic, 
persistent disease. The release of low levels of IFN-Dmay 
further sensitize the synovial macrophages to activation 
by endogenous TLR ligands. Thus, the local environment 
of the RA joint may provide the milieu for the perfect 
storm of chronic in" ammation.
TLRs Contribute to the Pathogenesis of 
Experimental Models of RA
Various experimental models of RA have been employed 
that contribute to our understanding of how TLRs might 
be involved in the pathogenesis of RA.
Streptococcal cell wall model 
To examine the role of TLR ligands in experimental 
arthritis, streptococcal cell wall (SCW)–induced arthritis 
was examined. A single SCW injection into murine joints 
resulted in joint in" ammation mediated through TLR2 
and MyD88 [37]. Repeated intraarticular SCW injec-
tions resulted in chronic destructive arthritis mediated in 
the late stages through TLR4 [38]. TLR4 was important 
in the destructive phase, and it contributed to matrix 
metalloproteinase–mediated cartilage damage and osteo-
clast formation [39]. Therefore, in this model of chronic 
arthritis, TLR2 was necessary initially and TLR4 was 
important later in the disease, suggesting that endogenous 
TLR4 ligands may contribute to the destructive phase.
Collagen-induced arthritis
Collagen-induced arthritis (CIA) is induced in susceptible 
mice following immunization with type II collagen and 
Figure 2. U ifying hypothesis f endogenous Toll-like receptor 
(TLR) ligands in the pathogenesis of rheumatoid arthritis (RA). 
The exposure of genetically susceptible individuals to an envi-
ronmental stimulus, such as smoking, may result in the activation 
of the innate and adaptive immune systems followed by infl am-
mation. Endogenous TLR ligands (eg, glucoprotein 96 [gp96]) are 
expressed and released as a result of the infl ammation. Other 
components released may also serve as autoantigens resulting 
in the formation of both pathogenic immune complexes and 
endogenous TLR ligands, capable of inducing a self-perpetuat-
ing infl ammatory process, driving the persistent expression of 
macrophage-related cytokines and chemokines, which play an 
important role in the pathogenesis of RA. DAMPs—danger-associ-
ated molecular patterns; FcRc—Fc receptor common c-chain; 
NLRs—nucleotide-binding oligomerization domain-like receptor; 
PAMPs—pathogen-associated molecular patterns. 
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1.3.3 The signaling of Toll-like receptors 
All the mammalian TLRs have a common structure, with amino-terminal leucine-rich 
repeats as ligand binding domain and a carboxy-terminal Toll/IL-1 receptor (TIR) 
homology domain conveying the signal. When a ligand binds, conformational 
changes in the TLRs lead to activation of a signaling cascade resulting in transcription 
of genes involved in inflammatory responses initiated to destroy the recognized 
invaders [8, 31]. As shown in figure 1.3.2, different TLRs activate different signaling 
cascades. Most of them utilize the myeloid differentiation primary-response protein-
88 (MyD88)-dependent pathway that activates nuclear factor-κB (NF-κB) and 
mitogen-activated protein kinases (MAPKs). This activation ultimately leads to the 
production of cytokines and other inflammatory mediators. In contrast to the other 
TLRs, TLR3 uses a MyD88-independent pathway, which TLR4 also is able to 
employ. This pathway results in expression of another set of genes via the 
transcription factor interferon regulatory factor-3 (IRF3). The genes activated by 
IRF3, such as IFN-α and IFN-β, are involved in inducing an anti-viral state in the cell 
[9, 31]. 	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Figure 1.3.2 A simplified illustration of the signaling cascades set off by the different TLRs upon ligand binding 
[8]. AP, activating protein; CD, cluster of differentiation; ERK, extracellular-signal regulated kinase; IFN, 
interferon; IKK, I-kappa B kinase; IκBα, inhibitor of NF-κB; IRAK, interleukin-1 receptor-associated kinase; IRF, 
interferon regulatory factor; JNK, c-jun N-terminal kinase; MAP, mitogen-activated protein; MD, myeloid 
differentiation protein; MyD88, myeloid differentiation primary-response protein-88; NF-κB, nuclear factor-κB; 
TBK, TANK-binding kinase; TIRAP, TIR domain-containing adaptor protein; TLR, Toll-like receptor; TRAF, 
TNF-α receptor-associated factor; TRAM, TRIF-related adaptor molecule; TRIF, TIR domain-containing adaptor-
inducing IFN- β 
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1.4 Phospholipase A2 in bone metabolism and inflammation 
Eicosanoids are a group of molecules considered to be important lipid mediators [39]. 
These molecules have both physiologic and pathologic roles in the skeletal 
metabolism [40]. Eicosanoids are important in inflammatory responses, and are also 
linked to autoimmune diseases, such as RA [41]. These molecules are subdivided into 
three major groups: 1) prostanoids, which include prostaglandins (PGs) and 
thromboxanes (TXs), 2) leukotrienes, lipoxins, and hydroxy-fatty acids, and 3) epoxy 
and omega derivatives. The grouping corresponds to the pathways that the molecules 
are synthesized via. Eicosanoids can be derived from the 20-carbon omega-6 
polyunsaturated fatty acid called arachidonic acid (AA). AA is normally esterified in 
membrane glycerophospholipids, but is released by the action of certain enzymes 
when needed. These enzymes are named phospholipase A2 (PLA2), and they are 
specific for hydrolysis of fatty acid ester bonds in the sn-2 position of membrane 
phospholipids [40]. 
The release of the 18-carbon omega-9 monounsaturated oleic acid (OA), together 
with AA, has been found in elevated levels upon stimulation in certain cell models. In 
these systems the OA release was due to sPLA2 and iPLA2 [42, 43]. OA has been 
shown to activate diverse pathways of immune competent cells and is often described 
as an anti-inflammatory mediator [44]. 
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Chapter 1
 INTRODUCTION 
 In the 37 years since prostaglandin E 2 (PGE 2 ) was first 
shown to stimulate cyclic AMP production and resorption 
in bone organ cultures ( Klein and Raisz, 1970 ), ample evi-
dence has accumulated to demonstrate that prostaglandins 
(PGs) and other eicosanoids have important physiologic and 
pathologic roles in skeletal metabolism. PGs are autocrine-
paracrine (or local) factors. They are not stored but are syn-
thesized and released as needed and rapidly metabolized in 
their passage through the lung. PG production is regulated 
by many systemic hormones and other local factors involved 
in bone metabolism, and PGs may function to integrate 
or amplify responses to these agents at the cellular level. 
Understanding the role of PGs in skeletal metabolism has 
been complicated because they act locally and transiently, 
they are regulated at multiple levels, and they have multiple 
receptors. Moreover, dual effects can be demonstrated for 
PGs in most test systems  in vitro . This chapter will sum-
marize current knowledge on the regulation of PG produc-
tion in bone and the effects of PGs and other eicosanoids on 
bone resorption and formation. 
 PG PRODUCTION 
 Metabolic Pathways 
 Eicosanoids are derived from 20-carbon polyunsaturated 
fatty acids (PUFAs). PUFAs result from metabolism of the 
dietary omega ( ω )6 (or n-6) and  ω 3 (or n-3) essential fatty 
acids, linoleic acid (C18:2 ω 6) and linolenic acid (C20:3 ω 3) 
 (Min and Crawford, 2004 ). The shorthand for fatty acids, 
X:Y ω Z, refers to X carbon atoms and Y double bonds, 
whereas Z is the position of the first double bond count-
ing from the terminal methyl (CH 3 ) group. There are three 
major families of eicosanoids ( Fig. 1 ): (1) prostanoids (PGs 
and thromboxane), synthesized via the cyclooxygenase
 58 
pathway; (2) leukotrienes, lipoxins, and hydroxy-fatty 
acids, synthesized via various lipoxygenase pathways 
(5-, 12-, and 15-lipoxygenase); and (3) epoxy and omega 
derivatives, synthesized via the cytochrome P-450-
dependent epoxygenase pathway ( Capdevila  et al. , 2000 ; 
 Murphy  et al., 2004 ;  Smith, 1989 ). Although important 
functions are being proposed for a rapidly growing num-
ber of metabolites generated by these pathways, the pros-
tanoids and leukotrienes are still considered the most 
important biologically active eicosanoids, and they are the 
ones most studied in bone. 
 Prostaglandins and Bo  M tabolism 
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 FIGURE 1  Major families of eicosanoids derived from arachidonic 
acid. The family of prostanoids (prostaglandins and thromboxane) is gen-
erated via the bifunctional cyclooxygenase (COX) enzyme, previously 
called prostaglandin G/H synthase (PGHS), which converts arachidonic 
acid to PGG 2 and PGG 2 to PGH 2 . Specific synthases subsequently con-
vert PGG 2 to various prostanoids. Other major families are (1) leukotri-
enes, lipoxins, and hydroxy fatty acids, (2) isoprostanes, and (3) products 
of the cytochrome P450–dependent epoxygenase pathway. 
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Figure 1.4.1 Pathway for synthesis of prostanoids, involving COX-1, COX-2, and different specific 
synthases [40]. The pathways of the other groups of eicosanoids are not shown in detail. COX, 
cyclooxygenase; PG, prostaglandin; TX, thromboxanes 
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1.4.1 Prostaglandin E2 is a potent activator of bone resorption 
The prostanoids are of the most studied eicosanoids in relation to bone metabolism. 
They are synthesized from AA via the cyclooxygenase (COX) pathway carried out by 
the enzymes COX-1, COX-2 and different synthases, as shown in figure 1.4.1 [40].  
Bone tissue normally express high levels of PGs, but they are often found to be even 
more elevated in inflammatory conditions, such as RA [40]. Early studies showed that 
the E series of PGs are the most potent activators of bone resorption in organ culture 
[45], and PGE2 is extensively studied within the field of osteology. In the body, 
exogenous PGE2 seems to induce both bone formation and resorption. However, the 
extent of each process is varying [40]. This means that bone loss is observed in some 
models [46], while formation of bone is seen in others [47]. These complex effects on 
bone are probably due to the many PGE2 receptors, EP1-EP4. Consequently, PGE2 
has the ability to activate various signaling pathways. Different receptors are found in 
both osteoblasts and osteoclasts [48, 49]. This complexity has made it difficult to 
determine the exact effects of endogenously PGs on bone remodeling, both under 
normal conditions and in disease. Nonetheless, many of the pro-inflammatory 
cytokines stimulate the expression of COX-2, and consequently the production of 
PGE2. Since PGE2 is a potent activator of bone resorption, it is blamed for 
contributing to the bone erosion seen in inflammatory diseases [40]. In addition, PGE2 
is shown to induce differentiation of osteoclasts by down-regulating the OPG 
expression of osteoblasts [50]. 
1.4.2 The secreted and the cytosolic phospholipase A2 
PLA2s, are gathered in a superfamily consisting of 15 groups. There are also a number 
of subgroups corresponding to the different structures and mechanisms of the 
enzymes [51]. There are four distinct types of PLA2 identified, namely the cytosolic 
PLA2 (cPLA2), the secreted PLA2 (sPLA2), the Ca2+-independent PLA2 (iPLA2), and 
the lipoprotein-associated PLA2 (LpPLA2). Each different type of PLA2 functions in 
lipid signaling, and has been linked to inflammatory diseases. There is therefore an 
increased interest in research concerning development of different PLA2 inhibitors 
[52].  
The sPLA2 and the cPLA2 are considered essential for the production of prostanoids 
[40]. There are several sPLA2 groups, and group IIA sPLA2 (GIIA sPLA2) have been 
found in high concentration in synovial fluid of RA patients [52]. Prof. Berit 
Johansen, currently the head of the PLA2 research group, participated in isolation, 
cloning and sequencing of the first discovered human, non-pancreatic PLA2 present in 
platelets and in rheumatoid synovial fluid [53]. It had characteristics similar to GII 
PLA2 isolated from snake venom, and was subsequently classified as GIIA sPLA2. It 
has later been demonstrated that different sPLA2s are present in RA and increase the 
production of PGs in cultured synovial cells. For the sPLA2s to carry out the catalysis, 
they need millimolar concentrations of Ca2+, and they have no AA selectivity [52].  
There are different groups of the cPLA2s, but group IVA cPLA2 (GIVA cPLA2) is the 
most studied. In contrast to the sPLA2, the GIVA cPLA2 is selective for AA release at 
the sn-2 position, and it is considered to be the most important cPLA2 for freeing AA. 
Its expression can be increased by PGs and inhibited by IL-4, but most cells express 
this enzyme constitutively. The GIVA cPLA2 also require Ca2+, not for catalysis, but 
for translocation to membrane surfaces [40]. The enzyme is subsequently activated by 
phosphorylation at serine residues [41]. The GIVA cPLA2 can be activated by 
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MAPKs like extracellular-signal regulated kinase (ERK) 1/2 and p38. Certain TLRs, 
for instance TLR4 on RA SFs, activate these MAPKs upon ligand binding [41]. It is 
established that GIVA cPLA2 is central in inflammatory diseases because of its 
extensive release of AA, which in turn are converted into components that induce 
pain and inflammation [52]. In fact, studies on GIVA cPLA2-deficient mice are 
showing that prevention of AA metabolism leads to weakening of the RA symptoms 
[54]. 
 
Prof. Berit Johansen and co-workers have shown that cPLA2 activates the 
transcription factor NF-κB in response to TNF-α and IL-1β in human keratinocytes. 
Phosphorylation of cPLA2 was found to be dependent on sPLA2 and 5-lipoxygenase 
activities, which subsequently regulate the release of AA [55]. Furthermore, it was 
demonstrated that atypical λ/ι protein kinase C (λ/ιPKC) is involved in this signaling 
cascade. The λ/ιPKC was found to function downstream of sPLA2 and 5-
lipoxygenase, and it promotes cPLA2 phosphorylation in a phosphatidylinositol 3 
(PI3) kinase-dependent manner [56]. 
 
1.4.3 Phospholipase A2 inhibitors 
Which PLA2 class that are targeted for inhibition, depends on the type of 
inflammatory disease. GIVA cPLA2 is one of the targets in RA. However, it is likely 
that several groups are involved in chronic diseases, possibly at different stages of the 
disease progression. By using selective PLA2 inhibitors, the role of each PLA2 can be 
further explored. The hope is that PLA2 inhibitors can treat inflammatory diseases 
such as RA. However, no selective PLA2 inhibitors are currently available for treating 
patients [52]. Nonetheless, animal experiments have shown promising results. For 
example, Tai and co-workers have developed a GIVA cPLA2 inhibitor and tested it on 
mouse models of collagen-induced arthritis (CIA). They found that arthritis was 
prevented if the inhibitor was given before the onset of disease. In mice already 
affected by arthritis, the inhibitor showed anti-arthritic activity by reducing the 
eicosanoid production [57]. Similar results of CIA models were recently obtained 
using novel GIVA cPLA2 inhibitors characterized in Prof. Berit Johansen’s lab 
(manuscripts in preparation). Tai and co-workers also detected a decreased expression 
of certain MMPs and COX-2 mRNAs as a result of GIVA cPLA2 inhibition [57]. The 
PLA2 research group has seen similar effects in the synovial SW982 cells [58]. 	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1.5  The SW982 cell line as a model for synovitis in RA 
The SW982 cells have their origin from a synovial sarcoma. At a clinic in Texas in 
1974, this specific sarcoma was surgically removed from a Caucasian woman in her 
mid-twenties. A. Leibovitz subsequently initiated the SW982 cell line from the 
surgical specimen. In 1982, a sample of this cell line was sent to the American Type 
Culture Collection (ATCC), where these cells can now be purchased [59]. The 
SW982 cells are assumed to be type B synoviocytes (SFs) due to the presence of 
vimentin and smooth muscle actin, and the absence of CD11B [60]. 
 
The advantage of using a cell line, in contrast to primary mammalian cells, is that they 
do not possess a limited replicative life span and do not exhibit signs of senescence. 
Moreover, obtaining samples from RA synovium is a complicated process [61]. 
Phenotypically the SW982 cells have been shown to express the pro-inflammatory 
cytokines IL-1β, IL-6, and TGF-β. Furthermore, the cells express intercellular 
adhesion molecule-1 (ICAM-1), COX-2 and certain MMPs. All these genes show a 
highly increased expression when the cells are treated with IL-1β [62]. The PLA2 
research group has verified the presence of all these phenotypic characteristics [58]. 
In addition, the group have demonstrated that the SW982 cells express several PLA2 
isoforms: sPLA2, cPLA2, and iPLA2 (manuscript in preparation). 
 
1.6 Gene expression analysis by real-time quantitative polymerase chain 
reaction 
A conventional polymerase chain reaction (PCR) results in end-point detection, and is 
used when a yes/no answer regarding the presence of PCR products is sufficient. In 
contrast, quantitative PCR (qPCR) is a method that enables researchers to monitor the 
amplification in real-time, thus making it possible to quantify specific nucleic acid 
sequences. The qPCR can be used in e.g. determination of viral load, detection of 
genetically modified organisms, single-nucleotide polymorphism (SNP) genotyping, 
and allelic discrimination. Moreover, it is commonly applied in gene expression 
analysis, which is the area of application in this master’s thesis. For this purpose RNA 
templates are used, but first the RNA is transcribed into complementary DNA 
(cDNA) by the enzyme reverse transcriptase [63]. 
 
1.6.1 Detecting qPCR products using SYBR Green I 
The detection of products in qPCR is based on fluorescence measurements during 
each cycle of the reaction - the amount of fluorescence is proportional to the amount 
of PCR product. There are several detection chemistries available for use in qPCR, 
such as fluorescent dyes and fluorescently labeled sequence-specific probes. The one 
used in this thesis is the fluorescent dye SYBR Green I. This dye emits fluorescence 
only when bound to double-stranded DNA molecules, as shown in figure 1.6.1. This 
means that the detection will occur during the extension steps of the reaction and the 
signal will increase as the qPCR products accumulate. The advantage of using SYBR 
Green I is that many different targets can be detected, and it is not necessary to make 
target-specific probes. Nonetheless, it is important that the primers used in the 
reaction are highly specific due to the risk of obtaining fluorescence from nonspecific 
products [63].  
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1.6.2 The ΔΔCq method for relative quantification 
Nucleic acids can be either absolutely or relatively quantified after performing a 
qPCR. Relative quantification is commonly used for gene expression analysis. In this 
case the ratio between the amount of target and the amount of an endogenous 
reference molecule, commonly a housekeeping gene, is determined. It is important 
that the expression level of the reference is constant under all experimental 
conditions. If this is the case, the ratio of different samples can be used for 
comparison of gene expression [63]. 
 
The choice of approach for relative quantification is based on whether the target and 
the reference gene are amplified with comparable or different efficiencies. If the 
amplification efficiencies are comparable, you can safely use the comparative method 
called the ΔΔCq method. Quantification cycle (Cq), also known as threshold cycle 
(CT), is a value denoting at which cycle the amplification plot crosses the threshold. 
The threshold is set within the log-linear phase of the amplification curve - above the 
background fluorescence baseline, but significantly below the plateau of the curve, as 
shown in figure 1.6.2 [63]. 
 
 
 
 
 
 
 
 
 
 
 
 
2. Detection of PCR products in real-time 
Real-time PCR and RT-PCR allow accurate quantification of starting amounts of DNA, cDNA, and RNA targets. Fluorescence
is measured during each cycle, which greatly increases the dynamic range of the reaction, since the amount of fluorescence
is proportional to the amount of PCR product. PCR products can be detected using either fluorescent dyes that bind to
double-stranded DNA or fluorescently labeled sequence-specific probes.
2.1 SYBR® Green
The fluorescent dye SYBR Green I binds all double-stranded DNA molecules,
emitting a fluorescent signal of a defined wavelength on binding (Figure 1).
The excitation and emission maxima of SYBR Green I are at 494 nm and
521 nm, respectively, allowing use of the dye with any real-time cycler.
Detection takes place in the extension step of real-time PCR. Signal intensity
increases with increasing cycle number due to the accumulation of PCR
product. Use of SYBR Green enables analysis of many different targets
without having to synthesize target-specific labeled probes. However,
nonspecific PCR products and primer–dimers will also contribute to the
fluorescent signal. Therefore, high PCR specificity is required when using
SYBR Green.
2.2 Fluorescently labeled sequence-specific probes 
Fluorescently labeled probes provide a highly sensitive and specific
method of detection, as only the desired PCR product is detected.
However, PCR specificity is also important when using sequence-specific
probes. Amplification artifacts such as nonspecific PCR products and
primer–dimers may also be produced, which can result in reduced yields
of the desired PCR product. Competition between the specific product
and reaction artifacts for reaction components can compromise assay
sensitivity and efficiency. The following sections discuss different probe
chemistries.
2.2.1 TaqMan® probes 
TaqMan probes are sequence-specific oligonucleotide probes carrying a
fluorophore and a quencher moiety (Figure 2). The fluorophore is attached
at the 5' end of the probe and the quencher moiety is located at the 3' end.
During the combined annealing/extension phase of PCR, the probe is
cleaved by the 5' → 3' exonuclease activity of Taq DNA polymerase,
separating the fluorophore and the quencher moiety. This results in detectable
fluorescence that is proportional to the amount of accumulated PCR product.
Examples of quencher moieties include TAMRA fluorescent dye and Black
Hole Quencher® (BHQ®) nonfluorescent dyes.
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Figure 1. SYBR Green principle. Principle of SYBR Green-
based detection of PCR products in real-time PCR.
Figure 2. TaqMan probe principle. Both the TaqMan probe
and the PCR primers anneal to the target sequence during
the PCR annealing step. The proximity of the quencher to
the fluorophore strongly reduces the fluorescence emitted
by the fluorophore.  During the PCR extension step,
Taq DNA polymerase extends the primer. When the enzyme
reaches the probe, its 5' → 3' exonuclease activity cleaves
the fluorophore from the probe. The fluorescent signal from
the free fluorophore is measured. The signal is proportional
to the amount of accumulated PCR product.
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Figure 1.6.1 Detection of qPCR products by the 
fluorescent dye SYBR Green I [63]. 
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4. Basic terms used in real-time PCR 
Before levels of nucleic acid target can be quantified in real-time PCR, the raw data must be analyzed and baseline and
threshold values set. When different probes are used in a single experiment (e.g., when analyzing several genes in parallel
or when using probes carrying different reporter dyes), the baseline and threshold settings must be adjusted for each probe.
Furthermore, analysis of different PCR products from a single experiment using SYBR Green detection requires baseline and
threshold adjustments for each individual assay. Basic terms used i  data an lysis are given bel w. For more information on data
analysis, refer t  the r commendations from the manuf c urer of your real-time cycler. Data are displ yed as sigmoidal-shaped
amplification plots (when using a linear scale), in which the fluorescence is plotted against the number of cycles (Figure 8).
Figure 9. Correct baseline and threshold settings are important for accurate quantification. Amplification product becomes
detectable within the baseline setting of cycles 6 to 15 and generates a wavy curve with the highest template amount.
Setting the baseline within cycles 6 to 13 eliminates the wavy curve. The threshold is set at the beginning of the detectable
log-linear phase of amplification.
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Figure 8. Typical amplification plot. Amplification plots
showing increases in fluorescence from 2 samples (A and
B). Sample A contains a higher amount of starting template
than sample B. The Y-axis is on a linear scale.
Baseline: The baseline is the noise level in early cycles, typically measured between cycles 3 and 15,
where there is no detectable increase in fluorescence due to amplification products. The number of
cycles used to calculate the baseline can be changed and should be reduced if high template
amounts are used or if the expression level of the target gene is high (Figure 9A). To set the
baseline, view the fluorescence data in the linear scale amplification plot. Set the baseline so that
growth of the amplification plot begins at a cycle number greater than the highest baseline cycle
number (Figure 9B). The baseline needs to be set individually for each target sequence. The average
fluorescence value detected within the early cycles is subtracted from the fluorescence value
obtained from amplification products. Recent versions of software for various real-time cyclers
allow automatic, optimized baseline settings for individual samples.
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Figure 1.6.2 Examples of amplification curves with 
the terms used in qPCR [63]. 
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Before applying the ΔΔCq method, amplification efficiencies must be compared. To 
compare the amplification efficiencies, a standard curve is generated. This is made by 
plotting the difference between the Cq value of the target gene and the Cq value of the 
reference gene, ΔCq, against the logarithm of input amount of RNA. The 
amplification efficiencies are considered comparable if the slope of the linear 
regression line is < 0.1. If this is the case, it is not necessary to generate standard 
curves in following experiments [63]. The change in gene expression of different 
samples (e.g. stimulated cells) relative to a calibrator sample (e.g. untreated cells) can 
then be calculated by the following steps [64]: 
 
1. Calculate ΔCq for each sample, including the calibrator sample, to normalize 
for the amount of template used: 
 
ΔCq (sample) = Cq target gene – Cq reference gene   (1) 
 
ΔCq (calibrator) = Cq target gene – Cq reference gene  (2) 
 
 
2. Normalize all samples to the calibrator sample by determining the ΔΔCq: 
 
ΔΔCq = ΔCq (sample) – ΔCq (calibrator)    (3) 
 
3. Calculate the normalized gene expression level of the target gene relative to 
the calibrator, referred to as fold change: 
 
Fold change = 2-ΔΔCq       (4)  
 
If the fold change of a target gene has a value of e.g. 4 in stimulated cells, it means 
that this gene is 4 times up-regulated in these cells relative to the untreated ones. In 
contrast, if the fold change of the target gene in the sample of interest has a value 
lower than in the calibrator sample (fold change = 1), it means that the gene is down-
regulated accordingly. 
 
1.6.3 Analysis software 
For easier handling of big data sets, analysis of the qPCR results can be done using 
appropriate computer software. In this master’s project LinRegPCR, developed by 
Ramakers and co-workers, was used. This is a program that performs regression 
analysis of imported raw fluorescence data. The program defines the baseline and 
performs a baseline correction, before it computes the amplification efficiencies. Then 
the Cq value is determined from the exponential phase of PCR amplification and the 
starting amount of cDNA can be calculated [65]. If relative quantification is desired, 
the Cq values from LinRegPCR can for example be entered into the relative 
expression software tool REST 2009 from Qiagen, as was done in this thesis. REST 
performs reference gene normalization and provides relative gene expression like the 
ΔΔCq method does, but it also takes the amplification efficiency into account. In 
addition, the software performs statistical analysis. Two groups, treated vs. control, 
are compared and tested for significant difference by using a randomization test [66]. 
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1.7 The aim of the thesis 
An ideal way of treating autoimmune diseases like RA would be to weaken only the 
autoimmune response, while not interfering with the rest of the immune system. This 
has proven to be very difficult [7]. The existing drugs for RA are basically divided 
into two major groups; non-steroidal anti-inflammatory drugs (NSAIDs) and disease-
modifying anti-rheumatic drugs (DMARDs). The purpose of the NSAIDs, such as 
ibuprofen, is to treat the symptoms by reducing PG synthesis through COX inhibition 
[3]. DMARDs, on the other hand, have various mechanisms of action. There are 
biological DMARDs aiming to e.g. inhibit TNF (adalimumab) or block IL-6 signaling 
(tocilizumab) [1]. In addition, there are non-biological DMARDs, such as 
methotrexate that exerts immunosuppressive effects through interference with DNA 
synthesis and cell replication [67]. In contrast to NSAIDs, the DMARDs can hinder 
disease progression by preventing pain, swelling and bone destruction [3]. Due to still 
unknown factors of RA pathogenesis and the heterogeneity of the disease, a treatment 
that gives remission in the majority of patients has not yet been found – and much less 
a cure. This means that a continued search for new treatment principles and drugs is 
necessary [1].  
 
As stated earlier, PLA2 enzymes have a central role in production of inflammatory 
mediators. Thus, controlling the activity of PLA2 constitutes an attractive therapeutic 
target for treating conditions like RA. As of today, not much research has focused on 
the effect of PLA2 inhibition on downstream cellular processes in bone metabolism. 
One of the main goals of this master’s thesis will therefore be to explore the 
possibility of cPLA2 being an upstream regulator of the pathways involving RANKL, 
OPG, and DKK1. This can give an indication on whether inhibiting cPLA2 will be 
beneficial to reestablish the bone homeostasis. Inhibition of cPLA2 could potentially 
address some of the underlying causes of RA, i.e. act as a DMARD. If effective, 
cPLA2 inhibitors would function on an earlier stage than NSAIDs. The cPLA2 
enzyme is a target of investigation with the aim of finding a drug that is more efficient 
and have less side effects [68]. Furthermore, little is known regarding cPLA2’s 
involvement in signaling via TLRs, at least not in association with RA. Another goal 
of this thesis will be attempting to establish the SW982 cells as a model system for 
TLR signaling by characterizing their expression of the TLRs known to be present in 
SFs. It is also of interest to explore the possibility of a connection between TLRs and 
the PG pathway. This will be groundwork for further research regarding the possible 
importance of cPLA2 in TLR signaling in these cells. 
 
Based on this introduction chapter and the statements above, the following questions 
have been deduced and will be pursued experimentally: 
 
1) Do the SW982 cells express RANKL, OPG, DKK1 and TLR1-TLR7? 
 
2) Do TLR agonists affect the expression levels of RANKL, OPG and DKK1 in 
SW982 cells? Are the cPLA2 and COX enzymes involved? 
 
3) Do TLR agonists affect the activity of PLA2s?  
 
4) Are RANKL, OPG, DKK1 and TLR1-TLR7 expression in SW982 cells 
affected by the pro-inflammatory cytokine TNF-α? Is cPLA2 involved? 
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2. MATERIALS & METHODS 
2.1 Reagents, solutions and materials 
All reagents, solutions, and materials used during this master’s project will be listed 
here. 
Cell culture and cell experiments 
SW982 cells were obtained from the ATCC. 75 cm2 and 175 cm2 cell culture flasks 
and cell scrapers were from Sarstedt. Dulbecco’s modified Eagle’s medium (DMEM), 
L-glutamine, Gentamicin solution, dimethyl sulfoxide (DMSO), and fatty acid free 
bovine serum albumin (fBSA) were all purchased from Sigma-Aldrich. Both fetal 
bovine serum (FBS) and 0.05% trypsin-EDTA were obtained from Gibco, while 
phosphate buffered saline (PBS) was from Oxoid. TNF-α (10 µg/ml) was purchased 
from R&D Systems and IL-1β (2 µg/ml) from Roche. The 6-well and 48-well plates 
were from Corning. The TLR agonists FSL-1 and Pam3CSK4 were obtained from 
InvivoGen, while Poly(I:C) and LPS were received from another NTNU lab. 
Inhibitors used in the cell experiments, and the suppliers, are listed in table 2.1. 
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Table 2.1 An overview of the inhibitors used in this master’s project, including suppliers and molecular targets. 
Inhibitor Supplier Target  
 
InhibX 
(real name not 
published) 
Prof. George 
Kokotos, 
University of 
Athens  
cPLA2 
AVX002 Synthetica Oslo GIVA cPLA2 [69] 
 
CAY10502 Cayman chemical GIVA cPLA2 [70] 
 
CAY10590 Cayman chemical GV sPLA2 [71] 
 
Varespladib 
(LY315920) 
Selleck chemicals GIIA sPLA2 [72] 
BEL Cayman chemical GVIA and GVIB iPLA2 [73] 
 
MAFP Cayman chemical GVIA iPLA2 + GIVA, GIVB and 
GIVC cPLA2 [73] 
Indomethacin Sigma-Aldrich COX-1 and COX-2 [74] 
 
 
RNA isolation 
RNeasy Mini Kit and RNase-free DNase Set were bought from Qiagen, and β-
mercaptoethanol from Sigma-Aldrich. 	  
cDNA synthesis 
5x first strand buffer, 0.1 M DTT, and moloney murine leukemia virus reverse 
transcriptase (M-MLV RT) were all obtained from Invitrogen. Deoxynucleotide 
triphosphate (dNTP) mix (10 mM) was purchased from Sigma-Aldrich, while both 
random primers and recombinant RNasin ribonuclease inhibitor were from Promega. 
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qPCR 
SYBR Green JumpStart Taq ReadyMix was bought from Sigma-Aldrich. This mix 
contains 20 mM Tris-HCl (pH 8.3), 100 mM KCl, 7 mM MgCl2, 0.4 mM of each 
dNTP (dATP, dCTP, dGTP and dTTP), stabilizers, 0.05 unit/µl Taq DNA 
Polymerase, JumpStart Taq antibody and SYBR Green I dye. RT2 qPCR primer 
assays for human OPG, RANKL, DKK1, TLR1, TLR2, TLR3, TLR4, TLR5, TLR6, 
TLR7, and 18SrRNA were all obtained from Qiagen. Primer pairs designed by the 
PLA2 research group were purchased from Sigma-Aldrich: IL-6 fwd, IL-6 rev, COX-
2 fwd, COX-2 rev, 18S rRNA fwd, and 18S rRNA rev. Non-skirted, natural colored 
96-well qPCR plates and optically clear adhesive seal sheets were obtained from 
Thermo Scientific. 
 
Gel electrophoresis 
Agarose, Trizma base, ethylenediaminetetraacetic acid (EDTA), and acetic acid 
solution were all purchased from Sigma-Aldrich. GelRed nucleic acid gel stain was 
bought from Biotium, 6x Orange loading dye from Fermentas, and 100bp DNA 
ladder from Promega. 
 
Enzyme-linked immunosorbent assay 
DuoSet enzyme-linked immunosorbent assay (ELISA) for human OPG, reagent 
diluent, substrate solution and normal goat serum were all obtained from R&D 
Systems. The PBS, wash buffer (0.05 % Tween20 in PBS) and stop solution (0.5 M 
H2SO4) was self-prepared. The PBS was from Gibco, Tween20 from Cayman 
Chemical Company, and the H2SO4 from Sigma-Aldrich. Clear polystyrene flat-
bottomed 96-well Nunc MaxiSorp microplates were purchased from eBioscience, 
while the aluminium seal films were from Corning. 
 
Arachidonic and oleic acid release assay 
AA[5,6,8,9,11,12,14,15-3H(N)] 0.1 mCi/ml, OA[1-14C] 0.1 mCi/ml and the 
scintillation cocktail OptiPhase Supermix were all purchased from Perkin Elmer. 
NaOH was from Sigma-Aldrich. 
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2.2 Cell culture and cell experiments 
SW982 cells were cultivated using 75 cm2 or 175 cm2 cell culture flasks. The medium 
used was DMEM with 10% FBS, 0.3 mg/ml L-glutamine, and 0.1 mg/ml gentamicin 
added – hereafter referred to as 10% DMEM.  
The cells were split in a sterile cabinet when they had reached a sub-confluent state, 
i.e. every 3-4 days. The split ratio varied from 1:3 to 1:6, depending on the density of 
the cells. The volumes presented here refer to the use of a 75 cm2 cell culture flask. 
When cells were split, they were washed 2 times with 10 ml room temperate PBS. 
They were then incubated with 1.5 ml of preheated (37 °C) 0.05% trypsin-EDTA for 
2 minutes at 37 °C. The flask was tapped against the lab bench for better loosening of 
the cells. To deactivate the trypsin, 4x volume of 10% DMEM was added. The whole 
solution was then transferred to a 15 ml tube and centrifuged at 700 rpm at 25 °C in 5 
minutes. The supernatant was discarded and the cell pellet was resuspended in 3-6 ml 
10% DMEM, depending on the split ratio. 1 ml of the cell suspension was put back in 
the culture flask with 9 ml fresh, preheated (37 °C) 10% DMEM. The culture was 
kept in a humidified CO2 incubator at 37 °C. 
When experiments were to be performed, the remainders of the resuspended cells 
were counted using a Bürker chamber and the cell suspension was diluted to obtain 
the appropriate cell amount for the type of experiment to be executed. Every step 
where 10% DMEM is used, the medium is preheated to 37 °C. The same goes for 
DMEM with only L-glutamine and gentamicin added (no FBS) – referred to as 
serum-free DMEM (SF-DMEM). 
 
2.2.1 Cell experiments for qPCR 
Stimulation with TLR agonists 
2 ml 10% DMEM was added to the wells in 6-well plates, and 1 ml with 300 000 cells 
was seeded in each well. The cell plates were placed in the incubator to grow 
confluent. They were incubated 3 additional days after reaching 100% confluence (~ 
30 hours after seeding), i.e. 3 days post-confluence. At 2 days post-confluence the 
cells were starved, meaning that the 10% DMEM in each well was replaced by 1.5 ml 
SF-DMEM. The following day the cells were stimulated. Old SF-DMEM was 
removed, and 1.5 ml fresh SF-DMEM was added to the control wells. In the test 
wells, 1.5 ml of the respective TLR agonist solution was added. TLR agonist 
concentrations used for stimulation were: 100 ng/ml of FSL-1, Pam3CSK4 (P3C), and 
LPS, and 5 µg/ml Poly(I:C) (PIC). 1.5 ml of 10 ng/ml IL-1β solution was added to a 
well as a positive control. If inhibitors were used, the cells were pre-incubated with 
1.5 ml inhibitor solution for 2 hours. Inhibitors used were InhibX, AVX002 and 
Indomethacin - all with a concentration of 5 µM. After the pre-incubation, 375 µl of 
the TLR agonists with 5x the concentrations above was added. The plates were left in 
the incubator for the desired time period (varied from 3-24 hours).  
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Stimulation with TNF 
1 ml with 300 000 cells was seeded evenly in each well of four 6-well plates with 2 ml 
10% DMEM per well. Again, the cells were incubated until reaching 3 days post-
confluence, including starvation with 1.5 ml SF-DMEM per well at 2 days post-
confluence. Old SF-DMEM was removed and replaced by 1.5 ml fresh SF-DMEM. 
The cPLA2 inhibitors, InhibX and AVX002, were diluted in SF-DMEM to a 5 µM 
and 1 µM concentration and 1.5 ml of each was added to separate test wells. After 
adding the inhibitors, the cells were pre-incubated for 2 hours. Then 375 µl of 50 
ng/ml TNF-α was added to the TNF-α well and to each of the inhibitor wells. 
Together these wells now contained 1875 µl, i.e. the final TNF-α concentration was 
10 ng/ml. Lastly, 375 µl of additional SF-DMEM was added to the control wells. The 
four plates were then left in the incubator for 6, 12, 24 and 48 hours respectively. 
 
2.2.2 Cell experiments for arachidonic and oleic acid release assay 
0.5 ml with 50 000 cells was seeded in each well of 48-well culture plates. Note that 
cells were not seeded in the wells of the uttermost row. I.e., only the inner 24 wells 
were used, due to risk of edge effect. 0.5 ml PBS was added to the uttermost wells. At 
3 days post-confluence, the cells were radioactively labeled with 0.1 mCi/ml AA[3H] 
and 0.1 mCi/ml OA[14C]. Labeling medium was made by mixing SF-DMEM with 3 
µl/ml AA[3H] and 0.6 µl/ml OA[14C]. Old 10% DMEM in the 48-well plates was 
removed. 160 µl of the labeling medium was then added to each well, and the plates 
were incubated for 16-20 hours. The labeling medium was aspirated and the 
unincorporated labeled fatty acids were removed by washing with 300 µl preheated 
PBS/0.2% fBSA (2 ml of 5% fBSA stock per 50 ml PBS). The cells were 
subsequently washed with 300 µl preheated PBS. When stimulating with TLR 
agonists alone, the PBS was replaced by 200 µl of the respective TLR agonist solution 
and 200 µl SF-DMEM in the control wells. Different TLR agonist concentrations 
were tested: 100 ng/ml vs. 50 ng/ml of FSL-1, 300 ng/ml vs. 100 ng/ml of P3C, and 5 
µg/ml vs. 1 µg/ml of PIC. 200 µl of 10 ng/ml IL-1 solution was added to wells as 
positive control. All treatments were performed in triplicates. The cell plates were 
incubated for the desired time period (varied from 3-24 hours). 
 
When using inhibitors, however, the triplicates were treated with 160 µl of the 
respective inhibitor solution and pre-incubated for 2 hours. Inhibitors used were 
AVX002, CAY10502, CAY10590, Varespladib, BEL and MAFP. AVX002 were 
used with a concentration of 5 µM, CAY10502 was 1 µM and the others were 10 µM. 
After the pre-incubation, 40 µl of the TLR agonists with 5x the desired concentrations 
was added. Final concentrations were: 50 ng/ml of FSL-1, 300 ng/ml of P3C, and 1 
µg/ml of PIC. The cells were then left in the incubator for 9 hours. 
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2.3 Collection of culture supernatants, lysis and RNA isolation 
There are different ways of isolating RNA. In this master’s project the RNeasy Mini 
Kit from Qiagen was used. This kit utilizes selective binding of silica-based 
membrane and microspin technology. The buffers in this kit provide a high-salt 
system, which enables the silica membrane to bind up to 100 µg of RNA longer than 
200 bases. By the use of a buffer containing the denaturing agent guanidine-
thiocyanate, the cells are first lysed and homogenized. To ensure that the RNA 
molecules are kept intact, RNases are inactivated by guanidine-thiocyanate. The 
samples are then mixed with ethanol and added to spin-columns containing the silica-
based membrane, where the ethanol will provide the right binding conditions. 
Contaminants, such as proteins, cellular debris, genomic DNA etc., are washed away 
in subsequent washing steps by adding different wash buffers and centrifuging. 
Lastly, the purified RNA molecules are eluted [75]. 
After the cells in 6-well plates from section 2.2.1 had been incubated for the desired 
time period, the cell culture supernatant was removed. The supernatants of interest 
were collected and placed in -80 °C for storage until further analysis. The cells 
remaining in the wells were subsequently lysed. For the lysis, Buffer RLT (lysis 
buffer) and β-mercaptoethanol (10 µl per ml Buffer RLT) were mixed. 350 µl of this 
mixture was then added in each well and left to take effect for ~2 minutes, before the 
cells were scraped off using cell scrapers. Lysed cells were transferred to eppendorf 
tubes, vortexed and stored at -80 °C until isolation of total RNA was performed. 
 
For the RNA isolation procedure, the RNeasy Mini Kit spin protocol for animal cells 
was followed. Firstly, the cell lysates were thawed and 350 µl 70% ethanol was added 
to each sample to homogenize. Lysate and ethanol were thoroughly mixed by 
pipetting, before transferring 700 µl of each sample to an RNeasy spin column in a 2 
ml collection tube. Lids were closed and the samples were centrifuged for 15 seconds. 
Flow-through was discarded, before adding 700 µl of Buffer RW1 to each RNeasy 
spin column. The samples were once more centrifuged for 15 seconds to wash the 
membrane in the column. Flow-through was discarded and 500 µl of Buffer RPE was 
added to each RNeasy spin column. Yet again, the samples were centrifuged for 15 
seconds for washing. Flow-through was discarded and 500 µl of Buffer RPE was once 
more added to each RNeasy spin column. The samples were now centrifuged for 2 
minutes for further washing. RNeasy spin columns were then placed in new 2 ml 
collection tubes and centrifuged at full speed for 1 minute. After this, each column 
was placed in 1.5 ml eppendorf tubes, and 30 µl of RNase-free water was directly 
added to each spin column membrane. The samples were incubated in room 
temperature for 5 minutes (not in the Qiagen protocol, but this has proved to increase 
the RNA yield) before they were centrifuged for 1 minute to elute the RNA. All the 
centrifugation steps were performed at 20–25°C with a speed of ≥ 10 000 rpm in a 
standard microcentrifuge. After the isolation procedure, the RNA concentration 
(ng/µl) and its purity were determined by adding 1.5 µl of the samples to a NanoDrop 
ND-1000 spectrophotometer. The RNA was subsequently stored at -80 °C. 
 
The Qiagen RNeasy Mini handbook states that it is normally not necessary to perform 
DNase digestion when using RNeasy kit. The kit’s silica-membrane technology is 
supposed to remove most of the DNA [75]. However, after some problems with one 
of the qPCR primers, an isolation protocol including on-column DNase digestion was 
used. The digestion was done with the RNase-free DNase Set and the steps differed 
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slightly from the above isolation procedure. The ethanol homogenizing and spin down 
were the same. Samples were then washed with 350 µl Buffer RW1 (15 seconds at ≥ 
10 000 rpm), and flow-through was discarded. 80 µl DNase I incubation mix (10 µl 
DNase I stock solution mixed in 70 µl Buffer RDD) was added directly onto the spin 
column membrane, and incubated in room temperature for 15 minutes. Then the 
DNase was removed by washing with 350 µl Buffer RW1 (15 seconds at ≥ 10 000 
rpm). From this point on, where the RPE Buffer washing step is started, the protocol 
is the same as the one above.  
 
2.4 Synthesis of complementary DNA 
Before the RNA samples, containing primarily mRNA, are used in qPCR, the RNA is 
converted into cDNA. It is not possible for eukaryotic cells to go from RNA and back 
to DNA. However, some viruses have an enzyme that can do this, and so the enzyme 
is called reverse transcriptase. Such an enzyme is utilized in the synthesis of cDNA. 
Furthermore, in this master’s project random primers are used for the cDNA 
synthesis. This results in cDNA from all mRNA molecules, although not in full 
lengths [76]. 
 
The RNA samples were thawed. RNA concentration and purity were measured by 
NanoDrop once more to ensure that the measurements were similar to the ones prior 
to freezing. The concentration values were then used for calculating the amounts of 
RNA and distilled water (dH2O) that were to be added in each cDNA synthesis 
reaction. For every reaction there should be 1 µg/µl RNA in a total of 20 µl. 
 
All reagents were thawed (stored at -20 °C), vortexed and spun down before use. A 
mastermix was then prepared. The following amounts per reaction were used: 4 µl 5x 
first strand buffer, 2 µl 0.1 M DTT, 2 µl dNTP mix and 1 µl random primers (diluted 
to 100 µg/ml).  Correct amounts of dH2O and RNA were mixed in new 0.5 ml tubes. 
1 µl of each of the enzymes recombinant RNasin and M-MLV RT was then added to 
the mastermix. The mastermix was vortexed, spun down and 11 µl was subsequently 
added to each tube with RNA and dH2O. Samples were incubated in room 
temperature for 10 minutes, before incubation at 37 °C (heating block) for 1 hour. The 
reaction was terminated by incubating the samples at 95 °C (heating block) for 5 
minutes. The cDNA samples were stored at -20 °C until further analysis. 
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2.5 Real-time quantitative polymerase chain reaction 
As explained in the introduction chapter, qPCR can be used for various purposes 
where the aim is to quantify the amount of nucleic acids present in a sample. The 
qPCR is often used to analyze gene expression, which is the area of application in this 
master’s project. To analyze the expression of certain genes, mRNA templates are 
used. However, before running the qPCR the mRNA has been transcribed into cDNA, 
as described in the last section. 
Before starting the qPCR set-up, the cDNA samples were thawed, diluted 1:12 and 
kept on ice. Mastermixes for the target gene (OPG, RANKL, DKK1 or TLR1-TLR7) 
and the reference gene (18SrRNA) were prepared. Firstly, 6.5 µl dH2O per reaction 
was pipetted into new tubes. 1 µl of the desired RT2 qPCR primer assay (a mix of 2 
primers, 10 µM each) per reaction was mixed into the dH2O. The primer assays were 
thawed (stored at -20 °C), vortexed and spun down before use. Lastly, 12.5 µl of the 
SYBR Green JumpStart Taq ReadyMix per reaction was added to the mastermixes. 
Mastermixes were vortexed and spun down, before pipetting 20 µl in each well of a 
96-well qPCR plate. 5 µl of the appropriate cDNA sample was subsequently added to 
the mastermix in each well. The plate was sealed and centrifuged for 1 minute at 1200 
rpm. The qPCR was conducted on a Mx3000P cycler (Stratagene). Cycling conditions 
used were obtained from the handbook attached to the RT2 qPCR primer assays [77]. 
The conditions started with an initial denaturation step at 95 °C for 3 minutes (shorter 
time than given in the handbook – optimized by the PLA2 group) to activate the Taq 
DNA Polymerase. Then followed 40 cycles of 15 seconds at 95 °C (denaturation), 40 
seconds at 55 °C (annealing) and 30 seconds at 72 °C (extension and fluorescence 
detection). These conditions were used for all the RT2 qPCR primer assays, except for 
the DKK1 primer, where the annealing temperature was set to 60 °C instead of 55 °C. 
Mx3000P melting curve program (1 cycle of 95 °C for 1 minute, 55 °C for 30 
seconds, and 95 °C for 30 seconds) was ran for dissociation curve analysis. The RT2 
qPCR primer assay details are listed in table 2.5.1. 
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Table 2.5.1 RT2 qPCR primer assays used in this master’s project. RefSeq accession # refers to the sequence used 
to design the RT2 qPCR primer assay, and the reference position is the position of the amplicon in the RefSeq 
sequence. The details were obtained from the primer assay data sheets. 
 
Gene UniGene # RefSeq 
accession # 
Reference 
position 
Product 
band size (bp) 
OPG 
(TNFRSF11B) 
Hs.81791 NM_002546.3 1373 157 
RANKL 
(TNFSF11) 
Hs.333791 NM_003701.3 2025 90 
DKK1 Hs.40499 NM_012242.2 1016 183 
TLR1 Hs.654532 NM_003263.3 586 189 
TLR2 Hs.519033 NM_003264.3 437 154 
TLR3 Hs.657724 NM_003265.2 2355 97 
TLR4 Hs.174312 NM_138554.3 5431 68 
TLR5 Hs.604542 NM_003268.5 2952 136 
TLR6 Hs.662185 NM_006068.4 2784 151 
TLR7 Hs.659215 NM_016562.3 318 195 
18S rRNA N/A X03205.1 1447 100 	  	  
In addition, primer pairs designed by members of the PLA2 research group were used. 
The same approach as for the RT2 qPCR primer assay was used when preparing 
mastermixes. However, there was a difference in reagent amounts: 0.75 µl of each of 
the forward and the reverse primer was added to 5.75 µl dH2O, and lastly 12.75 µl 
SYBR Green JumpStart Taq ReadyMix was added. Cycling conditions were also 
different: An initial step at 95 °C for 3 minutes followed by 40 cycles of 30 seconds at 
95 °C, 30 seconds at 60 °C and 30 seconds at 72 °C. The primer pairs and their details 
are listed in table 2.5.2. 
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Table 2.5.2 The primer pairs designed by the PLA2 research group that were used in this master’s project. 
 
Gene Sequence Product 
band size (bp) 
IL-6 fwd 
IL-6 rev 
5'-TGTGTGAAAGCAGCAAAGAG 
5'-GCAAGTCTCCTCATTGAATCC 
105 
COX-2 fwd 
COX-2 rev  
5'-GGGGATCAGGGATGAACTTT 
5'-TGGCTACAAAAGCTGGGAAG 
153 
18S rRNA fwd 
18S rRNA rev 
5'-GTAACCCGTTGAACCCCATT 
5'-CCATCCAATCGGTAGTAGCG 
150 
 
 
The resulting qPCR data were analyzed using LinRegPCR and REST 2009 software. 
 
2.6 Gel electrophoresis 
Gel electrophoresis is a method for separating DNA fragments, and agarose gels are 
the most commonly used. Agarose is a polymer consisting of agarobiose subunits. 
Upon gelation, the polymers form a network with a specific pore size, which is 
determined by the agarose concentration. The separation of DNA fragments is based 
on the fact that their phosphate backbone is negatively charged. Consequently, the 
fragments will migrate towards the positive anode when voltage is applied. The DNA 
molecules have a uniform mass/charge ratio, and they are therefore separated 
according to their size. The shortest fragments will travel furthest, because they will 
migrate faster through the pores of the agarose gel than the longer ones [78]. 
 
Before making the gel, tris-acetate-EDTA (TAE) buffer was prepared in a 50x stock 
solution. To prepare 1 liter, 242 g Trizma base, 57.1 ml glacial acetic acid, and 100 ml 
0.5 M EDTA were dissolved in 1 liter deionized water. A 1x working solution was 
then prepared by mixing the 50x stock with water at a 1:4 ratio.  
 
To make a 1.5% agarose gel, 100 ml 1x TAE was mixed with 1.5 g agarose powder, 
and the solution was heated until there were no visible agarose grains left. 12 µl of 
GelRed stain was added. When the solution was cold enough to handle, it was poured 
into a gel container. A comb with the desired number of spikes was placed in one of 
the ends, and the solution was left to solidify for about 30 minutes. While waiting, 13 
µl of each qPCR product was mixed with 2.5 µl loading dye. 3 µl of the standard 
ladder was also mixed with loading dye. After the gel had solidified, the comb was 
removed and the gel was placed in an electrophoresis container. 1x TAE buffer was 
poured in, until the entire gel was covered. Standard ladder and qPCR products were 
added in the wells of the gel, which faced the side of the negative electrode. 
Electrophoresis was carried out at 100V for 45 minutes. The resulting bands on the 
gel were visualized using a Gel Doc machine (Bio-Rad). 
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2.7 Enzyme-linked immunosorbent assay 
ELISA is a method used for detection and quantification of a specific protein, or 
another antigen of interest. The ELISA used in this master’s project is called 
sandwich ELISA. This type of ELISA is based on the use of two antibodies that bind 
the target protein, but at different epitopes. The first antibody is used for coating the 
test wells. The sample is then added, before the second antibody is allowed to bind. 
This will result in a sandwich, where the target protein will be located between the 
two antibodies. The second antibody has an enzyme, directly or indirectly, attached. 
This enzyme produces a colored product from a colorless substrate, meaning that the 
color intensity is directly proportional to the amount of target protein present [79]. 
Sandwich ELISA was performed as advised in the R&D Systems kit protocol, except 
for some minor adjustments that will be stated here. To prepare the plates, the capture 
antibody was diluted to a working concentration of 2 µg/ml in PBS, and the 96-well 
microplate was immediately coated with 100 µl antibody solution per well. The plate 
was sealed and incubated overnight at room temperature. For longer storage, the 
plates were placed in 2-8 °C.  
The samples used for analysis were frozen (-80 °C) cell culture supernatants collected 
after stimulation with TLR agonists, as described in section 2.2.1. Before use, the 
supernatants were thawed and centrifuged at 7000 rpm for 5 minutes at 4 °C. After 
the coating period, the wells in the coated plates were emptied and washed with 300 
µl wash buffer. The washing was repeated 4 times, making it a total of 5 wash steps 
(instead of 3 steps with 400 µl as in the kit protocol). After the last wash, the plate 
was blotted against paper towels to remove remaining wash buffer. The plate was 
subsequently blocked by adding 300 µl reagent diluent to each well, sealing it and 
incubating for minimum 1 hour at room temperature. The 5 washing steps were then 
repeated before adding 100 µl standard or sample per well. The samples were diluted 
1:10 in reagent diluent. The standard was first diluted to 4000 ng/ml, and then 2-fold 
serial diluted in 6 steps. Samples and the standard were added to the plate in 
duplicates, after which the plate was sealed and incubated for 2 hours at room 
temperature. 1-2 hours prior to use, the detection antibody was diluted to a working 
concentration of 200 ng/ml in reagent diluent with 2% normal goat serum. After the 
standard/sample incubation, the 5 washing steps were repeated and 100 µl detection 
antibody solution was added to each well. The plate was yet again sealed and 
incubated for 2 hours at room temperature. The 5 washing steps were performed once 
more, and 100 µl of Streptavidin-Horseradish peroxidase (HRP) working solution was 
added to each well. This working solution contained Streptavidin-HRP diluted 1:200 
in reagent diluent. The enzyme solution was left to bind for 20 minutes at room 
temperature. Wells were washed 5 times, and 100 µl substrate solution was added to 
each well. The substrate solution was a 1:1 mixture of color reagent A (H2O2) and 
color reagent B (tetramethylbezidine). The plate was incubated with this mixture for 
20 minutes at room temperature, after which 50 µl stop solution was added to each 
well. To ensure complete mixing, the plate was gently tapped. Finally, the optical 
density was determined using a Multiskan Ascent 354 plate reader (Labsystems) set 
to 414 nm (the reader did not have 450 nm as stated in the kit protocol). In addition, 
550 nm readings were done, for manual wavelength correction. A standard curve was 
created by performing a four parameter logistic (4-PL) curve-fit using ELISA 
software at elisaanalysis.com. The data was further processed in Microsoft Excel. 
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2.8 Arachidonic and oleic acid release assay 
The method for assessing the amount of AA and OA release used here is a 
radioactivity-based assay. The assay was started off by the cell experiment described 
in section 2.2.2, where the cells were labeled with radioactive AA and OA and 
subsequently treated with different TLR agonists. The AA/OA still left inside the 
cells’ membrane and the AA/OA released in the cell culture supernatant can then be 
measured by determining the radioactivity of each component. The amount of AA in 
the supernatant will reflect the activity of PLA2s releasing AA, such as GIVA cPLA2, 
whereas the OA release will reflect the activity of other PLA2s – mainly iPLA2 and 
sPLA2.  
 
After the 48-well plates from section 2.2.2 had been incubated for the desired period, 
the cell supernatant from each well was transferred into eppendorf tubes. Detached 
cells were cleared away by centrifuging for 5 minutes at 13 200 rpm. 160 µl of the 
supernatant was transferred to eppendorf tubes containing 1 ml scintillation cocktail. 
150 µl 1M NaOH was subsequently added to the wells now only containing cells. The 
cells were lysed by placing them on a hot plate at temp 1 for 7-8 minutes. Cell lysates 
were transferred to eppendorf tubes containing 1 ml scintillation cocktail. All the 
samples were mixed in the rack by placing another rack on top and turning this 
sandwich gently 3-4 times. Finally, the radioactivity of the samples was measured by 
liquid scintillation counting using a Tri-Carb 2900TR liquid scintillation analyzer 
(Packard). The resulting data of disintegrations per minute (DPM) were processed in 
Microsoft Excel. 
 
2.9 Statistical analysis 
For the qPCR experiments, randomisation tests performed by REST 2009 were used. 
Statistical analyses of ELISA and radioactivity assay results were performed using 
one-way ANOVA followed by Holm-Sidak multiple comparisons test in SigmaPlot 
12.3. The p values < 0.05 were considered significant. 
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3. RESULTS 
 
3.1 The SW982 cells express the RANKL, OPG and DKK1 genes 
The RANKL, OPG and DKK1 system is central in bone metabolism, and is involved 
in RA pathogenesis. RANKL is required to activate bone-degrading osteoclasts, while 
OPG can block this activation by acting as a decoy receptor for RANKL [25]. DKK1 
on the other hand, hinders differentiation of the bone-forming osteoblasts [26]. The 
SW982 cells are thought to originate from SFs, but there are no published data 
available regarding their RANKL, OPG and DKK1 gene expression. These genes 
were consequently investigated by qPCR analyses. It was found that synovial SW982 
cells express RANKL, OPG and DKK1 (figure 3.1.1). 
 
 
 
The bands of the qPCR products from gel electrophoresis (figure 3.1.1) have the 
expected sizes for OPG (157 bp), RANKL (90 bp) and DKK1 (183 bp). This is also 
the case for 18SrRNA (100 bp), which was used as reference gene. The gel picture 
was only used as a qualitative verification. The gel bands of the qPCR products have 
reached saturation following 40 cycles of amplification. Therefore the intensity 
cannot be compared to determine expression levels. 
 
The Cq values from qPCR suggest that the SW982 cells’ expression level of OPG and 
DKK1 is similar, as both had average values around 23 (data not shown). RANKL is 
less expressed with an average Cq value of 29. The 18SrRNA gave Cq values around 
5. Thus, as in most mammalian cells, 18SrRNA is highly expressed in the SW982 
cells. 
 
All weak shadows in the upper edge of the gel picture (figure 3.1.1) are residual 
primers. However, there is an additional weak band in the well of RANKL beneath 
the main band. This indicates that there is a nonspecific product present. This was 
also detected in the qPCR dissociation curve analysis, which shows the melting 
temperatures of the amplification products (figure 3.1.2). If the amplification had 
been specific, the melting curve would display only a single peak. This is not the case 
for the RANKL primer, because the melting curve has a small extra peak following 
the main peak. It was suggested by the supplier of the primer that this might be due to 
genomic DNA contamination in the samples, despite the fact that the Qiagen RNeasy 
Mini Kit is supposed to remove most of the genomic DNA. Therefore, DNase 
Figure 3.1.1 Gel electrophoresis showing the 
presence of OPG, RANKL and DKK1 gene 
expression in untreated SW982 cells. The 
presence of the reference gene, 18SrRNA, is 
shown as well. 
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digestion was performed in subsequent experiments. However, the RANKL qPCR 
melting curves still had an extra peak and even higher Cq values. As a result, it was 
decided to discontinue the use of the RANKL primer.  
 
 
 
 
The melting curves of OPG and DKK1 (not shown) gave only one single peak as 
expected of ready-made primers.  
 
For all the primers used in this master’s project the “no reverse transcriptase” control, 
for detection of genomic DNA contamination, gave Cq values that were 5 or more 
cycles higher than the genes of interest. This means that any DNA contamination will 
not affect gene expression analysis [80]. The “no template” control, which functions 
to reveal any nonspecific binding of the fluorescence binding dye SYBR Green I, 
gave Cq values above the detection limit (cycle 35) or no Cq value at all, for all the 
primers used. This indicates that minimal/no primer dimers or external DNA 
contamination were present in the qPCRs. Moreover, the amplification efficiency, 
accounted for in the expression analysis by the REST 2009 software, were 80% or 
higher for all primers. 
  
To summarize, the SW982 cells express the OPG and DKK1 genes and may thus be 
capable of producing the corresponding proteins. Furthermore, the cells may express 
the RANKL gene, but this will need further characterization due to the possibility of 
non-specific detection.  
Figure 3.1.2 The dissociation curve of a qPCR product from using the RANKL primer displays an additional peak to 
the right of the main peak, indicating non-specific amplification. 
	   37 
3.2 The SW982 cells express the TLR1-TLR7 genes 
The SFs are considered to be one of the dominant effector cells in RA, and they 
express certain TLRs. These receptors recognize different microbes, but can also bind 
endogenous molecules present in inflamed joints. TLRs are suggested to be some of 
the factors causing the perpetuation of the inflammation in RA [9]. With the goal of 
characterizing the expression of	  TLRs in the synovial SW982 cells, gene analysis by 
qPCR was performed. The SW982 cells were found to express all the TLRs in 
question: TLR1-TLR7 (figure 3.2.1). 
 
 
 
 
 
The clear gel electrophoresis bands (figure 3.2.1) of TLR1 (189 bp), TLR2 (154 bp), 
TLR3 (97 bp), TLR4 (68 bp), TLR5 (136 bp), TLR6 (151 bp) and TLR7 (195 bp) 
have sizes as expected from the information provided by the primer supplier. The 
same goes for the reference 18SrRNA (100 bp). Again, the gel picture was only used 
as a qualitative verification. 
 
The qPCR Cq values indicate that TLR2 is the TLR with the highest expression in the 
SW982 cells, with values of 21-22. TLR3, TLR4, and TLR6 follow behind with Cq 
values around 23-24, 25-26 and 25 respectively. TLR1, TLR5 and TLR7 have Cq 
values around 28-29, 29-30 and 30-31 respectively, and these are consequently the 
lowest expressed TLRs.  
 
All weak shadows in the upper edge of the gel picture (figure 3.2.1) are residual 
primers. Additional weak bands can be seen above the main bands in the wells with 
TLR1, TLR6 and TLR7. The melting curve analysis resulted in one smooth peak for 
both TLR1 and TLR6 (not shown), but for TLR7 a small peak prior to the main peak 
was observed (figure 3.2.2). Such small, early peaks are often due to primer dimers, 
but this is not likely to be the cause here since the bands in the gel are not less than 50 
base pairs. The explanation may be that the TLR7 primer is nonspecific, which can 
also be the case for the TLR1 and TLR6 primers even though nothing is abnormal 
with their melting curves.  	  
 
 
 
 
Figure 3.2.1 Gel electrophoresis showing the presence of TLR1-TLR7 
gene expression in untreated SW982 cells. The presence of the 
reference gene, 18SrRNA, is shown as well. 
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In summary, the SW982 cells express the TLR2, TLR3, TLR4, TLR5 genes, and 
probably TLR1, TLR6 and TLR7 too. There are indications that primers for the latter 
genes are nonspecific. Like the RANKL primer, these primers were not used any 
further. 
 	    
Figure 3.2.2 Dissociation curve of a qPCR product from using the TLR7 primer displays an additional peak to the 
left of the main peak, indicating primer dimers or non-specific amplification. 
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3.3 TLR agonists increase OPG and DKK1 gene expression 
Following the discovery that the SW982 cells express TLR1-TLR7, it was of interest 
to examine if TLR signaling affects the RANKL, OPG and DKK1 system in these 
cells. Because the RANKL primer was discarded for further use, only the OPG and 
DKK1 gene expression following TLR agonist stimulation were investigated. Gene 
analyses were done by qPCR.  
 
Initial experiments were performed by stimulating the SW982 cells with the TLR2/6 
agonist FSL-1, the TLR1/2 agonist P3C, the TLR3 agonist PIC, and the TLR4 agonist 
LPS, for 6 and 24 hours. This was in order to examine potential effects on the OPG 
and DKK1 gene expression levels, and whether these changed over time. Stimulation 
with the pro-inflammatory cytokine, IL-1β, was used as a positive control, because 
the signaling pathways activated by TLRs and IL-1β have many similarities [81]. This 
is due to the fact that the type I IL-1 receptor and the TLRs exhibit high homology in 
their cytosolic domain, which is for that exact reason called Toll/IL-1 receptor (TIR) 
domain. Moreover, IL-1β is known to induce gene expression of the characterized 
expressed genes in the SW982 cells [62]. 
 
The LPS batch seemed to be defect as it failed to evoke any transcriptional responses 
in the initial experiments performed. Even with ultrasonication, LPS stimulation may 
be hard to obtain [82]. Consequently, LPS treatment was discontinued in further 
experiments. 
 
In all the quantitative gene expression analyses performed in this master’s project, the 
expression of the gene of interest for the control (abbreviated by ctrl) is set to 1 and 
the expression of the treated samples is compared relative to this. This is referred to as 
fold change. Moreover, all figures presenting gene expression results show one 
representative experiment, unless otherwise is stated. The statistical significance 
shown in the figures is based on several biological replicas. The mean fold changes 
and the corresponding standard error of means (SEMs) for all replicas performed are 
presented in the appendix. 
 
FSL-1, P3C and IL-1β all gave a significant increase in OPG mRNA level compared 
to the untreated control after 6 hours stimulation of SW982 cells (figure 3.3.1 A). The 
FSL-1 and IL-1β resulted in the highest OPG increase. This was somewhat higher 
than the increase by P3C. Furthermore, the induction of OPG by PIC after 6 hours 
was not significantly different from the control (figure 3.3.1 A). After 24 hours 
stimulation, the OPG mRNA expression seems to be reduced to levels closer to the 
control, as none of the TLR agonists and neither IL-1β gave a significant OPG 
increase (figure 3.3.1 B).  
 
The expression of DKK1 after 6 hours stimulation showed similar trends as for OPG, 
with FSL-1 and IL-1β resulting in higher DKK1 mRNA increase than P3C and PIC 
(figure 3.3.1 C). However, the DKK1 up-regulation was smaller than seen for OPG, 
and none of them were significant. After 24 hours stimulation, the DKK1 fold 
changes were more uniform for all TLR agonists, but still not significantly different 
from the control (figure 3.3.1 D). Fold changes and SEMs from the two biological 
replicas, which the significance in this representative experiment is based on, are 
shown in appendix A. 	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From the results of the 6 and 24 hours experiments, it was presumed that a short 
stimulation period for the TLR agonists were better for detecting an increase in OPG 
and DKK1 mRNA levels. The next goal was to more exactly find the optimal duration 
of stimulation. To achieve this, experiments with 3, 6, 9 and 12 hours stimulation 
periods of the SW982 cells were performed. All these stimulation periods resulted in 
increased OPG mRNA expression (figure 3.3.2 A). FSL-1 and IL-1β were still the 
strongest inducers of OPG expression, and the OPG levels tended to be highest after 3 
and 6 hours stimulation. However, 9 hours stimulation was the only time period that 
gave a significant OPG increase for all the TLR agonists. Again, the DKK1 gene was 
less responsive and its mRNA levels did not seem to increase until after 6 hours of 
stimulation (figure 3.3.2 A). Also for DKK1, 9 hours stimulation was the time period 
giving significant up-regulation for all the TLR agonists. The time curves (figure 
3.3.2) are based on two biological replicas, and the mean fold changes and the SEMs 
are shown in appendix B. 
  
! !!!!!!!!!!!!
A) B) 
C) D) 
Figure 3.3.1 Relative OPG and DKK1 gene expressions obtained from REST 2009 using qPCR data from one 
representative experiment with SW982 cells. The asterisk indicates significant difference from control (p < 0.05). 
Statistical significance was calculated from the total number of biological replicas (n = 2). A) and B) show the 
OPG gene expression ratios after 6 and 24 hours of stimulation with the TLR2/6 agonist FSL-1, the TLR1/2 
agonist P3C, and the TLR3 agonist PIC, plus the cytokine IL-1β. C) and D) show the DKK1 gene expression 
ratios after 6 and 24 hours of stimulation with the same TLR agonists and cytokine as in A) and B). 
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In summary, treatment of the SW982 cells with FSL-1, P3C, PIC or IL-1β, increases 
the OPG and DKK1 gene expression. The stimulation time that gave a significant 
increase in the mRNA levels of these two genes, was found to be 9 hours. Moreover, 
the fact that the cells respond to these TLR agonists confirms that they express the 
corresponding TLRs and that they are functional.  
 	    
Figure 3.3.2 Time curves of mean relative gene expressions obtained from REST 2009 using qPCR data from 
experiments (n = 2 for all TLR agonists, n = 1 for IL-1β) with SW982 cells. Error bars and significance are not 
shown (see appendix B). A) The OPG mRNA fold changes after 3, 6, 9 and 12 hours of stimulation with the 
TLR2/6 agonist FSL-1, the TLR1/2 agonist P3C and the TLR3 agonist PIC, plus the cytokine IL-1β. B) The 
DKK1 mRNA fold changes after 3, 6, 9 and 12 hours of stimulation with the same TLR agonists and cytokine as 
in A). 
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3.4 OPG protein secretion is enhanced by TLR agonists increase 
As a consequence of the novel discovery that the TLR agonists induce OPG and 
DKK1 gene expression in the SW982 cells, it was decided to proceed with analysis at 
protein level. However, due to limited time and because OPG seemed to be slightly 
more responsive than DKK1, protein analyses were only performed for OPG. The 
analyses were performed using SW982 cell culture supernatants, from the same 
experiments as from where the cell material was analyzed at gene level, by sandwich 
ELISA.  
 
OPG protein level after 12 hours stimulation with the TLR agonists was compared to 
the 9 hours stimulation samples in initial analyses. The OPG protein concentration 
obtained from the 9 and 12 hours experiments did not differ much and they both 
showed the same trends. Moreover, both time periods resulted in similar OPG protein 
up-regulation relative to their control (data not shown).  
 
In the subsequent ELISAs, only supernatants from 9 hours experiments were further 
analyzed. FSL-1, P3C, PIC, and IL-1β all resulted in significant increase in OPG 
protein levels (figure 3.4.1). FSL-1 and IL-1β induced the highest OPG protein 
production, with a mean concentration of 17.5 ± 3.2 and 17.4 ± 2.7 ng/ml 
respectively. P3C and PIC stimulation led to significantly less induction, with mean 
concentrations of 10.7 ± 1.5 and 9.2 ± 2.3 ng/ml respectively. However, there was no 
significant difference between these two. The mean OPG concentration of the control 
was 4.3 ± 1.2 ng/ml. 	  
	  	  	  	  
 
 
 
The trend of FSL-1 and IL-1β giving the highest induction after 9 hours is the same 
trend as was seen for the OPG mRNA levels after 6 hours stimulation (figure 3.3.1 
A). This is as anticipated, because there is always a delay between gene expression 
and protein expression. 
Figure 3.4.1 The mean concentration of OPG (ng/ml) in SW982 cell 
culture supernatants, measured by ELISA, after 9 hours stimulation with 
the TLR2/6 agonist FSL-1, the TLR1/2 agonist P3C, the TLR3 agonist 
PIC, or the cytokine IL-1β. The asterisks indicate significant difference 
from control (* p = 0.01 - 0.05, ** p = 0.001 - 0.01, *** p < 0.001), and 
the error bars denote ± SD (n = 7 for FSL-1 and P3C, while n = 5 for 
PIC and IL-1). 
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3.5 TLR agonist-induced OPG expression involves COX activity 
Having found that SW982 cells increase their expression of OPG in response to 
certain TLR agonists and IL-1β, both on gene and protein level, it was of interest to 
investigate whether the cPLA2 enzyme is an upstream regulator of the OPG gene. The 
cPLA2 is considered to be the most central enzyme for formation of AA, which is 
converted into prostanoid precursors by COX-1 and COX-2. These precursors are 
further converted into inter alia PGs, which are found to be more prominent in bone 
tissue suffering from inflammation [40]. Finding out if cPLA2 is involved in the TLR 
agonist-induced expression of OPG, is a part of the attempt to clarify the TLR 
signaling events in the SW982 cell model for RA. It is of interest to see whether 
targeting the pathway responsible for AA and subsequently PG formation has any 
effect on OPG – the molecule capable of blocking differentiation of bone-degrading 
osteoclasts. With the aim of clarifying this, the SW982 cells were treated with either 
of the cPLA2 inhibitors, AVX002 or InhibX, or a COX inhibitor, Indomethacin, each 
in combination with the different TLR agonists, for 9 hours. As before, the gene 
analysis was done by qPCR.  
 
Due to time limitation, the gene analysis was only performed for FSL-1 and P3C. PIC 
was not included because it seemed to affect the cells negatively, as will be further 
described in the discussion chapter. Both FSL-1 and P3C showed similar levels of 
increase in the OPG mRNA expression, with fold induction values somewhat above 3 
(figure 3.5.1). Neither of the cPLA2 inhibitors, nor the COX inhibitor, gave any 
significant effect on the FSL-1-induced increase of mRNA OPG (3.5.1 A). In the case 
of P3C and inhibitors, however, there seemed to be a more distinct trend of reduction 
in the OPG mRNA levels compared to the TLR agonist alone, although only 
Indomethacin gave a significant inhibition (figure 3.5.1 B). Fold changes and SEMs 
from the five biological replicas, which the significance in this representative 
experiment is based on, are shown in appendix C. 
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Subsequently, the OPG protein concentration in cell culture supernatants from 9 hours 
treatment with the cPLA2 inhibitors and the COX inhibitor were analyzed by 
sandwich ELISA, to see whether the protein levels corresponded with the results 
obtained at mRNA level. These protein analyses also included PIC and the pro-
inflammatory cytokine IL-1β, in addition to FSL-1 and P3C. FSL-1, P3C and IL-1β 
alone all gave significant increase in the OPG protein level, but not PIC (figure 3.5.2). 
Still, FSL-1 and IL-1β results in the highest and similar induction. None of the 
inhibitors gave a significant reduction in the FSL-1-induced OPG protein increase 
(figure 3.5.2 A), which is the same as detected on the mRNA level. Nor was there any 
significant reductions found for the P3C-induced OPG protein increase with the 
different inhibitors (figure 3.5.2 B). Thus, the significant reduction in the P3C-
induced OPG response by Indomethacin found at gene level was not detected at 
protein level. Furthermore, no significant inhibition of the PIC- and IL-1β-induced 
OPG protein increase was found (figure 3.5.2 C and D). 	  
 
Figure 3.5.1 Relative OPG gene expressions obtained from REST 2009 using qPCR data from a representative 
experiment with SW982 cells. The asterisk indicates significant difference from control (p < 0.05), and the 
number sign denotes significant difference from the TLR agonist alone (p < 0.05). Statistical significance was 
calculated from the total number of biological replicas (n = 5). A) The OPG gene expression ratios after 9 hours of 
stimulation with the TLR2/6 agonist FSL-1 in combination with either of the cPLA2 inhibitors, AVX002 or 
InhibX, or the COX inhibitor, Indomethacin. B) The OPG gene expression ratios after 9 hours of stimulation with 
the TLR1/2 agonist P3C in combination with either of the cPLA2 inhibitors, AVX002 or InhibX, or the COX 
inhibitor, Indomethacin. 
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In summary, OPG expression was found to be induced by the TLR agonists FSL-1 
and P3C, both on mRNA and protein level. The PG pathway does not seem to be 
involved in the FSL-1-mediated OPG expression, as neither cPLA2 inhibitors, nor a 
COX inhibitor gave significant changes. This is valid for both OPG mRNA and 
protein. However, inhibitory tendencies, although not significant, were seen at protein 
level. The P3C-mediated OPG expression, on the other hand, might involve the PG 
pathway, because the COX inhibitor showed significant reduction of OPG mRNA. 
However, this was not significantly reflected at protein level. Furthermore, the TLR 
agonist PIC and the cytokine IL-1β resulted in enhanced levels of OPG protein. As 
stated earlier, these two treatments were not analyzed at gene level. 
Figure 3.5.2 The mean concentration of OPG (ng/ml) in SW982 cell culture supernatants measured by ELISA. 
The asterisks indicate significant difference from control (*** p < 0.001). If present, a number sign would denote 
significant difference from the TLR agonist alone (p < 0.05). The error bars indicate ± SD (n = 5 for FSL-1 and 
P3C, n = 3 for PIC and IL-1β). A) 9 hours stimulation with the TLR2/6 agonist FSL-1 in combination with either 
of the cPLA2 inhibitors, AVX002 or InhibX, or the COX inhibitor, Indomethacin. B) 9 hours stimulation with the 
TLR1/2 agonist P3C in combination with either of the cPLA2 inhibitors, AVX002 or InhibX, or the COX 
inhibitor, Indomethacin. C) 9 hours stimulation with the TLR3 agonist PIC in combination with either of the 
cPLA2 inhibitors, AVX002 or InhibX, or the COX inhibitor, Indomethacin. D) 9 hours stimulation with the 
cytokine IL-1β in combination with either of the cPLA2 inhibitors, AVX002 or InhibX, or the COX inhibitor, 
Indomethacin. 
 
!
A) B) 
C) D) 
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3.6 The cPLA2 and COX enzymes are involved in TLR agonist-induced 
DKK1 expression 
DKK1 is an inhibitor of the WNT pathway, which is important for differentiation and 
function of the bone-forming osteoblasts [26]. Although a slightly lower response was 
detected for DKK1 mRNA in the initial TLR agonist experiments, the DKK1 gene 
expression was investigated further for 9 hours stimulation with TLR agonists 
combined with either of the cPLA2 inhibitors, AVX002 and InhibX, or the COX 
inhibitor, Indomethacin. To further elucidate the TLR signaling and find out whether 
there is a connection to key components in bone remodeling, the involvement of the 
PG pathway in the TLR agonist-induced DKK1 response in SW982 cells was 
examined. 
 
As for OPG, the gene analysis was only performed for the FSL-1 and the P3C. The 
DKK1 fold change for FSL-1 was slightly above 2, which was not significantly 
different from the control. Regarding the inhibitors, only Indomethacin gave a 
significant inhibition (figure 3.6.1 A). In the initial 6 hours experiments, the DKK1 
mRNA expression was higher after FSL-1 treatment than for P3C. However, 
following 9 hours stimulation P3C seems to be a better inducer than FSL-1, 
increasing DKK1 gene expression nearly a 3-fold (figure 3.6.1 B). Both cPLA2 
inhibitors and the COX inhibitor significantly reduced the P3C-induced increase in 
DKK1 mRNA levels. The AVX002 and InhibX gave similar levels of inhibition, 
while Indomethacin seemed to be even more effective. All P3C and inhibitor 
treatments resulted in DKK1 fold changes that were close to the control. Fold changes 
and SEMs from the five biological replicas, which the significance in this 
representative experiment is based on, are shown in appendix D. 
 
 !
A) B) 
Figure 3.6.1 Relative DKK1 gene expressions obtained from REST 2009 using qPCR data from one 
representative experiment with SW982 cells. The asterisk indicates significant difference from control (p < 0.05), 
and the number sign denotes significant difference from the TLR agonist alone (p < 0.05). Statistical significance 
was calculated from the total number of biological replicas (n = 5).  A) The DKK1 gene expression ratios after 9 
hours of stimulation with the TLR2/6 agonist FSL-1 in combination with either of the cPLA2 inhibitors, AVX002 
or InhibX, or the COX inhibitor, Indomethacin. B) The DKK1 gene expression ratios after 9 hours of stimulation 
with the TLR1/2 agonist P3C in combination with either of the cPLA2 inhibitors, AVX002 or InhibX, or the COX 
inhibitor, Indomethacin. 
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To summarize, the TLR agonists, FSL-1 and P3C, resulted in up-regulation of the 
DKK1 gene, although this was non-significant for FSL-1. Each agonist treatment 
showed inhibitory tendencies for both cPLA2 inhibitors and the COX inhibitor. 
However, the down-regulation of DKK1 by all inhibitors was only significant for 
P3C. The COX inhibitor resulted in significant inhibition for FSL-1. These results 
suggest that the PG pathway is involved in P3C-mediated DKK1 expression. The 
involvement of this pathway in FSL-1-mediated DKK1 expression is less clear, but 
still possible. 
 
3.7 TLR agonist-induced IL-6 expression involves cPLA2 and COX 
enzymes 
The SW982 cells are known to express the pro-inflammatory cytokine IL-6, and the 
expression is highly enhanced by IL-1β [62]. IL-6 is one of the factors responsible for 
perpetuating the synovitis in RA by promoting B cell antibody production and 
activation of T cells, macrophages and osteoclasts [1]. In the TLR agonist 
experiments, the target genes, IL-6 and COX-2 (see next section for COX-2), were 
used as positive controls to ensure that the induction had been successful – although 
the result in itself is interesting for mapping TLR signaling events in the SW982 cells. 
 
Both FSL-1 and P3C were found to be strong inducers of IL-6 mRNA expression in 
the SW982 cells, with fold change values of 45 and 31 respectively (figure 3.7.1) – 
i.e. much higher induction than found for OPG and DKK1. The cPLA2 inhibitors, 
AVX002 and InhibX, did not give any significant effect on the FSL-1-induced IL-6 
expression, but the COX inhibitor, Indomethacin, gave a significant reduction (figure 
3.7.1 A). For the P3C-induced IL-6 expression, all the inhibitors resulted in 
significant inhibition (figure 3.7.1 B). Fold changes and SEMs from the five 
biological replicas, which the significance in this representative experiment is based 
on, are shown in appendix E. 
  
!
A) B) 
Figure 3.7.1 Relative IL-6 gene expressions obtained from REST 2009 using qPCR data from one representative 
experiment with SW982 cells. The asterisk indicates significant difference from control (p < 0.05), and the 
number sign denotes significant difference from the TLR agonist alone (p < 0.05). Statistical significance was 
calculated from the total number of biological replicas (n = 5).  A) The IL-6 gene expression ratios after 9 hours of 
stimulation with the TLR2/6 agonist FSL-1 in combination with either of the cPLA2 inhibitors, AVX002 or 
InhibX, or the COX inhibitor. Indomethacin. B) The IL-6 gene expression ratios after 9 hours of stimulation with 
the TLR1/2 agonist P3C in combination with either of the cPLA2 inhibitors, AVX002 or InhibX, or the COX 
inhibitor, Indomethacin. 
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In conclusion, both TLR agonists, FSL-1 and P3C, resulted in extensive induction of 
the IL-6 gene, implying that the TLR agonist stimulation was successful. Only the 
COX inhibitor had significant effect on FSL-1-mediated IL-6 expression. For P3C, 
however, both cPLA2 inhibitors and the COX inhibitor reduced the IL-6 induction 
significantly. This indicates that the PG pathway may contribute to IL-6 increase 
following FSL-1 stimulation, and the pathway is indeed involved in P3C-mediated 
IL-6 expression. 
 
3.8 TLR agonist-induced COX-2 is affected by cPLA2 and COX inhibitors 
Like IL-6, the COX-2 gene is among the genes whose expression has been 
characterized in the synovial SW982 cells, and it is known to be strongly induced by 
IL-1β [62]. As stated earlier, the COX-1 and COX-2 enzymes are responsible for 
converting AA into precursors of inter alia PGs, which are prominent in RA. COX-1 
is constitutive and is accountable for the basal levels of PGs, while COX-2 is the 
inducible isoform [83]. 
 
Both FSL-1 and P3C were found to highly induce COX-2 mRNA in the SW982 cells, 
with fold changes of 24 and 13 respectively (figure 3.8.1) – markedly higher than the 
OPG and DKK1 induction, but still not as much as the IL-6 induction. As for IL-6, 
FSL-1 was the most potent inducer. Only the COX inhibitor Indomethacin gave a 
significant reduction of the FSL-1-mediated COX-2 induction (figure 3.8.1 A), which 
was also the case for IL-6. The P3C-mediated COX-2 expression, on the other hand, 
was significantly inhibited by the two cPLA2 inhibitors, AVX002 and InhibX, and the 
COX inhibitor, Indomethacin (figure 3.8.1 B). Fold changes and SEMs from the five 
biological replicas, which the significance in this representative experiment is based 
on, are shown in appendix F. 	    
!
A) B) 
Figure 3.8.1 Relative COX-2 gene expressions obtained from REST 2009 using qPCR data from one 
representative experiment with SW982 cells. The asterisk indicates significant difference from control (p < 0.05), 
and the number sign denotes significant difference from the TLR agonist alone (p < 0.05). Statistical significance 
was calculated from the total number of biological replicas (n = 5). A) The COX-2 gene expression ratios after 9 
hours of stimulation with the TLR2/6 agonist FSL-1 in combination with either of the cPLA2 inhibitors, AVX002 
or InhibX, or the COX inhibitor, Indomethacin. B) The COX-2 gene expression ratios after 9 hours of stimulation 
with the TLR1/2 agonist P3C in combination with either of the cPLA2 inhibitors, AVX002 or InhibX, or the COX 
inhibitor, Indomethacin. 
	   49 
In conclusion, both TLR agonists, FSL-1 and P3C, resulted in a high up-regulation of 
the COX-2 gene, providing yet another proof that the TLR agonist stimulation was 
successful. Although all inhibitors used showed inhibitory tendencies, only the COX 
inhibitor had significant effect on FSL-1-mediated COX-2 expression. As for IL-6, 
both cPLA2 inhibitors and the COX inhibitor reduced the P3C-mediated COX-2 
expression significantly. Hence, the PG pathway contributes to the P3C-mediated 
COX-2 expression, and possibly also to the FSL-1-mediated. 
 
3.9 AA release increases in response to TLR agonists 
The aforementioned PGs, which are found to be elevated in RA, belong to the 
eicosanoid class of lipid mediators. Eicosanoids can be derived from AA, which is 
released from membrane phospholipids by PLA2s [39]. There are four different 
groups of PLA2 enzymes: cPLA2, sPLA2, iPLA2, and LpPLA2. All these have several 
subgroups [52]. The cPLA2 and the sPLA2 groups are considered the most important 
for PG formation, and GIVA cPLA2 is believed to be the major enzyme for AA 
release [40]. In parallel to AA release, certain cell models have been found to release 
OA, due to the actions of sPLA2 and iPLA2 [42, 43]. 
 
To establish whether there is a connection between TLR signaling and the PG 
pathway in the human synovial SW982 cells, the activity of PLA2 enzymes following 
TLR activation were investigated. This was done by determining the cells’ AA release 
after TLR agonist stimulation by a radioactivity assay. In addition, OA release was 
investigated. IL-1β was used as a positive control, because this cytokine is known to 
stimulate AA release in human SFs [84]. Different TLR agonist concentrations were 
tested over the same time periods as for the gene expression analysis, namely 3, 6, 9, 
12 and 24 hours. The results are given as fold change relative to the control, which are 
set to 1. 
 
The FSL-1, P3C and PIC all resulted in increased levels of AA release compared to 
untreated cells (figure 3.9.1). For FSL-1, the AA release was significantly increased 
after 6 hours for both the concentrations used, 100 ng/ml and 50 ng/ml (3.9.1 A). The 
FSL-1-mediated AA release peaked at a fold change of 4.4 after 9 hours with 100 
ng/ml, but there was no significant difference between the two FSL-1 concentrations. 
P3C significantly increased the AA release after 9 hours stimulation, which also was 
its maximum with a fold change of 3 (figure 3.9.1 B). However, this was only 
significant for 300 ng/ml, which generally resulted in higher release. The AA release 
following PIC stimulation was significantly increased already after 6 hours (figure 
3.9.1 C). For all time periods, there was no significant difference between 5 µg/ml 
and 1 µg/ml PIC. PIC-mediated AA release peaked after 12 hours with a fold change 
of 2.9. As expected, the positive control IL-1β resulted in elevated AA levels (figure 
3.9.1 D). The IL-1β time curve peaks at 9 hours with a fold change value of 4.5. This 
response is very similar to that of FSL-1. The time curves (figure 3.9.1) are based on 
three biological replicas, and the mean fold changes and the standard deviations (SDs) 
are shown in appendix G. 
 
The OA release, on the other hand, generally showed minimal, non-significant 
changes in response to the TLR agonists used here (data not shown).  
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To summarize, FSL-1, P3C, and IL-1β treatments led to increased AA release by the 
SW982 cells, and this peaked after 9 hours stimulation. There was little difference 
between 100 and 50 ng/ml FSL-1. The P3C response, on the other hand, was higher 
with the 300 ng/ml concentration, than with 100 ng/ml. PIC enhanced the AA release, 
but had its peak after 12 hours. However, this was not significantly different from the 
increase seen after 9 hours. There was no noticeable difference between 5 µg/ml and 1 
µg/ml PIC. Of the TLR agonists used here, FSL-1 was the one resulting in the highest 
AA release, which was comparable to that of IL-1β. 	    
Figure 3.9.1 Time curves of mean fold change (n = 3) of AA release in culture medium after TLR agonist 
stimulation of SW982 cells. The curves were generated from data obtained by radioactivity assays. Error bars and 
significance are not shown (see appendix G). A) Relative AA release after stimulation with the TLR2/6 agonist 
FSL-1. B) Relative AA release after stimulation with the TLR1/2 agonist P3C. C) Relative AA release after 
stimulation with the TLR3 agonist PIC. D) Relative AA release after stimulation with the cytokine IL-1β. 
!
A) ! B) !
C) ! D) !
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3.10 The GIVA cPLA2 is the dominant PLA2 responsible for the TLR 
agonist-induced AA release 
Having discovered that all the TLR agonists in question resulted in a significant 
increase in AA release from the SW982 cells, the next goal was to reveal which PLA2 
enzymes were responsible. As stated in the last section, the FSL-1- and P3C-mediated 
AA release peaked after 9 hours, and PIC also resulted in significant AA release 
increase with this stimulation time. Therefore, 9 hours were chosen as the stimulation 
time for the next experiments. To find the responsible PLA2 enzymes, the same 
radioactivity assay used in the last section was performed. However, before 
stimulating with TLR agonists, the SW982 cells were pre-treated with different 
cPLA2, sPLA2, and iPLA2 inhibitors for 2 hours. The inhibitors used and their details 
are listed in table 2.1 under “Materials and methods”. By inhibiting specific PLA2 
enzymes, it is possible to suggest which of them that may contribute to the TLR-
mediated AA release. 
 
Both GIVA cPLA2 inhibitors, AVX002 and CAY10502, were found to significantly 
reduce the FSL-1-mediated AA release from the SW982 cells (figure 3.10.1 A). In 
fact, CAY10502 resulted in complete inhibition down to basal level of AA release, 
while AVX002 showed around 60% inhibition. Furthermore, none of the sPLA2 
inhibitors, CAY10590 and Varespladib, significantly affected the FSL-1-mediated 
AA release. The iPLA2 inhibitor BEL, on the other hand, had an inhibitory effect that 
was similar to that of AVX002. MAFP, which inhibits both iPLA2 and cPLA2, 
resulted in nearly complete inhibition. In the case of the P3C-mediated AA release, 
the different PLA2 inhibitors showed the same inhibition trends as for FSL-1 (figure 
3.10.1 B). The inhibitors’ effects on the PIC-mediated AA release turned out to have 
similar tendencies as for FSL-1 and P3C (figure 3.10.1 C). However, the inhibitory 
effects of the cPLA2 inhibitor, AVX002, and the iPLA2 inhibitor, BEL, were non-
significant. 	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Figure 3.10.1 The mean fold change of AA release in culture medium after combination treatment with a TLR 
agonist and a PLA2 inhibitor. The red bars are a TLR agonist + cPLA2 inhibitors, the blue bars are a TLR agonist + 
sPLA2 inhibitors, and the green bars are a TLR agonist + iPLA2 inhibitors (MAFP inhibits both iPLA2 and cPLA2). 
The charts were generated from data obtained by radioactivity assays. The asterisks indicate significant difference 
from control (* p = 0.01 - 0.05, ** p = 0.001 - 0.01, *** p < 0.001), and the number signs indicate significant 
difference from the TLR agonist alone (# p = 0.01 - 0.05, # # p = 0.001 - 0.01, # # # p < 0.001). Error bars denote ± 
SD (n = 3) A) Relative AA release after stimulation with the TLR2/6 agonist FSL-1 and the different PLA2 
inhibitors. B) Relative AA release after stimulation with the TLR1/2 agonist P3C and the different PLA2 inhibitors. 
C) Relative AA release after stimulation with the TLR3 agonist PIC and the different PLA2 inhibitors. 
!
A) 
B) 
C) 
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In summary, the TLR agonists, FSL-1, P3C and PIC, all resulted in increased levels 
of AA release. GIVA cPLA2 seems to be the dominant PLA2 responsible for this. In 
addition, there are signs of possible iPLA2 involvement. 
 
3.11 TNF-α increases DKK1 gene expression 
As mentioned in the first result section, RANKL, OPG and DKK1 are key 
components in bone remodeling. RANKL is a ligand essential to differentiation of the 
bone-degrading osteoclasts, OPG can hinder osteoclast activation by competitive 
binding of RANKL, and DKK1 is an inhibitor of the bone-forming pathway. The pro-
inflammatory cytokine TNF-α is one of the factors believed to be a major contributor 
to RA pathogenesis, by e.g. induction of osteoclast formation [26]. 
 
A former master’s student in the PLA2 research group, Ahmed Siddik, investigated 
the effect of TNF-α on RANKL, OPG and DKK1 expression in the SW982 cells. By 
qPCR, it was found that TNF-α increased the expression of OPG and DKK1. The up-
regulation of TNF-induced OPG and DKK1 was small, but significant. Regarding 
RANKL, the primers used then did not work well in qPCR and the results were 
inconclusive.  
 
In this master’s project, qPCR analyses of SW982 cells stimulated in 6, 12, 24 and 48 
hours with TNF-α were performed to examine whether the RANKL, OPG and DKK1 
mRNA expression changed over time. This was performed prior to discontinuing the 
use of the RANKL primer, and it was during these experiments the primer was found 
to be nonspecific, as described in section 3.1. 
 
TNF-α gave no significant induction of RANKL for any of the stimulation periods 
(figure 3.11.1 A). This was also the case for OPG, whose expression showed even 
more statistical uncertainties (data not shown). DKK1 however, showed a significant 
2.8-fold change after 6 hours TNF-α stimulation (figure 3.11.1 B). Fold changes and 
SEMs from the three biological replicas, which the significance in this representative 
experiment is based on, are shown in appendix H. 
 
In the above-mentioned experiments, the cPLA2 inhibitors AVX002 and InhibX were 
included in two different concentrations (1 and 5 µM) to examine whether potential 
TNF-α-induced RANKL, OPG or DKK1 expression involved the cPLA2 enzyme and 
whether this was time and/or dose dependent. As stated above, neither RANKL nor 
OPG showed a significant increase after TNF-α treatment of the SW982 cells, while 
DKK1 gene expression did increase significantly after 6 hours. Furthermore, none of 
the cPLA2 inhibitors were found to give significant effects for any of the genes (data 
not shown).  
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RANKL and OPG gene expression analysis following TNF-α treatment were 
inconclusive, and the RANKL primer was suspected to be nonspecific. The DKK1 
gene, however, was significantly up-regulated after 6 hours TNF-α stimulation. The 
combination treatment with a cPLA2 inhibitor plus TNF-α showed no response in 
expression levels for any of the genes. 
 
3.12 TLR2 and TLR3 gene expressions increase in response to TNF-α 
SFs are known to express certain TLRs, and as shown in previous result sections, the 
SW982 cells express all TLRs from 1 to 7. TLRs are activated by molecular patterns 
on microbes and by endogenous molecules, such as those present in inflamed joints. 
This activation results in inter alia production of cytokines, such as IL-1, IL-6 and 
TNF-α [9]. 
 
6, 12, 24 and 48 hours TNF-α stimulation of the SW982 cells were performed 
followed by qPCR analyses, to investigate whether the TLRs expressed by these cells 
are affected by TNF-α and whether it would change over time. It was during these 
experiments there were found indications that TLR1, TLR6, and TLR7 primers may 
be nonspecific, as described in section 3.2. 
 
TLR1 showed no distinct induction by TNF-α (figure 3.12.1 A). For all stimulation 
periods, the TLR1 fold change was not significantly different from the control. This 
was also the case for TLR4, TLR5, TLR6 and TLR7 (data not shown). TLR2 and 
TLR3, on the other hand, showed significant increase in mRNA levels after TNF-α 
stimulation. TLR2 was the one that resulted in the highest induction, with fold change 
values of 4.6 and 4.2 after 6 and 12 hours (figure 3.12.1 B). The expression seemed to 
decrease for longer stimulation periods. TLR3 fold change was 2.2 after 6 hours and 
2.3 after 24 hours of TNF-α stimulation, and from there it decreased with time (figure 
3.12.1 C). Fold changes and SEMs from the three biological replicas, which the 
significance in this representative experiment is based on, are shown in appendix I. 
!
A) B) 
Figure 3.11.1 Time curves of relative gene expressions obtained from REST 2009 using qPCR data from one 
representative experiment with SW982 cells. The asterisk indicates significant difference from control (p < 0.05).  
Statistical significance was calculated from the total number of biological replicas (n = 3).  A) The RANKL 
mRNA fold changes after 6, 12, 24 and 48 hours of TNF-α stimulation. B) The DKK1 mRNA fold changes after 
6, 12, 24 and 48 hours of TNF-α stimulation. 
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In addition, the time-lapse experiments included the cPLA2 inhibitors, AVX002 and 
InhibX, in order to investigate if TNF-α-induced TLR expression involves the cPLA2 
enzyme. The inhibitors were used in two different concentrations (1 and 5 µM) to see 
if a potential response was time and/or dose dependent. However, the inhibitors 
showed no significant effect for any of the TLRs in question (data not shown).  
 
 
 
 
To summarize, TNF-α treatment resulted in a significant up-regulation of the TLR2 
and TLR3 genes. TLR1, TLR4, TLR5, TLR6 and TLR7 expression was not affected. 
However, TLR1, TLR6 and TLR7 primers showed signs of being nonspecific. 
Furthermore, the combination treatment with a cPLA2 inhibitor plus TNF-α showed 
no response in expression levels for any of the TLR genes.	  	    
! A) 
B) C) 
Figure 3.12.1 Time curves of relative gene expressions obtained from REST 2009 using qPCR data from one 
representative experiment with SW982 cells. The asterisk indicates significant difference from control (p < 0.05). 
Statistical significance was calculated from the total number of biological replicas (n = 3). A) The TLR1 mRNA 
fold changes after 6, 12, 24 and 48 hours of TNF-α stimulation. B) The TLR2 mRNA fold changes after 6, 12, 24 
and 48 hours of TNF-α stimulation. C) The TLR3 mRNA fold changes after 6, 12, 24 and 48 hours of TNF-α 
stimulation. 
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3.13 IL-6 gene expression following TNF-α stimulation 
TNF-α is known to increase the IL-6 production in human SFs [85]. Therefore the IL-
6 mRNA expression was used to check whether the TNF-α stimulation in the above-
mentioned (section 3.11 and 3.12) time-lapse experiments of the SW982 cells had 
been successful. TNF-α seemed to have increased the IL-6 expression in these 
experiments (figure 3.13.1), but the 9-fold change was non-significant. Mean fold 
change and its SEM from the three biological replicas, which the non-significance in 
this representative experiment is based on, are shown in appendix J. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
This IL-6 response is considerably weaker than what members of the PLA2 research 
group usually detect in TNF-α stimulated SW982 cells. TNF-induced IL-6 fold 
change values are normally above 20 [86]. The poor IL-6 response in the TNF-α 
experiments indicates that the stimulation has been non-optimal, and the results may 
not reflect the reality. 
 
  
Figure 3.13.1 Relative IL-6 gene expression obtained from 
REST 2009 using qPCR data from one representative 
experiment with 24 hours TNF-α stimulation of SW982 cells.  
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4. DISCUSSION 
This master’s thesis involves the study of two different pathways believed to be a part 
of the RA pathogenesis. On the one side, TLR signaling was investigated. On the 
other side, the effect of the pro-inflammatory cytokine TNF-α, which is a down-
stream consequence of TLR activation, was studied. Both regarding TLRs and TNF-
α, the aim was to reveal whether there was a connection between these and some of 
the molecules essential for bone remodeling, and whether the connection involved the 
cPLA2 enzyme. In addition, the effect of TNF-α stimulation on TLR expression was 
examined.  
 
All experiments performed during this master’s project were done on post-confluent 
SW982 synovial cells. Post-confluent cells have stopped proliferating due to contact 
inhibition. Results from flow cytometry, performed by other members of the PLA2 
research group, have shown that 85-90% of the cells are at this point in G1/G0 phase 
of the cell cycle. However, this analysis makes no distinction between the two phases. 
Assuming that the cells have entered the G0 phase, they would be in a state of 
quiescence. As opposed to senescence, apoptosis, and terminal differentiation, 
quiescence is reversible. The traditional view is that quiescent cells are dormant and 
have a reduced metabolism. However, recent evidence shows that quiescent cells are 
in fact exhibiting a special quiescence program, which e.g. involves the expression of 
genes that enforce this dormant state and genes that ensure the reversibility of the 
state [87]. Specifically regarding inflammation, it was found that quiescent fibroblasts 
activate inflammatory responses to a greater extent than proliferative fibroblasts do. 
Some of the results in this study were that quiescent fibroblasts have a distinctly 
higher expression of pro-inflammatory genes, such as COX-2, cytokines, CAMs and 
MMPs, than that of the proliferative ones [88]. 
 
4.1 RANKL, OPG and DKK1 gene expression 
The RANKL, OPG and DKK1 genes all code for key proteins involved in bone 
remodeling. Osteoclasts are the cell type responsible for degradation of bone, and 
RANKL is a component that is necessary for differentiation and function of these 
cells. OPG is a decoy receptor for RANKL, meaning it can competitively bind 
RANKL and prevent it from activating osteoclasts. OPG can thus exert protection 
against bone loss [19]. 
 
Osteoblasts are the counterpart to osteoclasts, and they are responsible for the 
formation of new bone tissue. Osteoblast differentiation and function are dependent 
on the WNT pathway, and the DKK1 protein functions as an inhibitor of this pathway 
[19]. In addition, it facilitates bone degradation by decreasing the expression of OPG 
[26]. 
 
Normally there is a balance between bone formation and degradation. In diseases like 
RA, however, this balance is no longer stable and bone loss is observed. Excessive 
bone degradation occurs, because the osteoblast function is reduced and the 
osteoclasts are overly activated. The reason for this seems to be an excess of RANKL 
relative to OPG. More specifically, it is likely that the RANKL/OPG ratio at the 
pannus-bone interface, the point where bone erosion occurs, is the determining factor 
[24]. This is believed to be true since RANKL has been found to be highly up-
regulated at pannus-bone interface in RA tissue, while the OPG expression was 
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minimal here. However, in other synovial membrane cells, away from this interface, 
the OPG expression was higher [25].  
 
In SW982 cells, OPG mRNA was detected. In addition, RANKL expression may be 
present, but the qPCR primer for this gene did not show the expected specificity. The 
Cq values indicate that the RANKL expression is considerably lower than the OPG 
expression in these cells. Ahmed Siddik was not able to detect RANKL in non-
stimulated SW982 cells with the primer used at the time. The PLA2 research group 
have used yet another RANKL primer without obtaining signals to any considerable 
degree in these cells. However, Siv Kristine Sola Strand, another former master’s 
student, succeeded in detecting RANKL in Saos-2 osteoblasts by using the same 
primer as Siddik, confirming that it was functional. When taking all these RANKL 
results into account, it would be safe to assume that RANKL is relatively weakly 
expressed in the SW982 cells. Because the use of the RANKL primer was 
discontinued, it was not possible to investigate the RANKL/OPG ratio.  
 
The SW982 cell line was established from a synovial sarcoma. and the cells are 
believed to originate from SFs. SFs from RA patients have been shown to express 
both RANKL and OPG, with OPG being present in the highest amount [89]. The fact 
that more OPG was present may indicate that these RA cells were not taken from the 
pannus-bone interface. The SW982 cells have similarities to these RA SFs, because 
they too express more OPG than RANKL. This is a further indication that the SW982 
cells may originate from SFs, and that this is a suitable cell model for studying RA-
related events in the synovium. However, it must be kept in mind that these are cancer 
cells and can for that exact reason exhibit different gene expressions then their normal 
state cells.  
 
Furthermore, DKK1 has in recent years been suggested to be just as important in the 
RA pathogenesis as the RANKL/OPG system. DKK1 is in fact found highly 
expressed in inflamed synovium, and especially in the SFs [26]. In the SW982 cells, 
the DKK1 gene is relatively highly expressed – at similar level as OPG. If the 
translation corresponds with this and the proteins are secreted, it can be assumed that 
although OPG is produced by RA SFs, similar levels of DKK1 can potentially reduce 
OPG’s bone-protective effect. This will be further discussed in section 4.4. 	  
4.2 TLR gene expression 
TLRs are a type of PRRs found on innate immune cells. They recognize various 
microbial components. In addition, TLRs can bind certain endogenous molecules, 
such as those found in arthritic joints. Upon activation, the innate immune cells pass 
on the signal and activate the adaptive immune system. It has been proposed that the 
TLRs are one of the major contributors in maintaining the inflammatory response in 
RA [9]. In e.g. RA SFs, TLR2, TLR3 and TLR4 activation have been found to 
increase the expression of RANKL mRNA and protein, which subsequently promotes 
osteoclast differentiation [15, 33]. 
 
SFs, which are among the key effector cells in RA, are known to express TLR1-6 [5]. 
Additionally, certain reports have shown elevated levels of TLR7 in RA SFs [8]. 
There are no published data on the TLR expression in the synovial SW982 cells. 
Consequently, the TLR1-7 gene expression in these cells was investigated. They were 
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found to express all the TLRs in question. The average Cq values suggest that TLR2 is 
the highest expressed TLR in the SW982 cells, closely followed by TLR3. TLR4 and 
TLR6 are intermediately expressed, while TLR1, TLR5 and TLR7 are moderately 
expressed. This is somewhat different from the findings in a study done on RA SFs 
[34]. The highest TLR expression in the RA SFs was found for TLR3, followed by 
TLR4. TLR2, TLR1 and TLR6 were readily detected as well. TLR5 was barely 
detectable, and TLR7 was not found in the cells used in this study. Even though the 
order of the TLR expression levels is not exactly the same in SW982 cells and RA 
SFs, the similarity is that TLR2, TLR3 and TLR4 are among the most highly 
expressed TLRs. This also coincides with another finding, which states that RA SFs 
have especially high levels of functional TLR2, TLR3 and TLR4 [5]. The fact that 
TLR7 was not detected in the mentioned RA SF study, but has been detected in other 
studies on RA SFs, shows that even though the same cell type are being analyzed, it 
does not necessarily give the same results. The reason may be that the RA SFs used 
were from different locations in the joint, or it may reflect the heterogeneity of the 
disease. All things considered, the SW982 cells seem like a good model for 
investigating TLR signaling. 
 
4.3 Suggested TLR signaling pathways in SW982 cells 
Before entering a detailed discussion related to TLR agonist stimulation of synovial 
SW982 cells, an overview of TLR signaling pathways in these cells is presented 
(figure 4.3.1). In the figure, the red block arrows in front of a component signify what 
was actually found in the TLR agonist experiments. The signaling proteins and the 
transcription factor were not investigated in this project, and are consequently based 
on suggestions or established knowledge. Mapping the signaling proteins involved in 
these processes in the SW982 cells are issues that can be addressed in further 
research.  
 
The transcription factor involved in the expression of OPG and DKK1 following 
TLR1/2, TLR2/6 and TLR3 activation is most likely to be NF-κB. As demonstrated in 
figure 4.3.1, TLR1/2 and TLR2/6 utilize the MyD88-dependent pathway that results 
in NF-κB activation [9]. NF-κB activation can also be obtained by TLR3 signaling 
through the kinase receptor-interacting protein (RIP1) [90]. OPG expression has been 
found to be dependent of NF-κB in dendritic cells [91], and the DKK1 gene has two 
NF-κB binding sites in its promoter [92]. Furthermore, the IL-6 and the COX-2 genes, 
used as positive controls, are known to be NF-κB dependent in SFs [93]. 
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Figure 4.3.1 TLR signaling pathways in SW982 cells activated by the TLR agonists FSL-1, P3C and PIC. 
The red block arrows in front of a component signify what was actually found in the TLR agonist 
experiments, and they symbolize an increase of the respective component. The dashed arrows are only 
suggested connections, while the solid ones symbolize connections found in the literature. AA, arachidonic 
acid; COX, cyclooxygenase; cPLA2, cytosolic phospholipase A2; DKK1, dickkopf homolog 1; EP, 
prostaglandin E2 receptor; ERK, extracellular-signal regulated kinase; FSL-1, synthetic diacylated 
lipoprotein; IκBα, inhibitor of NF-κB; IL, interleukin; iPLA2, Ca2+-independent phospholipase A2; IRF, 
interferon regulatory factor; MAPK, mitogen-activated protein kinase; MyD88, myeloid differentiation 
primary-response protein-88; NF-κB, nuclear factor-κB; OPG, osteoprotegerin; P3C, the synthetic 
triacylated lipoprotein Pam3CSK4; PG, prostaglandin; PIC, the synthetic dsRNA analog Poly(I:C); RIP1, 
receptor interacting protein 1; TIRAP, TIR domain-containing adaptor protein; TRIF, TIR domain-
containing adaptor-inducing IFN-β 
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4.4 OPG and DKK1 gene expression in response to TLR agonists 
As mentioned in section 4.2, stimulation of TLR2, TLR3 and TLR4 have been shown 
to increase the RANKL expression in RA SFs. Increased OPG expression has been 
detected after stimulation of TLR3 and TLR4 [91]. However, this was in dendritic 
cells. No published data were found regarding a connection between TLR activation 
and DKK1. Having found that the SW982 cells express all TLRs from 1 to 7, the next 
step was to explore whether there was a connection between TLR activation and the 
expression of RANKL, OPG and DKK1. As previously stated, the RANKL qPCR 
primer did not function as expected, hence only OPG and DKK1 were investigated.  
 
Upon stimulation with the TLR2/6 agonist FSL-1, the TLR1/2 agonist P3C, and the 
TLR3 agonist PIC, it was found that the SW982 cells increase their OPG gene 
expression. This increase was significant for all TLR agonists after a stimulation 
period of 9 hours. These findings coincide with the dendritic cell study, where 
stimulation of certain TLRs resulted in elevated OPG levels. Regarding the disrupted 
RA bone homeostasis, an OPG increase would be a positive event, as OPG binds 
RANKL and thereby reduces activation of bone-degrading osteoclasts. Because the 
TLRs are a part of the innate defense mechanisms, it is not surprising that they will 
activate protective responses, such as increased OPG. However, upon continuous 
activation of TLRs due to endogenous ligands, which is believed to occur in RA, 
there would probably be too much OPG produced. There is a possibility that an 
excess of OPG could lead to additional, unwanted effects, such as increased 
proliferation or reduced apoptosis of RA effector cells. In addition to being a decoy 
receptor for RANKL, OPG has been found to function as an antagonizing receptor for 
TNF-related apoptosis-inducing ligand (TRAIL), hence preventing apoptosis [94]. 
Furthermore, it has been demonstrated that this is happening in cultured RA SFs [95]. 
Elevated levels of OPG due to IL-1β stimulation caused reduced apoptosis of RA 
SFs, indicating a role for OPG in the synovial hyperplasia observed in RA. This may 
be something to investigate further in the SW982 cells, by e.g. treating the cells with 
external OPG and observe their growth. 
 
In initial experiments with 6 hours TLR agonist stimulation, P3C resulted in a smaller 
OPG induction than FSL-1, and PIC even less. FSL-1 generally showed a stronger 
induction than P3C for several of the responses studied. This may be due to the higher 
expression of TLR6, than TLR1, in the SW982 cells. If this is also shown to be true at 
protein level, it can be assumed that the more receptor present, the stronger the 
agonist response. However, after several biological replicas of 9 hours stimulation, 
the OPG fold induction mediated by FSL-1 and P3C was leveled. That the initial 
experiments showed minimal PIC induction, do not coincide with the finding that 
TLR3 expression seems to be fairly high in the SW982 cells. TLR3 is an intracellular 
receptor, and it may be assumed that PIC would need a longer stimulation period to 
evoke the same amount of response as FSL-1 and P3C. However, 24 hours PIC 
stimulation resulted in even less OPG induction than after 9 hours. Moreover, PIC 
negatively affected the SW982 cells’ morphology. The cells did not seem to thrive, 
and apoptosis was suspected. A lot more cells than usual loosened from the cell 
culture plate, and the ones remaining adherent adopted an abnormal morphology. The 
cells are usually thinner and longer upon serum starvation and stimulation, as this 
stresses the cells. With PIC stimulation, the cells were even thinner and there was 
more space between them. As the PIC stimulation period increased, more cells 
loosened. As a consequence, the PIC concentration was reduced. The lower 
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concentration (5 µg/ml) was better tolerated by the cells, but they still adopted a 
thinner shape and loosened from the culture plate. The SW982 cells are obviously 
very sensitive to this viral dsRNA analog. The PIC-mediated OPG response, and the 
other responses detected following PIC stimulation, may be due to apoptotic stress. 
However, according to the aforementioned dendritic cell study, an OPG up-regulation 
is anticipated upon TLR3 activation. 
 
The pro-inflammatory cytokine, IL-1β, used as positive control stimulation, induced 
OPG expression in the SW982 cells, in comparable levels to that of FSL-1. IL-1β is 
known to contribute to inter alia bone erosion in RA, but the cytokine has been shown 
to increase both OPG mRNA and protein levels in RA SFs [95, 96]. This illustrates 
the complexity of cytokine effects. Even though IL-1β increases the expression of the 
bone-protecting OPG in RA, this is not adequate to counteract other processes 
favoring bone loss. However, the OPG up-regulation following IL-1β stimulation of 
RA SFs can also function to prevent apoptosis, as previously discussed.  
 
Furthermore, FSL-1, P3C and PIC were found to induce DKK1 gene expression in the 
SW982 cells, although the response was generally weaker than for OPG. Because the 
DKK1 gene promoter has NF-κB binding sites [92] and the TLRs in question are 
known to activate this transcription factor, an increase in DKK1 expression is 
expected. Elevated DKK1 levels will lead to less activation of osteoblasts and hence 
reduced bone formation, consequently tipping the bone homeostasis towards 
degradation. More specifically, since there are fewer active osteoblasts, there will be 
less OPG production. This will consequently lead to more RANKL available and 
increased osteoclast activity. In addition, DKK1 expression in osteoarthritic SFs has 
been found to increase the production of angiogenic factors and cartilage degrading 
components [97], which both are hallmarks of arthritis. Thus, DKK1 seems to have 
several negative effects in RA.    
 
As for OPG, 9 hours was the stimulation period resulting in significant increase in 
DKK1 gene expression for all TLR agonist. After 9 hours stimulation, the DKK1 
increase was similar for FSL-1 and P3C, while PIC resulted in a higher induction. PIC 
showing the highest induction is the opposite of that seen for OPG. This suggests that 
the intracellular TLR3 activation, and subsequent activation of NF-κB, has a greater 
effect on the DKK1 expression. Again, this may be a result of apoptotic stress 
mediated by PIC. 
 
The positive control, IL-1β, increased the DKK1 expression of the SW982 cells, and 
this is also found to be the case in arthritic SFs. However, it has been demonstrated 
that IL-1β do not induce DKK1 directly. It increases the expression of the enzyme 
11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) that activates glucocorticoids, 
which then again induce DKK1 expression [98].  
 
In summary, all TLR agonists in question cause elevated mRNA levels of both OPG 
and DKK1 in SW982 cells. In a RA joint, it can be imagined that even though 
expression of OPG increases and reduce bone degradation, similar levels of DKK1 
may counteract this by preventing bone formation and OPG expression by 
osteoblasts. Specifically in the SFs, OPG may exert negative effects in a RA context 
by preventing apoptosis of these cells, hence contributing to synovial hyperplasia. 
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Moreover, DKK1 makes the SFs express angiogenic and cartilage degrading factors, 
which both are involved in RA. 
4.5 TLR activation and secretion of OPG protein 
The OPG protein analyses of cell culture supernatants, collected after 9 hours TLR 
agonist treatment, revealed the same trends as seen at mRNA level in the initial 6 
hours experiments. All TLR agonists resulted in OPG protein induction. The FSL-1- 
and IL-1β-mediated increase in OPG protein level was similar, and significantly 
higher than for both P3C and PIC. P3C seemed to evoke a slightly stronger induction 
than PIC, but the difference was not significant. The mRNA trend following 6 hours 
of stimulation coincided with the protein trend after 9 hours stimulation. This is 
anticipated, as the protein response always will be somewhat delayed relative to the 
gene response. The same trend was found in the first gene analyses after 9 hours 
stimulation. However, the more biological replicas performed, the more similar FSL-1 
and P3C response was observed. There was a hint of this tendency in an initial 
experiment where supernatants were collected after 12 hours stimulation. However, 
several replicas and inhibitor treatments were only performed with 9 hours 
stimulation periods, and therefore the supernatants were collected at this stimulation 
time. 
 
Taken together, OPG protein secretion increases due to TLR activation in the SW982 
cells. This may also be the case in SFs under RA development, as these cells are 
believed to originate from SFs and TLRs are known to be activated in RA.  OPG 
protein has in fact been detected in culture supernatants of RA SFs, and it was 
increased upon IL-1β stimulation [95]. A local increase of OPG protein in the joint 
will bind more RANKL, consequently causing less osteoclast activation and thereby 
less bone degradation. This may contribute to restoration of bone homeostasis. As 
previously mentioned, OPG have been shown to antagonize TRAIL-induced 
apoptosis in RA SFs, and thereby being partly responsible for the expansion of RA 
synovial lining [95]. OPG up-regulation is not only a positive thing, and the extent of 
OPG’s bone protective effect depends on the RANKL amount present in the joint, and 
probably also the DKK1 amount. Hence, the events are very complex and cannot be 
evaluated separately. Therefore, RANKL and DKK1 protein levels should be 
investigated, and all cells’ contribution should be considered. 
 
4.6 OPG gene expression and the prostaglandin pathway 
PGs are lipid mediators in the eicosanoid family, and they have a key role in 
inflammation [40]. Studies have demonstrated that PGE2 down-regulates OPG mRNA 
levels in human bone marrow stroma cells [99], and in mouse osteoblasts after LPS 
and IL-1 stimulation [50]. These findings indicate that the cPLA2 enzyme, which is 
responsible for producing the first precursor for PGE2, is involved in regulating the 
OPG expression. This implies that inhibiting the cPLA2 and COX enzymes may lead 
to less PGE2 and consequently more OPG may be expressed. In the 9 hours TLR 
agonist stimulation experiments performed in this master’s project, FSL-1-mediated 
OPG gene expression did not seem to change upon inhibition of the PG pathway in 
the SW982 cells. The cPLA2 inhibitors and the COX inhibitor resulted in a more 
distinct trend of inhibitory effect on the P3C-mediated OPG expression. However, 
only the COX inhibitor had a significant effect. This suggests that activation of 
TLR1/2 by P3C leads to increased activity of the COX enzymes – whether it is COX-
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1, COX-2, or both is impossible to tell due to the fact that Indomethacin is a 
nonspecific COX inhibitor. However, it is most likely to be COX-2, as COX-2 is the 
inducible isoform [83]. COX-2 expression was in fact found to be highly elevated by 
TLR agonist treatment of SW982 cells. Consequently, elevated levels of COX-2 
would cause an increase in PG levels, which might be one of the factors leading to the 
observed P3C-induced OPG mRNA increase. This is, however, the opposite of what 
was found in the above-mentioned bone marrow stroma cells and mouse osteoblasts 
studies [50, 99], where increased PGE2 levels resulted in a down-regulation of OPG. 
The difference may be attributed to variations between cell types, and the fact that 
PGE2 has several different receptors and can therefore evoke different responses [48]. 
 
In the OPG protein analyses of SW982 supernatants following 9 hours stimulation, 
minimal effects of the cPLA2 inhibitors and the COX inhibitor were detected – none 
were significant. Thus, the significant reduction of P3C-mediated OPG gene 
expression by COX was not found at protein level. This change could possibly have 
been detected at protein level after 12 hours stimulation. However, 12 hours inhibitor 
experiments were not performed, because 9 hours was the optimal stimulation period 
for TLR agonist induction of OPG and DKK1. Hence, the current results are not 
adequate to confirm that the PG pathway is involved in TLR agonist-induced OPG 
expression. 
 
4.7 Prostaglandin pathway involvement in DKK1 gene expression 
There is evidence suggesting that the WNT pathway in osteocytes is triggered by 
crosstalk with the PG pathway [100]. That is, PGE2 can activate the WNT pathway, 
which causes a decrease in the expression of WNT inhibitors like DKK1. However, 
there are no published data describing a connection like this in SFs. 
 
In the case of SW982 cell stimulation with FSL-1, it is unclear whether the PG 
pathway is involved, as the DKK1 increase was non-significant and only the COX 
inhibitor resulted in significant DKK1 inhibition. For P3C, however, both cPLA2 
inhibitors and the COX inhibitor reduced the DKK1 gene expression to levels similar 
to that of untreated cells. This suggests that the PG pathway is indeed involved in the 
increased DKK1 expression observed when the cells are treated with P3C. However, 
this is the opposite of what was found in osteocytes, where PGE2 release resulted in 
decreased DKK1 expression.  
 
The results discussed this far indicate that TLR1/2 signaling causes both increased 
OPG and DKK1 gene expression, and that this probably is due to activation of the PG 
pathway – at least in case of DKK1. The fact that the PG pathway contributes to the 
DKK1 increase, indicates that cPLA2 inhibitors may be a promising RA treatment by 
reducing the expression of this negative effector. If the PG pathway is in fact involved 
in TLR1/2-mediated OPG expression too, cPLA2 inhibition would be detrimental in 
respect to reducing OPG’s bone protection, but favorable in respect to reducing 
OPG’s apoptosis hindrance in RA SFs. All effects of cPLA2 inhibition, both positive 
and negative, need to be determined and assessed in a holistic manner. Therefore, 
cPLA2’s role in RA events must be further elucidated. 
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4.8 IL-6 and COX-2 gene expression following TLR activation 
Gene expression analysis of IL-6 and COX-2, which are highly inducible genes in the 
SW982 cells, were performed to ensure that the TLR agonist stimulation had been 
successful. The findings can also be used for clarifying the TLR signaling events in 
these cells. Both IL-6 and COX-2 are involved in RA pathogenesis. The pro-
inflammatory cytokine IL-6 is prominent in RA synovial fluid [101], and COX-2 
enzyme is found to be elevated in synovial tissue from RA patients [102]. 
 
FSL-1 and P3C have previously been found to induce IL-6 expression in human 
gingival fibroblasts [103]. Specifically in RA SFs, it has been demonstrated that 
ligands for TLR2-5 evoke IL-6 production [34]. Furthermore, IL-1β-induced IL-6 
production by RA SFs has been shown to be significantly reduced by the COX-2 
inhibitor NS-398 [83], indicating that the PG pathway is involved. In the SW982 
cells, both FSL-1 and P3C resulted in abundant IL-6 induction. These stimuli resulted 
in fold changes around 3 for OPG and DKK1, while the IL-6 fold change value was 
above 30. Hence, it can be concluded that the TLR agonist stimulation was 
successful. Regarding the inhibitors, only the COX inhibitor resulted in significant 
reduction of FSL-1-mediated IL-6 expression. For P3C-mediated IL-6 expression, on 
the other hand, both cPLA2 inhibitors had significant reducing effects. These results 
suggest that the PG pathway is involved in the IL-6 production following TLR1/2 
activation, and possibly following TLR2/6 activation. A potential explanation to why 
the cPLA2 inhibitors failed to reduce FSL-1-mediated IL-6 expression, is that the 
response actually is too strong and that an increased inhibitor concentration is 
required. The FSL-1-mediated IL-6 fold change was markedly higher than the P3C-
mediated.  	  
TLR2/6 and TLR1/2 ligands have been shown to induce COX-2 levels and activity in 
osteoblasts from mice [104]. This was confirmed by a distinct increase in PGE2 levels 
in the culture medium. Furthermore, the TLR2/6 and TLR1/2 ligand treatments 
showed an activation of the transcription factor NF-κB in the osteoblasts. In SW982 
cells, TLR agonist and inhibitor treatment resulted in the same COX-2 up-regulation 
trend as for IL-6: FSL-1 showed the strongest COX-2 induction, and only the COX 
inhibitor reduced this significantly. COX-2 expression increased after P3C 
stimulation, and both cPLA2 inhibitors plus the COX inhibitor had significant 
reducing effects. These results indicate that the FSL-1- and P3C-mediated COX-2 
expression exerts a positive feedback-loop, because inhibition of the PG pathway 
leads to reduced COX-2 mRNA. I.e., more production of PGs by the COX-2 will in 
absence of the COX inhibitor promote further COX-2 expression. In conclusion, a 
connection obviously exists between TLR activation and the PG pathway in the 
SW982 cells, which is equivalent to the findings in mouse osteoblasts. 
 
4.9 AA release in response to TLR agonists 
AA is the first precursor for eicosanoids, such as PGs. AA is incorporated in cell 
membranes and is released by cPLA2, sPLA2, iPLA2 or LpPLA2 [52]. Which PLA2s 
that participate in catalysis of AA release varies between cell types. GIVA cPLA2 is 
specific for AA release at the sn-2 position and is considered to be the major AA 
releasing enzyme [40]. The GIVA cPLA2 is activated by MAPKs, such as ERK1/2 
and p38. TLR3 and TLR4 signaling has been reported to activate both these MAPKs 
in RA SFs [105]. There are no published data on other TLRs’ connection to AA 
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release in human SFs. However, it has been demonstrated that stimulation of TLR1/2, 
TLR2, TLR3, TLR4, TLR2/6, and TLR7 in mouse macrophage-like cells leads to 
elevated levels of AA release [106].  
 
Here, activation of TLR2/6, TLR1/2, and TLR3 all resulted in a significant increase in 
AA release from the SW982 cells. The positive control, IL-1β, increased the AA 
release as expected. The AA responses in the SW982 cells were time-dependent for 
all TLR agonists. AA release following FSL-1, P3C and IL-1β stimulation peaked 
after 9 hours, while PIC-mediated AA release peaked after 12 hours. This may reflect 
the fact that PIC needs more time for reaching its maximum induction, even though 
this is not beneficial to the cells judged by their abnormal morphology, as previously 
discussed. P3C- and PIC-induced AA release were similar, while FSL-1 was the 
agonist resulting in the highest response. The FSL-1 AA fold change was similar to 
that of IL-1β. The trend that FSL-1 is the strongest inducer is the same as observed at 
gene level for IL-6 and COX-2, and at protein level for OPG. The SW982 cells’ 
responses are a little different from that of the mouse macrophage-like cells. In the 
mouse cell study, FSL-1 and P3C resulted in similar and intermediate AA release, 
while PIC stimulation showed the strongest response. The different responses may 
simply be due the fact that they are different cell types, from different species, and 
therefore react differently. That being said, the mouse cell study used higher 
concentrations for all TLR agonists: 1 µg/ml for FSL-1 and P3C (vs. 100 or 50 ng/ml 
for FSL-1 and 100 or 300 ng/ml for P3C), and 25 µg/ml for PIC (vs. 5 or 1 µg/ml). In 
addition, a different stimulation period was used: 20 hours (vs. 3, 6, 9, 12 and 24 
hours). Regardless, elevated levels of AA release may cause increased AA uptake by 
neighboring cells. This will provide more substrates for the COX enzymes, which 
ultimately leads to increased PG production and thereby stronger inflammatory 
reactions. 
 
Furthermore, experiments using different PLA2 inhibitors were performed in order to 
reveal which enzymes were responsible for the observed TLR agonist-induced AA 
release in the SW982 cells. FSL-1, P3C and PIC all resulted in similar AA release 
trends when combined with the inhibitors. The GIVA cPLA2 inhibitor AVX002 had 
significant inhibitory effects for both FSL-1 and P3C. This cPLA2 inhibition was 
confirmed by the use of CAY10502 that seemed to be even more effective and 
reduced the AA release to basal level. Even though AVX002 showed a tendency of 
inhibition for PIC as well, this was found to be non-significant. However, the other 
GIVA cPLA2 inhibitor, CAY10502, resulted in significant reduction to basal level for 
PIC. These results strongly indicate that the GIVA cPLA2 is the main PLA2 
contributing to the TLR agonist-induced AA release. For all three TLR agonists, 
neither of the sPLA2 inhibitors, CAY10590 and Varespladib, had significant 
inhibitory effect on the AA release. This suggests that sPLA2 is not involved in AA 
release in response to TLR agonists. MAFP, which inhibits both iPLA2 and cPLA2, 
reduced the AA release to basal level for all TLR agonists. This could be due to the 
cPLA2 inhibition alone, or due to both cPLA2 and iPLA2 inhibition. From the results 
using the iPLA2 inhibitor, BEL, the involvement of iPLA2 can be evaluated. BEL 
showed significant inhibition for FSL-1 and P3C, but non-significant for PIC. It can 
be assumed that iPLA2 is partly involved in the AA release induced by TLR agonists. 
However, BEL has also been found to inhibit cellular phosphatidic acid 
phosphohydrolase (PAP) -1 [107]. PAP-1 catalyzes the conversion of phosphatidic 
acid on membrane surfaces to inorganic phosphate and diacylglycerol (DAG). DAG 
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can then activate protein kinase C (PKC), which in turn have been found to contribute 
to GIVA cPLA2 activation upon e.g. TLR4 agonist stimulation [108]. Thus, the 
decreased AA release following BEL treatment of SW982 cells can possibly be 
attributed to PAP-1 inhibition. This should be further elucidated to find out whether 
BEL is actually acting on iPLA2 under the conditions used here (10 µM inhibitor). 	  
In the aforementioned study [106], where TLR stimulation led to increased AA 
release in mouse macrophage-like cells, it was found that GIVA cPLA2 is the key 
enzyme regulating AA release. It was suggested that GV sPLA2 contributed to the 
TLR-mediated release by amplifying the activation of GIVA cPLA2 via ERK1/2 
phosphorylation.	   As in the mouse macrophage-like cells, the TLR-mediated AA 
release is mainly due to the action of GIVA cPLA2 in the SW982 cells. In addition, 
the SW982 cell results indicate a possible involvement of iPLA2. The mouse cell 
study found no role for iPLA2, but for sPLA2. The sPLA2 should not be ruled out just 
yet in the SW982 cells. A possible reason for the lack of sPLA2 inhibitor effects can 
be the long pre-incubation period. 2 hours pre-incubation was used for all inhibitors. 
This may be too long for the sPLA2 inhibitors to keep their proper function. In 
contrast, the mouse cell study only used a 30 minutes pre-incubation period, although 
they used another sPLA2 inhibitor (scalaradial) and cPLA2 inhibitor (pyrrophenone). 
Furthermore, the study stated that they had performed an extensive characterization of 
the inhibitors’ effect on the cells, and ensured that the inhibitor concentrations used 
did not interfere with other PLA2 activities than those the inhibitors are directed 
against. A similar analysis would be required for the SW982 cells, to find out whether 
the observed effects are in fact due to the PLA2s suggested here. 
 
SW982 cells’ OA release was investigated in parallel to AA release, since certain cell 
models show an increase in OA release too, e.g. in response to the TLR4 ligand LPS 
[42]. OA release reflects the activity of AA-non-selective PLA2s. The TLR agonist 
stimulation generally resulted in unchanged OA release in the SW982 cells. If there 
was a change, this was negligible compared to the AA fold change. The same goes for 
the experiments with the different PLA2 inhibitors. Although this could suggest that 
the TLR agonists do not activate non-selective PLA2s, the BEL effect on TLR-
mediated AA release indicates that iPLA2 is activated. The reason for not detecting 
this effect in the OA release is probably that this AA/OA assay is not sensitive enough 
to detect changes in OA levels. 
 
4.10 TNF-α effects on RANKL, OPG and DKK1 gene expression 
As a consequence of TLR activation, several pro-inflammatory mediators are 
produced, including cytokines. TNF-α is a cytokine considered especially important 
in RA pathogenesis, as it leads to e.g. angiogenesis and activation of leukocytes, 
endothelial cells, and SFs [4]. Regarding bone remodeling components, TNF-α has 
been found to induce RANKL mRNA expression in SFs from RA patients [109]. 
However, the same study also showed that these RA SFs expressed OPG and that the 
OPG mRNA expression was further enhanced by TNF-α stimulation, suggesting a 
bone-protective role for TNF-α. This has been demonstrated in other studies as well 
[20, 110]. These findings are probably related to the fact that TNF-α exhibits different 
roles during different disease stages: pro-inflammatory in the initiation phase and 
disease-suppressive at a later stage. In addition, the OPG/RANKL ratio is the critical 
determinant for whether TNF-α causes bone degradation or protection against this 
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[109]. It must be stated again that OPG increase is not necessarily beneficial in a RA 
context. It is indeed positive in respect to bone homeostasis, but it can also prevent 
TRAIL-induced apoptosis of RA SFs [95]. I.e., OPG is considered a partaker in 
synovial hyperplasia. 
 
Furthermore, DKK1 has been found to be elevated in response to TNF-α in arthritic 
SFs [24]. More recent findings showed that, as for IL-1β, it is not TNF-α directly that 
causes the elevated DKK1 levels in RA SFs. It is, however, its contribution in 
increasing the expression of the enzyme 11β-HSD1, which activates glucocorticoids. 
It is the glucocorticoids that actually induce the DKK1 expression [98]. Whether 
cPLA2 is involved in expressing 11β-HSD1 may also be an area to explore in the 
SW982 cells. 
 
TNF-α time-lapse experiments performed on the SW982 cells were not conclusive. 
No significant OPG or RANKL induction was observed. Ahmed Siddik, the former 
master’s student, was able to detect a small, but significant increase in OPG gene 
expression in response to TNF-α, but was not able to detect RANKL in non-
stimulated SW982 cells. The RANKL primers used then did not work in qPCR, but 
conventional PCR indicated the presence of RANKL upon TNF-α stimulation. 
Therefore, it was expected to observe RANKL and OPG fold changes with the new 
primers. However, three biological replicas showed no significant changes. The trends 
in the different replicas differed, and it was not possible to determine potential 
outliers. The results may be influenced by differences in generation numbers on the 
cell cultures used for experiments. Cells used in two of the replicas were close in 
generation number (#67 and #69), but one replica was different (#37) and from 
another cell batch. Cell lines do not show signs of senescence. However, they may 
change their gene expression profile as the number of cell division cycles increases. 
No obvious trend for this was recognized in the TNF-α experiments. Regardless, the 
experiments with the TLR agonist stimulations were performed on cell cultures close 
in generation number. 
 
Another indication of non-optimal TNF-α experiments was the IL-6 gene analysis that 
revealed a rather small induction. The fold change was around 9, and also non-
significant. Moreover, this is a considerably smaller induction than what the PLA2 
research group normally obtains in SW982 cells. The IL-6 fold change values are 
usually above 20 in response to TNF-α [86]. The weak response might have been 
because of an impaired batch of TNF-α, or because the cells were abnormal due to 
e.g. contamination. In addition, it was in these TNF-α experiments the use of 
RANKL, TLR1, TLR6 and TLR7 primers was discontinued due to indications of non-
specific products. 
 
Despite the varying results, a significant increase in DKK1 gene expression was 
detected after 6 hours of TNF-α stimulation. An increase was anticipated based on 
mentioned findings in RA SFs, and based on Siddik’s findings in SW982 cells. If this 
increase in DKK1 mRNA corresponds to an increase of DKK1 protein and secretion 
of this, as it does in RA, this will lead to increased inhibition of the WNT pathway 
and consequently less osteoblast activation. As indicated several times, whether this 
causes an unbalance of bone homeostasis also depends on the RANKL/OPG ratio. 
Thus, this ratio needs to be evaluated, but this was not possible based on the results 
obtained from these experiments. 
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A study of human dental pulp cells has showed that a cPLA2 inhibitor reduces the 
increase of RANKL mRNA levels induced synergistically by TNF-α and IL-1-α 
[111]. To investigate whether there is a connection between cPLA2 and TNF-α-
induced RANKL, OPG and DKK1 in SW982 cells, the TNF-α time-lapse 
experiments included the cPLA2 inhibitors AVX002 and InhibX. The latter is a novel 
inhibitor whose structure has not yet been published, and InhibX is a cover name used 
in this master’s thesis. Neither AVX002 nor InhibX showed significant effects on any 
of the bone remodeling components. Because these TNF-α experiments were 
inconclusive, it is not possible to conclude whether these no-response cPLA2 inhibitor 
results are actually valid. Hence, the experiments would need to be repeated to 
evaluate cPLA2’s involvement in TNF-α-induced expression of RANKL, OPG and 
DKK1. 
 
A desired scenario is that the cPLA2 enzyme was found to up-regulate the expression 
of both DKK1 and RANKL in response to TNF-α. Consequently, this would 
strengthen the cPLA2 inhibitors' candidacy as anti-rheumatic drugs aiming to 
reestablish the bone homeostasis. Furthermore, if an OPG increase following TNF-α 
treatment had taken place, it would not have been beneficial to the bone homeostasis 
if the cPLA2 inhibitors reduced the OPG expression. However, it would have been 
advantageous in respect to increasing the apoptosis of RA SFs. Again, it is essential to 
map all negative and positive effects of cPLA2 inhibition. 	  
4.11 TLR gene expression following TNF-α stimulation 
As previously stated, the expression of cytokines like TNF-α is a result of TLR 
signaling. There is evidence that TNF-α affects the TLR expression. E.g., in RA SFs, 
TNF-α was found to increase TLR2 expression [34]. The same TNF-α time-lapse 
experiments as discussed in the previous section were analyzed at gene level for TLR 
expression, to investigate TNF-α’s effect on TLR1-TLR7 in SW982 cells. As for 
OPG and RANKL, the TLR results varied and there were few significant changes. 
Only TLR2 and TLR3 gene expression were significantly increased. For both these 
TLRs, short TNF-α stimulation periods, such as 6 and 12 hours, resulted in the 
highest induction. Moreover, the TLR2 response seemed to be stronger than the TLR3 
response. Although none of the other TLRs showed significant changes in gene 
expression, the possibility of them being affected by TNF-α cannot be excluded solely 
based on these experiments. As stated in the previous section, the induction of IL-6 
was unusually poor, and this indicates that the TNF-α stimulation has not been 
optimal. I.e., repetition is necessary to verify these results. However, the SW982 
results coincide with the previously mentioned RA SFs study [34], regarding TNF-α 
increasing the TLR2 expression. Moreover, the RA SFs study found that TLR3, TLR4 
and TLR5 expression were unaffected by TNF-α. This seems to be the case for 
SW982 cells too, except that TLR3 was indeed affected.  
 
It could be imagined that TNF-α-induced TLR expression could contribute to a 
vicious circle in RA. Activation of certain TLRs would lead to more TNF-α, which 
then again would cause an increase in TLR expression. The cells would then be more 
vulnerable to endogenous TLR ligands present in the inflamed joint, and subsequent 
TLR activation would produce a stronger immune response. This would involve 
increased TNF-α expression and the circle would go on.  
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Furthermore, TNF-α-induced TLR2 expression has been linked to inter alia cPLA2 
activation in human gingival fibroblasts in a study associated with the chronic 
inflammatory disease periodontitis [112]. In the SW982 cells, the cPLA2 inhibitors, 
AVX002 and InhibX, had no significant effect on the TNF-α-induced TLR 
expression. Again, the results are inconclusive and cPLA2’s involvement should not 
be ruled out just yet. 	  
4.12 Limitations of cell culture experiments 
When working with cell cultures in general, it must be kept in mind that there is a risk 
of deceptive results when cells are removed from their physiological environment. 
Inside the body, the behavior of the cells is highly dependent on interactions with 
other cell types and the extracellular matrix. These components are obviously not 
present in an in vitro two-dimensional (2D) culture and are therefore not fully 
representable for what happens in the body [113]. Moreover, in cell culture 
experiments, the researcher has limited spatial and temporal control regarding e.g. 
addition of stimuli. An up-and-coming alternative to 2D cell cultures is the so-called 
cell chips. These are microsystems that can provide both a more authentic three-
dimensional (3D) environment for the cells and more controllable ways of regulating 
transport of fluids and soluble factors [114]. In addition, microsystems enable single 
cell studies, which may be a more correct way of analyzing cells’ responses to e.g. 
certain compounds. Cells in a culture are often assumed to be homogeneous, and the 
average response of the cells is then considered as the response of all cells in that 
culture. The fact is, that even though cells are of the same type, they can be different 
from each other. This heterogeneity should be taken into consideration [115] . 
 
4.13 Future research 
All the SW982 cell experiments performed in this master’s project should be 
performed on a different SF cell line as well, to exclude the risk of obtaining cell-
specific effects and to ensure that the results are physiologically relevant. Optimally, 
the results should be verified in primary SFs to ensure that the observed effects are 
not due to the cancer state of the cell line. Even though the TLR agonist stimulation 
results must be verified, this study of TLR signaling can serve as a valuable guidance 
for further research concerning the connection between TLRs, cPLA2, the PG 
pathway, bone remodeling components and pro-inflammatory mediators in RA. 
Because the SW982 cells express TLR1-TLR7, additional TLR agonists (than only 
the TLR2/6, TLR1/2 and TLR3 agonists) should be included in further studies. 
Examining DAMP-mediated TLR signaling to see whether this will evoke different 
responses than PAMP-mediated, would also be of interest. Furthermore, possible 
expression of other human TLRs (TLR8-TLR10) should be investigated in the 
SW982 cells. The experiments regarding the involvement of cPLA2 in expression of 
RANKL, OPG, DKK1 and TLRs in response to TNF-α were inconclusive, and should 
be repeated. 
 
Finally, it should be mentioned that the gene expression analysis software REST 2009 
(Qiagen) used in this thesis, is no longer subject to further development. In future 
gene studies it should therefore be considered to use another program, e.g. qbase+ 
(Biogazelle). This program has more functions integrated and will make it easier to do 
extensive qPCR data-analysis.  
	   71 
5. CONCLUSION 
This thesis involves the study of synovial SW982 cells’ responses to TLR agonists 
and TNF-α, and the involvement of the cPLA2 enzyme in the expression of the bone 
remodeling components RANKL, OPG and DKK1. It was demonstrated that SW982 
cells express OPG and DKK1, and probably RANKL. In addition, the cells were 
found to express TLR1-TLR6, and most likely TLR7 as well.  
 
Furthermore, stimulating the cells with a TLR2/6 agonist (FSL-1), a TLR1/2 agonist 
(P3C), or a TLR3 agonist (PIC) resulted in an increase of OPG gene expression and 
consequently more OPG protein secretion, which could potentially prevent osteoclast 
activation. However, this would depend on the amount of RANKL present, but this 
was not possible to determine due to a nonspecific RANKL primer. In addition, the 
TLR agonists induced higher levels of DKK1 gene expression. If this would 
correspond to an increase in DKK1 translation, secreted DKK1 would inhibit 
osteoblast activation and thereby reduce OPG expression. FSL-1 and P3C stimulation 
highly increased the gene expression of COX-2 and IL-6, which both are pro-
inflammatory mediators. 
 
The gene expression trends indicated that the PG pathway (i.e. cPLA2 and COX 
enzymes) is involved in P3C-induced expression of DKK1, IL-6 and COX-2, but 
possibly OPG as well. For FSL-1-induced expression of these genes the involvement 
of the PG pathway is not as evident as for P3C, but still likely. PIC-induced 
expression was not studied at gene level with cPLA2 and COX inhibitors. 
 
FSL-1, P3C and PIC all increased the release of the inflammatory intermediate AA – 
the first precursor of PGs. The GIVA cPLA2 enzyme was found to be the main PLA2 
responsible for this AA release, with a possible involvement of iPLA2. 
 
Even though the bone-protective OPG is up-regulated by activation of TLR2/6, 
TLR1/2 and TLR3, this activation may have more negative effects in a RA context as 
the levels of DKK1, COX-2, IL-6 and AA release are also increased. In addition, an 
OPG increase may contribute to synovial lining hyperplasia due to prevention of SF 
apoptosis. Thus, from the results in this study, cPLA2 seems like an attractive target 
for inhibiting inflammatory responses set off by TLRs.  
 
The SW982 cells were found to up-regulate their DKK1, TLR2 and TLR3 gene 
expression in response to the pro-inflammatory cytokine TNF-α, which is one of the 
components produced following TLR activation. The no-response results for 
RANKL, OPG, TLR1, and TLR4-7 are inconclusive, partly because the TNF-α 
stimulation was found to be non-optimal. The same goes for the no-response results 
regarding cPLA2’s involvement in TNF-α-induced expression of the mentioned genes. 	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Appendix 
A. All biological replicas for the representative experiment in figure 3.3.1 
 
Mean OPG mRNA fold changes and	 ±SEMs (n = 2): 	  
Table A.1 Mean OPG fold changes after TLR agonists and IL-1β treatment for 6 hours. The asterisk denotes 
significant difference from the control (p < 0.05), which is set to 1. 
Treatment, 
6h 
OPG 
fold change 
SEM 
Lower Upper 
FSL-1 6.4 * 3.2 18.6 
P3C 4.8 * 2.2 12.8 
PIC 2.3 1.1 9.1 
IL-1β 6.7 * 3.8 22.8 
 
 
Table A.2 Mean OPG fold changes after TLR agonists and IL-1β treatment for 24 hours.  
Treatment, 
24h 
OPG 
fold change 
SEM 
Lower Upper 
FSL-1 1.7 0.4 14.5 
P3C 1.2 0.3 10.4 
PIC 0.7 0.2 5.9 
IL-1β 1.7 0.5 12.8 
 
 
Mean DKK1 mRNA fold changes and	 ±SEMs (n = 2): 
 
Table A.3 Mean DKK1 fold changes after TLR agonists and IL-1β treatment for 6 hours.  
Treatment, 
6h 
DKK1 
fold change 
SEM 
Lower Upper 
FSL-1 2.6 1.5 5.2 
P3C 1.4 0.6 4.6 
PIC 1.2 0.7 2.3 
IL-1β 2.8 1.7 5.7 
 
 
Table A.4 Mean DKK1 fold changes after TLR agonists and IL-1β treatment for 24 hours.  
Treatment, 
24h 
DKK1 
fold change 
SEM 
Lower Upper 
FSL-1 1.5 0.7 4.2 
P3C 1.9 1.0 6.4 
PIC 1.1 0.5 2.8 
IL-1β 1.4 0.7 4.5 
 	    
	   III 
B. Data for time curves in figure 3.3.2 
 
Mean OPG mRNA fold changes and	 ±SEMs (n = 2, except for IL-1 where n = 1): 
 
Table B.1 Mean OPG fold changes after TLR agonists and IL-1β treatment for 3 hours. The asterisk denotes 
significant difference from the control (p < 0.05), which is set to 1. 
Treatment, 
3h 
OPG 
fold change 
SEM 
Lower Upper 
FSL-1 4.5 * 3.7 5.7 
P3C 2.5 2.0 3.1 
PIC 2.2 * 1.8 2.8 
IL-1β 5.2 - - 
 
 
Table B.2 Mean OPG fold changes after TLR agonists and IL-1β treatment for 6 hours. The asterisk denotes 
significant difference from the control (p < 0.05), which is set to 1. 
Treatment, 
6h 
OPG 
fold change 
SEM 
Lower Upper 
FSL-1 4.6 3.7 5.7 
P3C 3.2 * 2.0 3.1 
PIC 2.4 1.8 2.8 
IL-1β 5.0 - - 
 
 
Table B.3 Mean OPG fold changes after TLR agonists and IL-1β treatment for 9 hours. The asterisk denotes 
significant difference from the control (p < 0.05), which is set to 1. 
Treatment, 
9h 
OPG 
fold change 
SEM 
Lower Upper 
FSL-1 3.6 * 2.8 4.6 
P3C 3.3 * 2.8 4.0 
PIC 2.6 * 2.2 3.1 
IL-1β 4.3 - - 
 
 
Table B.4 Mean OPG fold changes after TLR agonists and IL-1β treatment for 12 hours. The asterisk denotes 
significant difference from the control (p < 0.05), which is set to 1. 
Treatment, 
12h 
OPG 
fold change 
SEM 
Lower Upper 
FSL-1 2.4 2.0 3.0 
P3C 3.0 2.6 3.4 
PIC 2.1 * 1.9 2.4 
IL-1β 2.4 - - 
 
  
	   IV 
Mean DKK1 fold changes and	 ±SEMs (n = 2, except for IL-1 where n = 1): 
 
 
Table B.5 Mean DKK1 fold changes after TLR agonists and IL-1β treatment for 3 hours. The asterisk denotes 
significant difference from the control (p < 0.05), which is set to 1.	  
Treatment, 
3h 
DKK1 
fold change 
SEM 
Lower Upper 
FSL-1 0.3 * 0.3 0.4 
P3C 0.5 0.4 0.6 
PIC 0.3 * 0.2 0.3 
IL-1β 0.4 - - 
 
 
Table B.6 Mean DKK1 fold changes after TLR agonists and IL-1β treatment for 6 hours. The asterisk denotes 
significant difference from the control (p < 0.05), which is set to 1.	  
Treatment, 
6h 
DKK1 
fold change 
SEM 
Lower Upper 
FSL-1 2.7 1.9 3.7 
P3C 1.1 0.8 1.4 
PIC 2.5 * 2.4 2.7 
IL-1β 4.8 - - 
 
 
Table B.7 Mean DKK1 old changes after TLR agonists and IL-1β treatment for 9 hours. The asterisk denotes 
significant difference from the control (p < 0.05), which is set to 1.	  
Treatment, 
9h 
DKK1 
fold change 
SEM 
Lower Upper 
FSL-1 2.3 * 2.0 2.7 
P3C 2.1 * 2.0 2.1 
PIC 4.0 * 3.8 4.1 
IL-1β 2.5 - - 
 
 
Table B.8 Mean DKK1 fold changes after TLR agonists and IL-1β treatment for 12 hours. The asterisk denotes 
significant difference from the control (p < 0.05), which is set to 1.	  
Treatment, 
12h 
DKK1 
fold change 
SEM 
Lower Upper 
FSL-1 1.7 * 1.7 1.8 
P3C 1.9 * 1.9 2.0 
PIC 4.8 * 4.2 5.4 
IL-1β 1.6 - - 
 
  
	   V 
C. All biological replicas for the representative experiment in figure 3.5.1 
 
Mean OPG mRNA fold changes and	 ±SEMs (n = 5):	  	  
 
Table C.1 Mean OPG fold changes after 9 hours stimulation with the TLR2/6 agonist FSL-1 or FSL-1 plus a 
cPLA2 inhibitor (AVX002 or InhibX) or a COX inhibitor (Indomethacin). The asterisk denotes significant 
difference from the control (p < 0.05), which is set to 1.  
Treatment, 
9h 
OPG 
fold change 
SEM 
Lower Upper 
FSL-1 3.5 * 2.0 6.4 
FSL-1 + AVX002 3.7 1.9 8.1 
FSL-1 + InhibX 3.5 1.7 8.3 
FSL-1 + Indomethacin 2.8 1.5 5.7 
 
 
Table C.2 Mean OPG fold changes after 9 hours stimulation with the TLR1/2 agonist P3C or P3C plus a cPLA2 
inhibitor (AVX002 or InhibX) or a COX inhibitor (Indomethacin). The asterisk denotes significant difference from 
the control (p < 0.05), which is set to 1, and the number sign symbolizes significant difference from the TLR 
agonist alone (p < 0.05). 
Treatment, 
9h 
OPG 
fold change 
SEM 
Lower Upper 
P3C 3.6 * 2.2 6.0 
P3C + AVX002 2.6 1.4 4.2 
P3C + InhibX 2.1 1.2 4.5 
P3C + Indomethacin 2.1 # 1.2 3.4 
 	    
	   VI 
D. All biological replicas for the representative experiment in figure 3.6.1 
 
Mean DKK1 mRNA fold changes and	 ±SEMs (n = 5):	  
 
 
Table D.1 Mean DKK1 fold changes after 9 hours stimulation with the TLR2/6 agonist FSL-1 or FSL-1 plus a 
cPLA2 inhibitor (AVX002 or InhibX) or a COX inhibitor (Indomethacin). The number sign symbolizes significant 
difference from the TLR agonist alone (p < 0.05). 
Treatment, 
9h 
DKK1 
fold change 
SEM 
Lower Upper 
FSL-1 2.3 0.9 5.5 
FSL-1 + AVX002 2.5 0.9 7.3 
FSL-1 + InhibX 2.0 0.7 5.5 
FSL-1 + Indomethacin 1.0 # 0.3 2.5 
 
 
Table D.2 Mean DKK1 fold changes after 9 hours stimulation with the TLR1/2 agonist P3C or P3C plus a cPLA2 
inhibitor (AVX002 or InhibX) or a COX inhibitor (Indomethacin). The asterisk denotes significant difference from 
the control (p < 0.05), which is set to 1, and the number sign symbolizes significant difference from the TLR 
agonist alone (p < 0.05). 
Treatment, 
9h 
DKK1 
fold change 
SEM 
Lower Upper 
P3C 3.2 * 1.1 7.7 
P3C + AVX002 1.5 # 0.6 3.5 
P3C + InhibX 1.4 # 0.5 3.4 
P3C + Indomethacin 0.9 # 0.3 2.3 
 	    
	   VII 
E. All biological replicas for the representative experiment in figure 3.7.1 
 
Mean IL-6 mRNA fold changes and	 ±SEMs (n = 5):	  
 
 
Table E.1 Mean IL-6 fold changes after 9 hours stimulation with the TLR2/6 agonist FSL-1 or FSL-1 plus a 
cPLA2 inhibitor (AVX002 or InhibX) or a COX inhibitor (Indomethacin). The asterisk denotes significant 
difference from the control (p < 0.05), which is set to 1, and the number sign symbolizes significant difference 
from the TLR agonist alone (p < 0.05). 
Treatment, 
9h 
IL-6 
fold change 
SEM 
Lower Upper 
FSL-1 84.0 * 54.5 123.2 
FSL-1 + AVX002 81.6 50.4 125.1 
FSL-1 + InhibX 99.6 51.6 248.5 
FSL-1 + Indomethacin 38.3 # 25.9 59.3 
 
 
Table E.2 Mean IL-6 fold changes after 9 hours stimulation with the TLR1/2 agonist P3C or P3C plus a cPLA2 
inhibitor (AVX002 or InhibX) or a COX inhibitor (Indomethacin). The asterisk denotes significant difference from 
the control (p < 0.05), which is set to 1, and the number sign symbolizes significant difference from the TLR 
agonist alone (p < 0.05). 
Treatment, 
9h 
IL-6 
fold change 
SEM 
Lower Upper 
P3C 48.0 * 28.7 75.2 
P3C + AVX002 22.3 # 13.6 34.9 
P3C + InhibX 20.6 # 13.8 33.9 
P3C + Indomethacin 15.3 # 9.2 25.0 
 	    
	   VIII 
F. All biological replicas for the representative experiment in figure 3.8.1 
 
Mean COX-2 mRNA fold changes and	 ±SEMs (n = 5):	  
 
 
Table F.1 Mean COX-2 fold changes after 9 hours stimulation with the TLR2/6 agonist FSL-1 or FSL-1 plus a 
cPLA2 inhibitor (AVX002 or InhibX) or a COX inhibitor (Indomethacin). The asterisk denotes significant 
difference from the control (p < 0.05), which is set to 1, and the number sign symbolizes significant difference 
from the TLR agonist alone (p < 0.05). 
Treatment, 
9h 
COX-2 
fold change 
SEM 
Lower Upper 
FSL-1 29.9 * 14.8 64.2 
FSL-1 + AVX002 20.4 9.8 41.4 
FSL-1 + InhibX 23.5 12.4 55.1 
FSL-1 + Indomethacin 15.3 # 8.5 33.3 
 
 
Table F.2 Mean COX-2 fold changes after 9 hours stimulation with the TLR1/2 agonist P3C or P3C plus a cPLA2 
inhibitor (AVX002 or InhibX) or a COX inhibitor (Indomethacin). The asterisk denotes significant difference from 
the control (p < 0.05), which is set to 1, and the number sign symbolizes significant difference from the TLR 
agonist alone (p < 0.05). 
Treatment, 
9h 
COX-2 
fold change 
SEM 
Lower Upper 
P3C 14.4 * 7.1 32.3 
P3C + AVX002 4.8 # 2.0 12.2 
P3C + InhibX 4.6 # 2.6 9.4 
P3C + Indomethacin 5.9 # 3.1 12.3 	   	  
	   IX 
G. Data for time curves in figure 3.9.1 	  
Mean AA release fold changes and ±SDs (n = 3): 
 
 
Table G.1 Mean AA release fold changes after TLR agonists and IL-1β treatment for 3, 6, 9, 12 and 24 hours. The 
asterisk denotes significant difference from the control (p < 0.05), which is set to 1. 
Treatment 3h 6h 9h 12h 24h 
FSL-1 100 ng/ml 1.8 3.9 * 4.4 * 3.9 * 2.6 
±SD 0.9 1.5 1.3 0.7 0.5 
	      
FSL-1 50 ng/ml 1.7 4.2 * 4.1 * 4.2 * 2.6 
±SD 0.6 1.6 1.2 0.8 0.5 
      
P3C 300 ng/ml 1.1 2.4 3.0 * 2.9 * 1.9 
±SD 0.2 1.0 1.1 0.5 0.3 
	      
P3C 100 ng/ml	 1.0 1.9 2.3 2.3 1.7 
±SD 0.2 1.0 0.9 0.6 0.3 
	      
PIC 5 µg/ml	 1.1 2.0 * 2.5 * 2.9 * 2.2 * 
±SD 0.4 0.3 0.4 0.5 0.3 
	      
PIC 1 µg/ml	 1.0 1.9 * 2.3 * 2.9 * 2.2 * 
±SD 0.3 0.3 0.5 0.5 0.3 
	      
IL-1β 10 ng/ml	 1.5 3.8 * 4.5 * 4.4 * 2.9 
±SD 0.4 1.8 1.6 0.8 0.6 
 	   	  
	   X 
H. All biological replicas for the representative experiment in figure 3.11.1 
 
Mean RANKL mRNA fold changes and	 ±SEMs (n = 3): 	  	  
Table H.1 Mean RANKL fold changes after TNF-α treatment for 3, 6, 12 and 24 hours. 	  
TNF-α 
treatment 
RANKL 
fold change 
SEM 
Lower Upper 
6h 1.2 0.3 6.6 
12h 1.0 0.3 3.8 
24h 0.9 0.4 3.3 
48h 0.9 0.3 3.1 
 
 
Mean DKK1 mRNA fold changes and	 ±SEMs (n = 3):	  
 
 
Table H.2 Mean DKK1 fold changes after TNF-α treatment for 3, 6, 12 and 24 hours. The asterisk denotes 
significant difference from the control (p < 0.05), which is set to 1.	  
TNF-α 
treatment 
DKK1 
fold change 
SEM 
Lower Upper 
6h 2.6 * 1.2 5.9 
12h 1.4 0.8 2.0 
24h 1.6 0.9 2.6 
48h 1.3 0.8 2.2 	  	   	  
	   XI 
I. All biological replicas for the representative experiment in figure 3.12.1 
 
Mean TLR mRNA fold changes and	 ±SEMs (n = 3): 
 
 
Table I.1 Mean TLR1 fold changes after TNF-α treatment for 3, 6, 12 and 24 hours. 	  
TNF-α 
treatment 
TLR1 
fold change 
SEM 
Lower Upper 
6h 1.6 0.6 6.7 
12h 1.1 0.4 3.9 
24h 1.2 0.3 8.9 
48h 0.7 0.1 3.2 
 
 
Table I.2 Mean TLR2 fold changes after TNF-α treatment for 3, 6, 12 and 24 hours. The asterisk denotes 
significant difference from the control (p < 0.05), which is set to 1.	  
TNF-α 
treatment 
TLR2 
fold change 
SEM 
Lower Upper 
6h 5.7 * 3.9 8.5 
12h 5.8 * 4.6 7.1 
24h 3.2 * 2.6 3.9 
48h 2.5 1.4 4.9 
 
 
Table I.3 Mean TLR3 fold changes after TNF-α treatment for 3, 6, 12 and 24 hours. The asterisk denotes 
significant difference from the control (p < 0.05), which is set to 1.	  
TNF-α 
treatment 
TLR3 
fold change 
SEM 
Lower Upper 
6h 3.1 * 2.6 3.8 
12h 2.2 1.5 3.0 
24h 1.8 * 1.6 2.0 
48h 0.8 0.7 0.9 	  	   	  
	   XII 
J. All biological replicas for the representative experiment in figure 3.13.1 
 
Mean IL-6 mRNA fold change and	 ±SEM (n = 3): 
 
 
Table J.1 Mean IL-6 fold change after TNF-α treatment for 24 hours.	  
TNF 
treatment 
IL-6 
fold change 
SEM 
Lower Upper 
24h 12.4  4.5 47.3 
 	  
